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Metastatic spread is the cause of 90% of cancer-related deaths. Melanoma cells with high actomyosin 
contractility, driven by high Rho-Rho Kinase (ROCK) signalling, exhibit a rounded amoeboid type 
movement and are found at the invasive fronts of primary tumours and in metastases. ROCK is a novel 
therapeutic target of melanoma as it has recently been shown that small molecule inhibitors of ROCK 
can reduce melanoma growth and the number of metastases in vivo. 
 -Omics level studies of biological systems are quickly becoming an integral and routine part of 
biological research. Nuclear Magnetic Resonance (NMR) Metabolomics is a relatively cheap and highly 
reproducible means of identifying 30-100 different metabolites in a biological system. To date there has 
not been an -omic level study of ROCK regulation of cancer cell metabolism and this thesis addresses 
this gap in knowledge.  
In this thesis, we investigate how ROCK controls proliferation and promotes the rounded morphology. 
Applying NMR metabolomics to murine melanomas and human A375M2 melanoma cells we identify a 
substantial shift from glutamine metabolism to anaerobic respiration as the main effect of ROCK 
inhibition/silencing/knockout with substantial reductions in intracellular glutamate and myo-inositol and 
increases in saturated lipids and the methyl groups of lipids also detected.  
Further, analysis of glucose or glutamine-glutamate metabolism gene expression in melanoma patients 
reveals a greater dependence on the Warburg effect in primary tumours. Glutamine utilisation, 
correlated with ROCK, increases during metastasis.  
In the final section of this work, we show that ROCK1/2 silenced morphological, proliferative and 
metabolomic phenotypes in A375M2 cells are reproduced by silencing selected glutamate and/or 
glutamine transporters and, respectively, inhibition and silencing of AMPA and kainate receptors. It is 
possible that autocrine ionotropic glutamate receptor mediated signalling underpins ROCK dependent 
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Chapter 1 : Thesis Summary
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Cancer is currently the leading cause of death in the UK (1) and while incredible advances have been 
made in the treatment of the disease, challenges still remain with regards to non-response to therapies 
and resistance that develops in patients. Thus there is still a need for new research into alternative 
targeted therapies. Melanoma Is the fifth most common form of cancer in the US and, while much less 
common in the UK, incidence has risen 400% since the 1970s (2). Rho Kinase (ROCK) has recently 
been suggested to be a therapeutic target of melanoma (3,4) and while its role in regulating the actin 
cytoskeleton and melanoma proliferation (5) are well established, much less is known about its 
regulation of cancer cell metabolism. Since metabolomics has now become an established part of 
biomedical research and NMR metabolomics is a highly reproducible, low cost method of conducting -
omic levels studies of the metabolism of biological systems, the aim of this thesis is to address this gap 
in knowledge and conduct a metabolomic level study of melanoma cell metabolism after perturbing 
ROCK activity. Understanding the metabolic pathways that are altered by ROCK activity will give 
additional leads for further research into melanoma cell metabolism during disease progression and 
metastasis. The following paragraphs outline the chapter structure of the thesis.  
Chapter 2 establishes the framework for this thesis. It will review the history and research background 
of first cancer metabolism and then NMR metabolomics, examining the history, sample preparation and 
data analysis required for successful metabolomic studies. It will then review malignant melanoma, the 
development of treatments of melanoma and current trends in targeting the metastatic cascade for 
therapy. Particular focus will be spent on cancer cell migration strategies and the Rho/ROCK signalling 
pathway, which promotes cancer cell invasion as well as melanoma proliferation. Finally, the available 
literature linking Rho/ROCK signalling to cancer metabolism will be examined.  
Chapter 3 will detail the materials and methods used in this thesis with overviews of the data processing 
and pattern-recognition systems used in this thesis.  
Chapter 4 is an NMR metabolomic study of ROCK activity in an in vitro model of metastatic melanoma. 
We will use the following strategies to interfere with ROCK activity or expression and study both whole 
cells with HR-MAS NMR and a liquid NMR study of the spent cell culture media: 
 
 
 Small Molecule inhibition of ROCK activity in human A375M2 melanoma cells 
 Silencing ROCK expression via siRNA in human A375M2 melanoma cells 
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 Genetic deletion of ROCK in a spontaneous murine model of malignant melanoma 
The NMR metabolomics data combined with network analysis suggest that ROCK regulates 
intracellular levels of glutamine, glutamate and glutathione amongst other metabolites involved in lipid 
and inositol biology. ROCK1 and ROCK2 Knockout murine melanoma cells had distinct metabolic 
profiles, pointing to both redundant and unique regulation of metabolism by the two isoforms. These 
metabolic changes seem to be additive in the double knock-out model. ROCK inhibition leads to an 
increase in the Warburg effect, which can possibly be explained as a response to increases in 
oxidative stress resulting from ROCK inhibition and/or to make up for the loss of glutaminolysis. 
Melanoma cells were also observed to secrete glutamate, which points to the importance of glutamate 
in melanoma not just as a metabolite, but also as a signalling molecule.  
Chapter 5 aims to address whether the data collected in chapter 4 can be applicable to the clinical 
setting. A conceptual integration of the metabolomic data and publically available transcriptomic data 
from melanoma patient microarrays is used to conduct a bioinformatics based search for potential 
therapeutic targets of metastatic melanoma. Echoing the experimental results of the previous chapter, 
the results point to the importance of glycolysis in primary tumour formation in melanoma while 
glutamine and glutamate metabolism plays a more important role in metastasis compared to primary 
tumours. Glutamine transport genes’ expression also correlated with ROCK expression in melanoma 
patients and genes from both glycolysis and glutamine metabolism correlated with poor patient 
outcomes. 
Chapter 6 returns to in vitro studies of metastatic melanoma, this time focussing on how interfering with 
glutamine/glutamate metabolism or glutamate signalling alters melanoma cell proliferation, morphology 
and metabolic profiles. siRNA and small molecule inhibitors targeting different stages of glutamine and 
glutamate metabolism as well as glutamate signalling are studied. siRNA knockdowns of genes involved 
in glutamine absorption and small molecule inhibition of glutaminase indicate that the ability of cells to 
maintain glutamine influx is essential for cell proliferation. Additionally, siRNA knockdowns of genes 
involved in glutamine and glutamate efflux suggest extracellular glutamine/glutamate to play a role in 
maintaining a rounded morphology in melanoma cells.  
Antagonists of ionotropic glutamate signalling are shown to effectively inhibit cell proliferation at low 
does and siRNA knockdowns of an ionotropic glutamate receptor gene (GRIK2) is shown to regulate 
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cell morphology and actomyosin contractility in both human and mouse melanomas, while not 
affecting cell proliferation. 
Chapter 7 concludes this thesis with a short discussion of all the collected data, suggests a model for 
how ROCK regulation of proliferation and actomyosin contractility may involve autocrine and/or 
paracrine signalling via ionotropic glutamate receptors and proposes future research directions. 
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Chapter 2 : Introduction, Background, and Review
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2.1 Cancer and Therapy 
Cancer has now surpassed cardiovascular disease as the leading cause of death in the UK. In 2014 
there were 147,000 cancer related deaths, accounting for 29% of total deaths in the UK (1). However, 
breakthroughs in cancer awareness, prevention, diagnosis and treatment have resulted in an 8% 
decrease in cancer deaths for women and 11% decrease for men since 2004 in the UK(1). This is a 
testament to the resources dedicated to medical research and the resulting discoveries. 
Cancer is a broad group of diseases characterised by uncontrolled cell proliferation with the potential 
to spread to secondary sites in the body. This process is known as metastasis (6). Great strides have 
been made in the last 40 years in understanding the molecular mechanisms driving the disease, which 
have permitted drastic improvements in diagnosis and treatment. For example, understanding the 
V600E BRAF (B-Rapidly Accelerated Fibrosarcoma) mutation in human melanoma demonstrates how 
understanding the biochemistry of cancer has translated into new hope for patients in the clinic. The 
last five years have seen the arrival of therapies such as vermurafenib which targets the V600E BRAF 
mutation present in 50% of human melanomas(7). There are also several other cancer therapies 
coming onto the market which would have been unthinkable just a decade ago; since 2011 seven 
immunotherapies that activate patient immune responses to melanoma have been approved for clinical 
use by the FDA(8). 2015 also saw a first in kind re-engineered viral therapy to target malignant 
melanoma cells approved by the FDA(9).  
Despite these many exciting developments, several challenges remain. The incidence of certain 
cancers such as invasive breast, prostate and melanoma continue to increase (Figure 2.1). In the past 
ten years they have increased by 4%, 5% and 46% respectively (10).  
There were 14,500 new cases of malignant melanoma in the UK diagnosed in 2013 (2). This rise in 
cancer incidence can largely be attributed to the increased life expectancy in the developed world as 
cancers are, for the most part, age-related diseases. In the specific case of melanoma, increased 
incidence can be attributed to increased exposure to ultraviolet radiation (UV) through exposure to sun, 
or artificially via sunbeds (11). Resistance to available therapies has always been an issue in the clinic. 
Amongst patients treated with vermurafenib, resistant tumours present within 6-7 months and 15% of 
patients treated do not respond (12). In addition, vermurafenib is only effective for patients whose 
melanomas harbour the V600E mutation of BRAF which is present in 50% of human melanomas (7). 
Patients treated with immunotherapies have shown a response rate between 45-52% (13) meaning that 
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a need remains for alternative therapies for the large number of patients who do not respond to currently 
available treatments. There is also a need to address how to treat not just the primary tumour but distant 
metastases. Current treatments have been suggested to increase the number of circulating tumour cells 
as the primary tumour is targeted, increasing the risk of metastasis (14). 
 




2.2 Oncology and Cancer Cell Metabolism 
One potential avenue of research in oncology, which could reveal novel therapies for disease, is to 
target the altered energetics of tumour cells. Indeed, this thesis aims to study how cancer cell 
metabolism is altered in melanomas with higher metastatic potential. To help understand the purpose 
of this work, it is helpful to understand the history of our understanding of cancer metabolism and the 
direction this field of research has taken.  
In 1923 Otto Warburg first reported that even in the presence of oxygen, tumour cells preferentially 
fermented glucose to lactic acid rather than converting it to pyruvic acid and channelling it into the more 
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efficient TCA cycle(15). He continued this line of research for decades and this observed phenomenon 
was denoted ‘The Warburg Effect’ in his honour (16). 
 
Figure 2.2. The Warburg Effect. Even in the presence of oxygen, many tumour tissues and cells preferentially 
generate energy through glycolysis. This effect is observed by the secretion of large amount of lactic acid. Figure 
reproduced with permission from (15). 
 
 
In his 1956 lecture he argued that cancer originates by two phases (17); the first being an ‘injury to 
respiration’ followed by the struggle of these injured cells to survive. Those that survive adopt anaerobic 
glycolysis as a metabolic strategy and have the side effect of rapid proliferation. Interestingly he 
concludes his lecture with this statement: 
 
‘From this point of view, mutation and carcinogenic agent are not alternatives, but empty words, unless 
metabolically specified. Even more harmful in the struggle against cancer can be the continual 
discovery of miscellaneous cancer agents and cancer viruses, which, by obscuring the underlying 




It is interesting that, just three years after the publication of the structure of DNA, Warburg was so 
adamant that the only way to eventually reach a cure for cancer would be to target the damaged 
respiration of these cells. He maintained this stance of altered respiration as the prime cause of cancer 
well into 1966 (18), just a few years before his death. 
Vander Heiden et al 2008
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His strong stance was erroneous as in the following years the genetics of cancer took the main focus 
of biochemical and biomedical research. The discovery of the src oncogene in 1970 initiated a string of 
discoveries of the genetics of oncogenesis that continues in our ‘post-genomic’ era. This is not to say 
that studies into cancer metabolism halted completely. In fact, there has been a steady increase in the 
number of papers published regarding cancer metabolism year on year. One example of the 
development of research into cancer metabolism was the discussion between Warburg and Weinhouse 
on whether oxidative phosphorylation still occurred in tumour tissue despite increased glycolysis. 
Isotope studies showed that the high glycolytic rate in tumours occurs despite normal levels of oxidative 
phosphorylation (19). 
 
Figure 2.3. PubMed search results of the number of research papers published per year which contain the words 
"cancer" (in black) or "cancer metabolism" (in red). After 1980 there is a steady increase in publications regarding 
cancer metabolism.  
 
 
It is only in the mid 1980’s that we see a sharp transition in the number of published papers investigating 






What has led to this growth of interest into cancer metabolism? There may not be any one definitive 
answer, however the development of technical platforms that allow for large scale studies of the 
metabolism of biological systems has contributed greatly to the renewed interest of studying cancer 
metabolism. In the early 20th Century Otto Warburg measured glucose and lactate using biochemical 
assays such as the Hagedorn-Jensen method for estimating glucose concentrations (20). Today’s 
researchers have much more powerful tools such as mass spectrometry and nuclear magnetic 
resonance (NMR) spectroscopy available to obtain a biochemical ‘snapshot’ containing hundreds and 
even thousands of small molecules of their system of interest, discussed below.  
2.3 Altered Energetics of Cancer Cells 
The Warburg effect was the first metabolic pathway dysregulated in many cancer types to be 
understood. Since then there have been several other pathways and metabolites that are understood 
to be changed in different cancer types.  
 
Figure 2.4. ‘The Emerging Hallmarks of Cancer Metabolism’. Cancer cells rewire their metabolism to facilitate the 
behavioural changes in cancer cells. These can be largely categorised by increased nutrient uptake, 
reprogramming of intracellular metabolism, and metabolite directed changes in cell behaviour and/or function. 




Pavlova et al propose six ‘emerging hallmarks of cancer metabolism’ (21). These are: 
1. Deregulated uptake of glucose and amino acids 
2. Use of opportunistic modes of nutrient acquisition 
3. Use of glycolysis/TCA cycle intermediates for biosynthesis and NADPH production 
4. Increased demand for nitrogen 
5. Alterations in metabolite-driven gene regulation 
6. Metabolic interactions with the microenvironment.  
Cancers are a very heterogeneous set of diseases and do not necessarily present all six hallmarks 
simultaneously. Some specific examples are shortly discussed here. Many cancers seem to require 
exogenous glutamine to be able to sustain their increased levels of growth and proliferation. This 
phenomenon has been termed ‘Glutamine addiction’ (22). What makes it an interesting area for 
investigation is that glutamine is the most abundant amino acid present in the body and is a non-
essential amino acid for most cell types. However not all cancers are addicted to exogenous glutamine. 
For example, breast cancers display distinct levels of glutamine dependence. Basal-type breast cancers 
tend to be glutamine dependent while luminal-type breast cancers tend to be independent of glutamine 
(23). 
Another example of metabolic rewiring in cancer was demonstrated with the proposal of the first 
metabolic oncogene. Gain-of-function mutations in the Isocitrate Dehydrogenase genes IDH1 and IDH2 
have been found in up to 80% of gliomas(24) and mutant IDH2 is sufficient to induce tumorigenesis in 
several classes of glioma (25). These mutated enzymes lead to the aberrant presence of 2-
hydroxyglutarate (2-HG), which has been coined as an onco-metabolite. 2-HG is currently being 
clinically tested as a biomarker for gliomas (clinicaltrials.gov ID: NCT02388659). While the functional 
effects of this onco-metabolite are still being studied, it is already recognised that 2-HG interferes with 
the activity of TET (Ten-eleven translocation) hydroxylases which are responsible for the removal of 
DNA methylation (25).  
The rewiring of cellular metabolism by cancer cells has many clear advantages in that it allows cells to 
sustain increased biosynthesis of building blocks for many aspects of cell growth and proliferation. It 
can also allow cells to avoid apoptosis by regulating reactive oxygen species and down-regulating pro-
apoptotic signalling. The downside to this is that increased growth and proliferation lead to large 
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increases in energy demands and toxic metabolites such as lactate can accumulate either intracellularly 
or in the extracellular environment (16).  
2.4 Metabolomics 
The idea of using metabolic features to study biological systems can be traced all the way back to the 
idea that changes in biological fluids (humours) were indicative of diseases in the time of ancient 
Greece. In the middle ages of diagnostic ‘urine wheels’ linking various colours, smells and taste of urine 
to various pathological conditions (26). The term ‘metabolome’ appears first in the 1998 study by Oliver 
et al. (27) and the term was further defined by Oliver Fiehn in 2002(28) as ‘the set of metabolites 
synthesised by an organism’. The field of metabolomics is thus the study of the metabolome. 
 Additionally, a slightly different field of study of metabolic responses of organisms to diverse stimulation 
was defined as the field of metabonomics by Jeremy Nicholson in 1999 (29): 
 
`the quantitative measurement of the dynamic multi-parametric metabolic response of living systems to 
pathophysiological stimuli or genetic modification’   
 
As in most fields, the formal definition that facilitates deeper discussion is usually proposed once a body 
of research has been established that requires definition. Thus it is not a straightforward task to 
establish when the metabolomics field began. The first paper using the phrase ‘metabolic profile’ was 
published in 1971 by Horning and Horning (30) just a year after the death of Otto Warburg. There are 
also many examples of metabolomics type studies in the 70s, 80s and 90s, mainly developing the 
platforms and technologies that are still used today. Linus Pauling himself dabbled in some 
‘metabolomic’ work; in 1971 he published work attempting metabolic profiling of urine and breath vapour 
by gas-liquid partition chromatography (31). 
NMR had also been used to study complex mixtures of biological systems well before metabolomics 
was defined. In the 1970’s there are examples of NMR being used to study the pH of animal blood by 
31P NMR (32), red blood cell metabolism by 1H spin echo NMR (33), and of whole organs (34). 
However, these types of studies weren’t widely adopted until the development of higher field magnets 
and the appropriate computational methods that make these techniques more accessible to biologists 
rather than specialist chemists or physicists.  
Currently the main methods used for metabolomic studies are Mass Spectrometry (MS) coupled with 
Chromatography (liquid or gas) and by NMR (35). Each method has its respective advantages and 
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disadvantages (Table 1). NMR is a highly reproducible technique that can process samples within a 
few minutes in a non-destructive manner(36). However, its main limitation is its low sensitivity. MS is a 
highly sensitive technique that can reveal information on thousands of different metabolites. The main 
challenges associated with MS are questions about reproducibility(37) and the identification of 
metabolites in the signal. There are other lesser used methods, such as Fourier Transform Infrared 
Spectroscopy (FTIR) (38) and Raman Spectroscopy (39,40), however they will not be discussed here 
as they are beyond the scope of this thesis.  
 
Table 1. Comparison of Mass Spectrometry, NMR and HR-MAS NMR for Metabolomic studies. 
 
 
The growth of the field has led to many more systematic investigations to establish optimal methods 
and protocols for various metabolomic methods and various centres have been developed across the 
world spearheading these methods. The development of the field of metabolomics and a resurgence in 
interest in cancer cell metabolism has led to the acceptance of the recognition of the altered energetics 
of cancer cells as an emerging hallmark of cancer in Weinberg and Hannahan’s 2011 update to their 
seminal review of the hallmarks of cancer (41). These topics were then expanded in more cancer 
metabolism specific reviews referenced above (Figure 2.4)(21). 
Metabolomic studies can be designed to be non-targeting, aiming to gain a general picture of the 
biological system of interest (35); these types of studies are used to generate hypotheses for further 
investigation. Following these studies, metabolomic methods can often be altered for a targeted study 
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introduced into the system and how they are metabolised can be studied. These targeted ‘flux’ studies 
can be used with mass spectrometry (42) and, to a lesser extent, NMR (43). 
Metabolomics methods are very flexible and have been applied to clinical studies (44) as well as basic 
biological research, to gain more mechanistic knowledge into biological systems of interest (45).  
2.5 Nuclear Magnetic Resonance Spectroscopy 
NMR is a technique that has found applications in a wide range of physical, chemical and biological 
research. In metabolomics it has proven to be a highly reproducible technique with the added benefit 
of not destroying the samples of interest. The following section, while not an exhaustive review, will give 
a short overview of the theoretical and practical aspects of applying NMR to metabolomics research, in 
particular the study of whole cells with High Resolution Magic Angle Spinning NMR (HR-MAS NMR).  
2.5.1 Theory 
The theory of NMR can be broadly explained by classical models. However, more in depth 
understanding of NMR requires an understanding of quantum mechanical models, which goes beyond 
the scope of this work. In this brief description of the physics driving NMR, we will be using the classical 
vector models.  
NMR spectroscopy takes advantage of the behaviour of the magnetic properties of atoms. Atomic nuclei 
are comprised of protons and neutrons and are thus positively charged. Any object with an electrical 
charge creates a magnetic field. The magnetic moment arises from the inherent angular momentum or 





Figure 2.5. Atomic nuclei with non-zero spin can release detectable electromagnetic energy. A) A nucleus placed 
in a static external magnetic field will ‘spin’ or precess with a certain frequency. When a second perpendicular 
electromagnetic field is imposed, the nucleus can absorb this energy and ‘flip’ its spin state. When B1 is removed, 
nuclei may return to their original natural state (relaxation) and will release the absorbed energy in the process. B) 
The energy required to induce a change in orientation is dependent on the strength of the external magnetic field 
B0 . 
 
If the number of protons and neutrons are equal in the nucleus, then the total spin state is equal to zero. 
However, if the number of protons and neutrons are not equal then the spin state is non-zero. Therefore, 
certain nuclei ( 𝑯𝟏 , 𝑪𝟏𝟑 , 𝑷𝟑𝟏 , 𝑵𝟏𝟓 ) possess a non-zero spin. The most commonly studied nucleus is the 
hydrogen atom (1H) comprised of a single proton. We can imagine the hydrogen atom (comprised of a 
single proton) as an object with its spin represented as a vector. 
When placed in a static external electrical field, if the magnetic moment of the nucleus does not oppose 
the applied magnetic field it is said to be in the lower energy level. In this magnetic field, the nucleus 
precesses around the magnetic field (Figure 2.5A). The frequency of this precession is called the 
Precessional Orbit









Magnetic Field  𝟏
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Larmor precession frequency. When the electromagnetic radiation applied is equal to the Larmor 
precession frequency, resonant absorption can occur. When the nucleus absorbs energy, the magnetic 
moment of the nucleus ‘flips’ to oppose the applied field, and this is termed the higher energy state. The 
energy required to induce a change in orientation corresponds to the energy difference between the 
two orientations and depends on the strength of the magnetic field (  , Figure 2.5B) in which the 
nucleus is placed. This can be described by the following equation: 
𝜟𝑬 =  𝜸𝒉  /𝟐𝝅 
where 𝒉 is Planck's constant (𝟔. 𝟔𝟑 ∗  𝟏𝟎−𝟐𝟕 𝑱 𝒔)    is the strength of the magnetic field and 𝜸 is the 
gyromagnetic ratio (26.7522128 ∗  107 𝑟𝑎𝑑 𝑇−1𝑠−1 for proton). The transition from the lower energy state 
to the higher energy state absorbs energy while the transition from the higher energy state to the lower 
energy state emits energy. At the Bohr condition (𝜟𝑬 =  𝒉𝝂), where the angular momentum is an integer 
multiple of 𝒉 the frequency 𝝂  of the nuclear transition can be written as 
𝝂  =  𝜸  /𝟐𝝅 
Thus far we have only been considering a single nucleus. In an experimental sample we deal with many 
more nuclei, each which their own magnetic moment. At this scale we then deal with bulk magnetization. 
When all the individual magnetic moments are averaged out, we can visualise the bulk magnetisation 




Figure 2.6. Bulk magnetisation and the classic NMR experiment. A) when all the magnetic moments in a sample 
are averaged out, the resulting bulk magnetisation can be visualised as a vector. B) In the classic NMR experiment, 
a perpendicular electromagnetic pulse is applied to the sample so as to induce a 90˚ change in orientation of the 
bulk magnetisation. This is known as the 90 ̊pulse. When the pulse is switched off, the sample ‘relaxes’ back to its 
original orientation emitting the induced voltage. C) this relaxation can be detected by a receiving coil around the 
sample. The resulting data presents itself as a wave function of time and is known as the Free induction decay 
(FID). This data can be Fourier transformed into a function of frequency. This mathematical transformation is what 
gives the typical NMR spectra.  
 
In the simplest NMR experiment, a radiofrequency pulse of the same frequency of the nuclei of interest 
is applied perpendicular to   . The duration of the pulse is enough that the bulk magnetisation is tilted 
by 90˚, thus the name of the 90˚ pulse. Nuclei then absorb energy and when the radiofrequency pulse 
is removed, the nuclei ‘relax’ back into their natural state and release energy as a radio wave (Figure 
2.6C). This energy can be detected by a receiver coil in the NMR magnet and the resulting data presents 























2.6C). This data can be mathematically manipulated, namely via Fourier transform, which transforms 
the wave function into a function of frequency. This transformation gives a resulting NMR spectra which 
is then used for analysis.  
NMR is a very powerful technique that has the main strength of being highly reproducible. However, 
one of its major limitations is its lack of sensitivity. This limitation is an inherent part of NMR and can be 
explained by the population distributions of spin states in a sample.  
The energy difference between the spin states in hydrogen can be used in the Boltzmann Equation to 
calculate the population distributions. The occupancy of spin states can be described by a Boltzmann 
distribution: 
𝑵𝜷/𝑵𝜶 =  𝒆−𝜸  /𝒌 𝑻 
Where 𝑵𝜷 and 𝑵𝜶 represent the population of nuclei in upper and lower energy states, 𝒌  is the 
Boltzmann constant, and 𝑻 is the absolute temperature (K). The signal intensity any spectroscopic 
method depends on the population difference between the two energy levels 𝑵𝜷 and 𝑵𝜶. NMR is a low 
sensitivity technique due to the ratio between 𝑵𝜷 and 𝑵𝜶 being close to 1. For example, with a 500MHz 





1.380662∗10−23 JK−1∗293K  =  0.999485259… 
This means that the upper and lower energy states are almost equally populated and thus cancel each 
other out(46). It is only in the population difference of spins where a net absorption or release of energy 
is detected and makes up the signal intensity in NMR. This factor describes the relative low sensitivity 
of NMR and represents a limitation for the application of NMR to biological systems.  
As seen from the equations of the Boltzmann distribution, the use of stronger magnetic fields will 
increase the population ratio and consequently the resolution of the NMR spectra (47). In addition, the 
signal to noise ratios (S/N) of spectra can also be improved by increasing the number of nuclei in the 
sample, e.g., by raising the concentration (without causing molecular aggregation) or by increasing the 
volume of the sample detected. These are some of the strategies that can be implemented to improve 
the quality of NMR spectra (48). 
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2.5.2 Chemical shift 
When a molecule containing the nucleus of interest is put in a magnetic field 𝐵𝑜, the electromagnetic 
theory dictates that the 𝐵𝑜 field induces electrons in the molecule to orient themselves into a plane 
perpendicular to the applied magnetic field. The induced currents will then determine a small magnetic 
field that is opposed to the applied field. These partially cancel the applied field, thus shielding the 
nucleus. The resonant frequency at which a particular nucleus achieves resonance is determined by 
the effective magnetic field at the nucleus. The effective magnetic field is affected by electron shielding 
which in turn is derived from the surrounding chemical environment. Thus, information about the 
chemical environment of a nucleus can be obtained from its resonant frequency (ν in Hz), called 
chemical shift (δ in ppm) when compared to a standard which is usually spiked into the sample of 
interest.  
The chemical shift of any resonance is independent from the strength of the applied magnetic field. 
However, any factor which alters the electron density around the proton will affect the chemical shift, 
causing either shielding (up-field shift), or de-shielding (downfield shift in resonance). For example, the 
presence of α-electronegativity groups linked by covalent bonds, decreases the electron density 
surrounding the nucleus and reduces the shielding in the 1H resonance. Other examples include 
noncovalent effects such as the presence of neighbouring π-bonds, called ring-current shift. The 
chemical shift is also affected by hybridization effects, by the solvent and H-bonding (49,50).  
While chemical shifts for the resonances do not change with increasing field, the actual frequency 
differences do increase and therefore peaks are narrower at higher field strengths (50). Thus there is 
less risk of overlapping peaks which reduce S/N in NMR studies. For this reason, as well as the effect 
on the Boltzmann distribution mentioned above, there is a general interest in creating and making use 
of machines capable of generating ever more powerful electromagnetic fields. Experiments in this thesis 
were performed at 1H frequencies of 400 and 700 MHz.  
There are additional methods in development attempting to overcome the low sensitivity of NMR, in 
particular Dynamic Nuclear Polarisation (DNP) NMR. DNP NMR is an exciting development that can 
hopefully increase the sensitivity of NMR experiments. In short, by irradiating the sample with 
microwaves, magnetisation transfer can occur between unpaired electrons to nuclei, increasing the 
nuclear signal (51). What is exciting about DNP NMR is that it can theoretically increase the sensitivity 
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of NMR experiments by a factor of 104 for 13C experiments and 103 times for 1H experiments (52). 
Although still in its infancy, initial work exploring how DNP NMR can be applied to metabolomics (53,54). 
Other experiments have been conducted using hyper-polarised metabolites to improve sensitivity in 
magnetic resonance imaging (55). 
2.5.3 Solid-state NMR: dipolar coupling and magic angle spinning 
Solid-state NMR spectroscopy is another available method to investigate biological samples and detect 
and quantify small molecule metabolites of a biological system of interest. The most visible difference 
between the NMR in solution and solid-state NMR is that in solid-state NMR  transitions are broad, due 
to the full or partial effects of orientation-dependent interactions (anisotropy) being observed in the 
spectrum and shorter 𝑇2 transverse relaxation times due to the restricted motion of the molecules(47). 
In solution, spectra consist of a series of sharp transitions because orientation dependent contributions 
are usually averaged out (56). Specifically, factors that determine line broadening and a loss of spectral 
resolution in solid-state NMR are heteronuclear and homonuclear dipolar coupling between 
neighbouring nuclei, the chemical shift anisotropy and, for nuclei with 𝐼 >  
1
2
, the electric quadrupole 
interaction (57). 
The dipolar coupling comes from the interaction through space of one nuclear spin with a magnetic field 
generated by another nuclear spin, and vice versa. This coupling is stronger than spin-spin coupling, 
which instead is through bonds. The size of the interaction is related to: the inter-nuclear distance, 
inversely dependent on the distance between the nuclei; the gyromagnetic ratio of the nuclei; and the 
orientation of the inter-nuclear vector relative to the applied field Bo. In an isotropic liquid the molecular 
orientations are quickly changed by Brownian motion, thus averaged out and not observed. In crystals 
and solids molecular motion is restricted and this leads to NMR signals being split with a coupling 
constant (47).  
Dipolar couplings can, to a certain extent, be removed in high-resolution solid-state NMR by rapidly 
rotating the sample about an axis oriented at an angle of 54.7356° degrees (the diagonal of a cube) 
with respect to the axis of the static magnetic field    (Figure 4). This is called the “magic angle” and 
therefore the technique is denoted magic-angle spinning (MAS).  In the case of biological samples, the 
molecular motion within the semi-solid samples also partially removes some of the anisotropic 
interactions, as well as average out differences in magnet field inhomogeneity and magnetic 
susceptibility within a biological sample. Magnetic susceptibility is a dimensionless proportionality 
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constant that indicates the degree of magnetisation of a material in response to an applied magnetic 
field.  
2.5.4 HR-MAS NMR 
High-resolution Magic Angle Spinning solid-state NMR is a particular method of NMR that mechanically 
averages the anisotropic spin interactions by rotating a sample in a rotor. The rotor is set at the 'magic 
angle', which is 54.7356° with respect to the z axis of the static magnetic field. This is the angle that is 
made by the cross diagonal of a cube. Any point on this diagonal now has identical x, y, z coordinates 
and thus the anisotropic detail is lost (58). By increasing the spinning rate, the broad lines from the 
immobile sample become increasingly narrowed with a significant improvement in the signal amplitude 
and sensitivity. When the spinning rate is higher than the width of the anisotropically broadened NMR 
spectrum, the spectrum collapses to an isotropic-like spectrum (58). It should be noted however that 
these high spinning rates are only required to displace spinning side bands outside the spectral range 
of interest in metabolomics studies (59). 
As conditions can be created with solids that generate NMR spectra similar to liquid state NMR, HR 
MAS-NMR can therefore be used as a highly versatile tool to analyse complex biological systems such 
as intact tissues and whole cell samples (60,61). 
 
Figure 2.7. A Comparison of NMR spectra obtained on Mouse melanoma cells with (top) and without (bottom) MAS 
spinning. Tilting the samples at the ‘magic angle’ and spinning at high velocity narrows NMR peaks to become 







The ability to study whole cells and tissues represents a major advantage of HR-MAS NMR over liquid 
state NMR, despite its inability to achieve the spectral resolution of liquid-state NMR. Another advantage 
to studying whole cells and tissues over liquid state NMR is that HR-MAS NMR does not require the 
extensive extraction protocols used in liquid state NMR. In addition, whole cells can be lyophilized and 
re-suspended directly in deuterium oxide before insertion into an NMR insert (Figure 6) significantly 
reducing the amount of residual water in the sample. This increases the reproducibility and reliability of 




Figure 2.8. Workflow for in vitro whole cell HR-MAS NMR Metabolomics Studies. Whole cell studies remove the 
need for metabolite extraction protocols thus increasing reproducibility of experiments. A) Cells grown in culture 
are harvested, pelleted and snap frozen in liquid nitrogen. Pellets are then suspended in D2O transferred to HR-
MAS inserts and inserted into the NMR magnet. B) Once in the NMR magnet, the sample is tilted at the ‘magic 




Liquid state NMR requires molecules to be in solution to obtain spectra of good resolution, therefore 
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that produce broad linewidths in the resulting NMR spectra. Additional methods can also separate polar 
and non-polar phases of the sample. These protocols add complexity to experimental set ups and often 
make use of carcinogenic chemicals such as chloroform, although alternatives are available, such as 
methyl-tert-butyl ether (MTBE). Each additional step of protocols also introduces the opportunity for 
human error in sample handling. A final challenge arises in the case of experiments with adherent cell 
lines as there is the concern for metabolite leakage when attempting to detach the cells from a plate(62).  
There are several studies that have investigated optimal methods for metabolite extraction (62,63), 
while other methods attempting to eliminate the solvent extraction steps have been proposed, instead 
making use of sonication of samples (63). In certain studies, HR-MAS has been shown to be preferable 
to solution state NMR as it also gives information on lipid profiles as well as information on small polar 
metabolites (64). Although it should be noted that issues with spectral peak overlap are an issue with 
HR-MAS NMR.  
On the other hand, whole cell NMR means that there is potential for polar and nonpolar components of 
cells to overlap each other in the NMR spectra. This can become a problem as changes in metabolite 
concentrations can become masked by overlapping peaks. Extraction protocols can remove this issue 
as the different phases can be investigated separately, increasing the number of observed metabolites. 
These considerations must be taken into account when designing metabolomic studies.  
The reliability of metabolite stability can be an issue with metabolomic work as several steps are taken  
2.5.5 Pulse sequences 
Methods for reducing the contributions of large macromolecules to NMR analysis have also been 
developed with alternative pulse sequences to the standard 1D NMR experiment. The most widely used 
is the Carr-Purcell-Meiboom-Gill sequence (CPMG). As mentioned earlier, large macromolecules have 
very short 𝑇2 relaxation times due to restricted motion of molecules. This leads to broad lines that can 
overlap with other peaks, reducing the amount of information that can be obtained from an NMR 
spectrum Figure 2.9A.  
The CPMG pulse sequence takes advantage of the phenomenon known as the Hahn echo. The pulse 
sequence is comprised of a 90˚ pulse, which forces the nuclei into the transverse plane, a 180˚ inversion 
pulse, which flips the nuclei vectors, and after time tau the Hahn echo appears, which is when the nuclei 
become perfectly phased again. This refocussing of the magnetisation vectors can improve the signal 
in the NMR spectra that can arise due to both inhomogeneity in the magnetic field as well as the short 
 26 
 
𝑻𝟐 relaxation times that arise due to large macromolecules in a sample (Figure 2.9B)(59), thus 
facilitating the observation of low molecular weight metabolites. If the 180˚ pulse is repeated multiple 
times, the echo can be repeated, however there is a loss of signal with each successive 180˚ due to T2 
relaxation. This phenomenon can be taken advantage of as one can thus repeat the 180˚ and only 
record once the initial signal from large macromolecules, which have very short T2 relaxation times, is 
edited out. 
 
Figure 2.9. The Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence can edit out broad peaks in NMR spectra 
through 𝑇2filters. A) Large macromolecules have short T2 relaxation times which lead to broad signals in the Fourier 
transformed spectra. The contribution of these signals to the NMR spectrum can be edited out by taking advantage 
of the Hahn echo. B) When a 90-degree pulse is put onto a sample different nuclei relax at different rates, leading 
to a dephasing of the magnetisation vectors. The introduction of a 180-degree pulse allows the magnetisation 
vectors to refocus and leads to generation of the spin echo. The 180 degree pulses are repeated to filter out the 

















A final consideration has to be made for the large amount of water in biological samples. In HR-MAS 
NMR there is often a large amount of residual water in the sample that requires suppression. As stated 
previously water can be removed from the sample through lyophilisation, however it is nearly impossible 
to completely remove all water from a sample. In a standard CPMG experiment this is achieved through 
pre-saturation which is achieved by a long low pulse targeting the frequency of the solvent prior to the 
initial pulse sequence (Figure 2.9C) (36).  
2.6 Data Processing in NMR Metabolomics 
2.6.1 Data Pre-Processing 
Once NMR data is collected, the spectra must be pre-processed prior to analysis to reduce as much as 
possible the entry of noise into the successive analysis. Spectra are base-line adjusted, phased, aligned 
and binned prior to analysis.  
In this thesis, we make use of the software for NMR analysis developed in the Mason lab that have 
been previously published (65-68). There are several developments that have been added that should 
be considered. Those are the introduction of more advance alignment and binning algorithms into the 
analysis pipeline that hadn’t previously been used. Previous work resorted to basic alignment methods 
and occasionally making use of correlation optimized warping (COW) algorithm (69) and manual 
bucketing methods. 
Alignment of NMR spectra is important to ensure that pattern recognition methods used are not simply 
observing a change in pH as a signal in the analysis. There are several alignment algorithms available, 
reviewed by Vu and Laukens (70). Currently there is no accepted golden-standard method. The 
Correlation Optimised Warping (COW) algorithm has previously been used in the Mason group for 
spectral alignment, however it is very computational intensive and slows data processing considerably. 
For alignment of one dimensional NMR spectra we made use of the Icoshift algorithm (71) as it proves 
to be much faster computationally than COW and gives comparable results (70). 
Binning allows a reduction in data size when analysing NMR spectra which can speed up analysis and 
further force spectra into alignment. However, it does not handle larger peak shifts, for example shifts 
caused by variation in pH between samples. The optimized bucketing algorithm (OBA)(72) allows the 
user to set the initial bucket size as well as the ‘slackness’ or the percentage of variability the algorithm 
is allowed when choosing the final bucket size in its search for local minima. Implementing these two 
features into our pre-processing pipeline has both greatly sped up pre-processing and increased the 
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reliability of the pre-processing compared to the previous manual bucketing and simple alignment tools 
used in previous publications of the Mason group. 
2.6.2 Multivariate Analysis of NMR Data 
Each one dimensional NMR spectrum is a collection of thousands to tens of thousands of data points. 
This increased complexity of the data requires specialised methods of data handling and multivariate 
statistical analyses to detect distinctions between groups of spectra depending on study design.  
 
Figure 2.10. NMR metabolomic data multivariate statistics. NMR spectra represent tens of thousands of data points. 
Data reduction and multivariate models of the data can aid researcher to identify patterns in data sets and find 
discriminatory variables between groups. Unsupervised statistics such as principle component analysis (PCA, 
above) allow for initial visualisation of data and the identification of outliers. Supervised Discriminant Analysis, in 
this case Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA) generates models of which features 
can be identified that discriminate between classes and traced back to the variables (metabolites) that are 
contributing to the separation between classes. This is visualised through the back-scaled loadings plot which is a 
pseudo-NMR spectrum showing which variables (chemical shifts) in the data sets correlate with a class (peak 
height) and if that correlation is highly weighted (colour of peak). 
 
 
The statistical methods used in interpreting metabolomic data have been reviewed extensively (73). 
The standard, accepted techniques in use are Principle Component Analysis (PCA), Partial Least 







Metabolomic studies generate quite large datasets and as such many different algorithms and machine 
learning methods can and have been applied to analyse metabolomic data. Some of these other 
methods are support vector machines (74), artificial neural networks (75), and random forests (76).  
Each of these methods has its respective strengths and weaknesses. While some analytical methods 
may have more predictive power, there is a high barrier of entry for many non-expert researchers when 
applying more complex machine learning algorithms to metabolomic data. Currently the vast majority 
of metabolomics analyses make use of PCA and PLS.  
Prior to multivariate analysis, data needs to be normalised and scaled to reduce variability between 
experiments as well as to avoid variables with highest signal intensity in dominating the data analysis. 
In addition, feature selection is an important aspect of data pre-processing to improve models generated 
in supervised machine learning algorithms. These pre-processing techniques will be discussed in 
chapter 3. 
2.6.3 Principle Component Analysis (PCA) 
PCA is an unsupervised algorithm that is used to reduce the number of dimensions of a given dataset 
to either increase computational speed or to more easily visualise high dimensional data. In PCA, the 
original variables are transformed into new variables called Principle Components which explain the 
largest possible amount of variation in the data. The data can be then plotted as points in a two or three 
dimensional space. This is known as the ‘scores plot’. The individual principle components are 
uncorrelated and orthogonal to each other, therefore each principle component represents independent 
variation within the data.  
Along with the scores plot of PCA, the contribution of individual variables to each principle component 
can also be visualised, this is called the ‘loadings plot’ and can give a picture of which original variables, 
or in this case which NMR resonances are contributing to the variation within the dataset. 
PCA is principally used for initial analysis of the data, visualisation of clustering patterns within the data, 
and identification of outliers within the data. As stated above, the loadings can be used to identify which 
NMR resonances and thus metabolites are contributing to the variation in the dataset. 
2.6.4 Partial Least Squares/ Projection onto Latent Structures (PLS) 
PLS is a supervised machine learning algorithm that creates a linear regression model that projects 
predicted variables and observed variables into a new space. The underlying model of the PLS 
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algorithm uses the original data matrices X and Y Where X is a 2-dimensional matrix of dimensions of 


















And is a decomposition of those matrices: 
𝑋 = 𝑻𝑃𝑇 + 𝐸 
𝑌 = 𝑼𝑄𝑇 + 𝐹 
T and U are matrices that are projections of X and Y respectively, these are the ‘scores’; P and Q are 
the orthogonal loading matrices, also known as the loadings when interpreting the data; E and F are 
the error terms. X and Y are decomposed to maximise the covariance between T and U.  In 2002 the 
Orthogonal Projection on to Latent Structures, a variation of the PLS algorithm was proposed(77). In 
OPLS, variation in X that is not correlated to Y is removed. Thus the OPLS model is: 
𝑿 = 𝑻𝑷𝑻 + 𝒕𝟏𝒑𝟏 + 𝑬 
𝒀 = 𝑼𝑸𝑻 + 𝑭 
 
Where t1 and p1 are the ‘Y-orthogonal’ projections of X that do not correlate with Y, while T and P are 
the Y-Predictive projections. Geometrically, this transformation can be imagined as rotating the data X 
to emphasize the variation in X that correlates with Y. This facilitates interpretability of the data; 
however, it does not improve the predictive ability of the algorithm. 
PLS and OPLS can create linear regression models when working with continuous variables. In the 
case of discrete variables, such as group classifications or comparing two groups, Discriminant Analysis 
is applied to the PLS or OPLS algorithm, hence the final term of OPLS-DA. In the work presented in 
this thesis, OPLS-DA is the main algorithm used which is calculated using the non-linear iterative partial 
least squares (NIPALS) algorithm. 
2.6.5 Cross Validation 
Modelling high dimensional data is a very powerful method to get information from very large datasets. 
However, there is always the risk that the generated models explain the given data too well, and include 
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random noise into the model. This leads to a poorly generalised model that will not perform well to other 
datasets. This is known as ‘over-fitting’ a model. Over-fitting is especially an issue in -omics level 
biological research as in most cases the number of variables available to the research vastly out scale 
the number of biological samples available and so the risk of random noise being interpreted as signal 
is a major issue that needs to be addressed in the study design. Over-fitting can be addressed through 
cross-validation, or a model validation method where the model is tested against an independent set of 
data (78).  
The standard method of cross validation is to split the available data into smaller subsets. Part of the 
data is used to generate the model and is known as the training set. Then the generated model is used 
to make predictions regarding the remaining data, known as the test set.  
In our studies we use a double cross validation strategy (2CV) (79) whereby the training set is again 
split into its own training and test sets and undergoes a cross-validation process to select the optimal 
number of components to generate the model.  This is followed by a model generation over the original 
training set and predictions on the original test set (Figure 2.11).  
 
Figure 2.11. The double cross validation method (2CV). Samples in the dataset are randomly assigned to either a 
test, validation or training set. In a first step a model is created using the training set and is tested on the validation 
set to select the optimal number of parameters for model construction. Then the training and validation sets are 
combined and used to generate a final model which is the tested on the test set.  
 
This process is repeated a few hundred or thousand times, and in each repeat samples are randomly 
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strategy as in the 2CV method the model is constructed in absolute absence of the test set. It is also 
important to note that pre-processing steps such as normalisation and scaling are conducted separately 
on the training and test sets to ensure independence between the two sets of data. A representative 
cross validated OPLS-DA output is seen in Chapter 3. 
2.7 Integration of -Omics data 
The field of metabolomics has matured to a point where it is now being adopted to be used as a piece 
of larger studies of biological systems. While individual –omics studies are very powerful tools that can 
generate hypotheses that would otherwise be overlooked in traditional research, there is even more 
hope that running the same samples on several –omics platforms contemporaneously can exponentially 
increase the amount of available data of the biological system of interest. In an idealised example one 
could design an experiment which integrates genomic data on single nucleotide polymorphisms (SNPs) 
and merge them with transcriptome, proteome, phosphor-proteome and metabolome to reveal how 
SNPs effect the downstream biochemistry of a system. It should be obvious that increasing the amount 
of data to such a scale will bring up increased challenges in separating the signal from the noise and in 
quality control and assurance of the data generated from each platform. In addition, bioinformatics 
platforms have to be able to process with relative speed the enormous amount of generated data. 
This field is very new and reviews on the topics are few. Cavill et al (80) suggest a theoretical framework 
on which the methods for multi-omics experiments can be conducted. They group the methods into 
three categories with differing levels of statistical power.  
The ever increasing size of data generated in biological studies requires novel methods of analysis and 
data integration. Currently used methods are mainly conceptual, with statistical integration becoming 
more routine. The end goal would be to generate mathematical models of biological systems informed 
and refined by empirical evidence. The computational requirements for creating these models are 
currently unrealistic for most cases. Those methods are 1) Conceptual based integration 2) Statistical 
Based integration and 3) Model based integration (Figure 8).  Conceptual based integration follows the 
more traditional path of scientific inquiry whereby datasets are analysed separately and hypotheses are 
made based on the data produced.  
Statistical based integration makes use of different methods to find patterns between data blocks to 
generate novel hypothesis. A method of statistical based integration that has received quite a bit of 
attention in recent years is Metabolome Genome Wide Association Studies (mGWAS) which attempts 
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to identify genetic alterations that cause changes in the metabolism of the biological system of interest 
(81). In genome wide association studies large numbers of genomes are sequenced in an attempt to 
find statistically significant gene alterations, often SNPs. These types of studies fall into the conceptual 
and/or statistical based integration of –omics data. Often previous knowledge of metabolic networks is 
used to perform network analysis of the genomic and metabolomic data. 
More powerful methods of statistical integration are the use of Multivariate models of multi-block 
datasets. Recent years have seen the development of computational methods allowing researchers to 
design studies that integrate different -omics techniques. A couple of examples of these methods are 
the Multi Block PLS algorithm (82) and the more recent consensus OPLS algorithm (83). Examples of 
the application of these statistical models are still few. As of May 2016 only five articles on PubMed cite 
the Consensus-OPLS algorithm.  
The work presented in this thesis falls under a conceptual integration of -omics data whereby the 
metabolomic data generated will inform a bioinformatics screen of how metabolic related genes are 
expressed in a panel of melanoma patients. More advanced methods of -omics data integration fall 
outside the focus of this thesis, however, they will be discussed as future avenues of research in 
Chapter 7.  
Finally, model based integration would aim to use generated data to build and refine mathematical 
models of biological systems of study. There is a growing field of research into whole cell modelling 
(84), bolstered by the rapidly growing field of synthetic biology. While historically these studies are 
mostly restricted to more simple systems of prokaryotes (85), there have been recent advances into the 




Figure 2.12. Integration of multiple -omics datasets can give greater information of a biological system than an 
individual dataset. A theoretical framework for –omics data block integration has been presented as follows: A) 
Conceptual integration of datasets where explanations of the observed phenomenon are given after analysing each 
dataset separately. In statistical integration associations between datasets can be found to explain a biological 
system. The optimal integration of -omics data would be to build mathematical models of systems that can explain 
biological phenomenon and used empirical data to refine the models. B) Statistical integration of diverse –omics 
datasets can be performed in four ways: 1) simple correlation based integration 2) Dataset concatenation-based 
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2.8 Malignant Melanoma  
We have spent time discussing cancer and metabolomics in a general sense. In the following sections 
we will discuss melanoma and melanoma therapy more specifically. There will also be a discussion of 
Rho and Rho Kinase (ROCK) as a novel therapeutic target of melanoma, particularly in the view of its 
potential role in regulating melanoma cell metabolism.  
Melanomas are non-epithelial tumours arising from melanocytes, melanin-producing cells found 
predominantly in the epidermis. Melanocytes are derived from the neural crest during development and 
there is a growing body of work that links the stem cell properties of neural-crest derived melanocytes 
to the properties of malignant melanoma (87).  This has been bolstered by the proposal that the cancer 
stem cell theory could apply to melanomas (88) although it remains debated as markers for melanoma 
cancer stem cells are still being discovered (89). 
Approximately 90% of melanoma is a skin cutaneous melanoma. Traditionally the classification of 
primary melanomas has focused on the sites of origin, tumour thickness and histological subtype. 
Cutaneous melanomas have been classified into four major subtypes: superficial spreading, lentigo 
maligna, acral lentiginous, and nodular. Whilst these are clinically and histopathologically distinct, the 
most useful prognostic indicator is the Breslow depth which assesses the depth of tumour cell invasion 
(90).  
50% of human melanomas harbour BRAF mutations, in particular the V600E mutation which drives 
oncogenesis (7). The BRAF gene encodes for the serine/threonine protein kinase BRAF. The RAF 
family of protein kinases was first linked with cancer in 1983 and its high mutation rate in human 
melanoma was first discovered in 2002 (91). In normal tissue, BRAF is involved in the RAS/MAPK 
pathway, which regulates response to growth signals in the cell (92). The V600E mutation leads to a 
much more catalytically active kinase than the wild type and its oncogenic power has been shown in 
several genetically engineered mouse models (91). Another 15-20% of melanomas have mutations in 
NRAS (93). Knowledge into these driving mutations of the disease have bolstered the study and design 
of small molecule inhibitors of oncogenes which have recently found their way into the clinic.  
2.8.1 Melanoma Therapy 
Although melanoma is the fifth most common cancer in the USA (94), it is much less common in the 
UK, accounting for only 4% of cancer diagnoses in the UK in 2013 (2). Nevertheless, incidence has 
increased 360% since 1970; In fact it is the most rapidly rising cancer in terms of incidence and 
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diagnosis, with over 75,000 cases in 2014 in the US and a steadily increasing average rate of 2.6% 
over the past 4 decades (94). Malignant melanoma is responsible for over 80% of all skin cancer related 
deaths (95).  
Surgical resection of primary melanoma is an effective way to prevent disease progression. However if 
the patient is diagnosed with melanoma which has progressed to malignancy, median survival is less 
than 30% after five years(2). Novel clinical treatments have changed this statistic, but long term survival 
is only now being collected for patients given new treatments, discussed below. 
Historically when treating cancer clinicians have used the ‘cut, burn, and poison’ strategy alluding to 
surgery, radiotherapy and chemotherapy respectively (96). While Early stage melanomas are relatively 
easily resected surgically, malignant and metastasized melanomas become difficult if not impossible to 
surgically remove. Chemotherapy has a success in late stage malignant melanoma of only 15-20% 
(97), therefore the need for better therapies has pushed research to develop targeted therapies of 
melanoma. The treatment of melanoma has been revolutionised in the past ten years with the 
emergence of immunotherapies and BRAF and MEK inhibitors. For example, Vermurafenib is a 
monoclonal antibody targeting the V600E BRAF mutant present in 50% of human melanomas. It was 
approved for use in the clinic by the FDA in 2011 and is currently the gold standard of treatment in the 
clinic (98).  
There are many other treatments currently being tested pre-clinically and in clinical trials. Amongst 
these, immunotherapies and attenuated viruses are some of the most promising. Seven 
immunotherapies have been approved for use by the FDA since 2011. Anti-PDL1 and anti-CTL4 
antibodies which help the host immune system to overcome the immune evasion of cancer cells have 
shown dramatic effects in patients (13). As these treatment have made their way into the clinic, 
chemotherapy is now seen as a second line treatment for malignant melanoma(98). 
In 2015 the FDA approved a first in kind viral therapy to treat melanoma, Talimogene Laherparepvec 
(trademark name Imlygic) (99). The viral vector is a re-engineered Herpes Simplex virus (HSV-1) that 
is programmed to secrete the immune promoter Granulocyte macrophage colony-stimulating factor 
(GM-CSF). The mechanism of action of this treatment is still being elucidated, however it is suggested 
that the virus works in two phases. First, the virus itself can induce lysis in infected cells. Secondly, GM-
CSF is a hematopoietic growth factor that is involved in the maturation of dendritic cells and the 
activation of T cells (100). Phase three clinical trials demonstrated that 16.3% of enrolled patients had 
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a ‘durable response rate’ (response that lasts more than 6 months) when compared to the 2.1% of 
patients with durable response when given GM-CSF only (99). 
Despite the incredible progress seen in recent years, research into novel treatments is far from 
complete. Tumours that are initially sensitive to current treatments eventually develop resistance as 
shown by the median progression-free survival of 6-7 months (101). Long term clinical data for patients 
that have received newly developed drugs is only now being studied and published.  
Patients who respond to vermurafenib show a 15.6 month median overall survival (102) and patients 
who continued vermurafenib after the initial local treatment showed a 20.6 month median overall 
survival (103). Puznov et al followed the analysis of the 48 patients from the phase 1 clinical trial of 
vermurafenib and 44 of the 48 patients presented with progressive disease. This highlights how 
understanding cells resistant to treatment is an important area of research and identifying different 
signalling pathways driving the disease could lead to improved outcomes in the clinic. It is understood 
that melanomas treated with vermurafenib eventually reactivate the MAPK pathway as well as 
upregulate PI3K/AKT signalling to overcome BRAF inhibition (104). Therefore, combination therapies 
are also being looked at to improve survival rates (101,105-108). 
As stated earlier, 90% of cancer related deaths are due to the metastatic spread of cancers (6). All of 
the currently available targeted treatments are mainly designed to stop tumour cell proliferation or 
tumorigenesis and do not address the issue of metastasis (109). Part of the issue is that there is an 
added difficulty in designing clinical trials to assess metastatic spread (110). Looking at the metastatic 
cascade for possible therapeutic targets of disease represents an attractive strategy as there are 
multiple pathways that could eventually offer benefits for patients. Such pathways include angiogenesis 
(111,112), cancer cell dormancy (113), with immune evasion the area that has been addressed with 
the advent of immunotherapies for treating metastatic melanoma, discussed above. Another area that 
has received attention is tumour cell migration and invasion.  
2.8.2 Cancer Proliferation and Metastasis 
The process of cancer cells migrating and colonising a secondary site is known as metastatic cascade 
(114). This is a multi-stage process made up of (115): 
 Invasion 
 Intravasation in the circulatory system (Invasion basal membrane into the circulatory system) 
 Survival in circulation  
 Extravasation (anchoring onto the epithelium of the capillary and exiting circulation) 
 Colonisation and proliferation in a secondary site 
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Each of these steps present cancer cells with different selective pressures, from surviving the shear 
stress of travelling in the circulatory system (116), to evading the immune response of the body (117), 
to colonising a secondary site which may have a very different physiological environment to that of the 
tissue of origin (115).  
 
Figure 2.13. The metastatic cascade is comprised of five major steps. 1) Invasion 2) Intravasation 3) Survival in 
the Circulation 4) Extravasation 5) Metastatic colonisation. Each step presents evolutionary pressures on cancer 
cells before successful metastatic colonisation can occur. Figure reproduced with permission from (118). 
 
 
2.8.3 Tumour Cell Plasticity 
The ability to migrate is a fundamental aspect of many different stages of the metastatic cascade, from 
invading into local tissue, extravasation, intravasation and migrating through a secondary site (119). 
Cancer cells also maintain plasticity in their modes of migration in order to adapt to different 
environmental challenges (120). One illustration of this plasticity is in how cancer cells can migrate 
either collectively or as individual cells (121) (Figure 2.14). While it has been observed that cells can 
migrate collectively through the lymphatic system, only single cells are able to invade through the 
basement membrane, blood vessels and settle at distant sites (122). Within single cell migration, cells 
can be classified according to their mode of migration. There is the rounded-amoeboid mode 
characterised by membrane blebbing and low adhesion. The second mode is the elongated-
mesenchymal mode of migration characterised by actin rich protrusions, an elongated morphology and 




Figure 2.14. Cell Morphology and modes of migration. Cancer cells can invade and migrate either collectively or 
as individual cells and cellular morphology is connected to the mode of migration. Individual migration can be 
classified into elongated-mesenchymal type migration or rounded-amoeboid type of migration. Figure reproduced 
with permission from (120). 
 
 
These modes of migration are promoted by Rho/Rock signalling (discussed below) and Rac signalling 
respectively and mutually supress each other (124). When thinking about targeting cell migration for 
therapies, one must consider that both amoeboid and mesenchymal migration require certain levels of 
actomyosin contractility, and simply targeting an individual mode of migration may not be sufficient to 
obtain a clinically relevant outcome. This is being addressed in current studies with the development of 
novel kinase inhibitors (3). 
2.9 Rho GTPase/ROCK signalling 
2.9.1 Rho GTPases 
The Rho family of GTPases are small (~23KDa) monomeric G proteins that are part of the Ras 
superfamily of proteins. These proteins are known as ‘molecular switches’ that go from an inactive GDP 
(Guanosine Diphosphate) bound state to and Active GTP (Guanosine Triphosphate) bound state. They 
contain lipid modifications which target them to the cellular membrane. The binding of GTP and the 
successive hydrolysis of GTP to GDP are mediated by associated proteins Rho-Guanine Nucleotide 
Exchange Factors (Rho-GEFs) and Rho-GTPase Activating Proteins (Rho-GAPs) respectively (125). 
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In mammals there are 22 members of the Rho GTPase family, which are divided into 8 subclasses 
(126). The eights subclasses are: Cdc42, RhoUV, Rac, RhoBTB, RhoH, Rho, Rnd, and RhoF. The Rho 
subclass contains three members, RhoA, RhoB and RhoC. 
After their initial discovery in 1985 (127), Rho GTPases were noted for their control of cellular 
morphology and the actin cytoskeleton. Since then a large body of research has grown to show their 
effects on cellular growth, proliferation and cell survival, all of which are of interest in cancer (125,128). 
The three best studied members of the Rho GTPases are Rac1, Cdc42 and RhoA. One of the major 
downstream targets of active RhoA and RhoC are the Rho Associated Protein Kinases (ROCK). 
2.9.2 Rho Associated Kinase (ROCK) 
ROCK is a family of serine threonine kinases with a molecular weight of about 160 kDa. The ROCK 
family of proteins comprises ROCK1 and ROCK2, which have a 62% sequence homology overall and 
92% sequence homology in the kinase domain (129) (Figure 2.16). The kinase domain is located near 
the N-terminus of the protein sequence. Near the carboxyl terminus the Pleckstrin homology domain is 
located. These two regions are separated by a coiled coil region which contains the Rho binding domain 
(RBD) where RhoA binds, thus freeing the kinase domain and activating ROCK (130),  #0}. When in 
monomer form, ROCK can be in an inactive form whereby the Pleckstrin domain and the RBD bind to 
the N-terminal Kinase domain, blocking it from activity. ROCK in solution is primarily a homodimer and 
dimerization occurs through the C-terminal domains and the coiled-coil region (131), which leaves the 
C-terminal Kinase domain free for catalytic activity. Other methods of activation in include the binding 




Figure 2.15. ROCK inhibitors are ATP competitors and H1152 forms more interactions with ROCK than Y27632 
thanks to additional methyl groups, conferring higher binding affinity. A) Cartoon structures of H1152 (left) and 
Y27632 (right) bound to the catalytic pocket of ROCK1. B) Schematic illustration of H1152 (left) and Y27632 (right) 
and the interactions with ROCK1 residues. Figures in (A) generated in Pymol (132) and figures in (B) reproduced 
with permission from (131). 
 
 
Most small molecule inhibitors of ROCK are ATP binding competitors (133) and several structures have 
been described showing the binding of the principle small molecule inhibitors of ROCK to the ATP 
binding pocket of the kinase domain of ROCK1 (133)(Figure 2.15A). Those inhibitors are H1152-p, 
Fasudil, and Y27632. In the study by Jacobs et al (131) they demonstrate that the higher affinity for 
ROCK of H1152 compared to other inhibitors such as Fasudil and Y27632 is due in part to the 
isoquinoline methyl group which limits the low energy conformations available to H1152, thus reducing 
the entropic cost of immobilising the rotatable bonds in binding to the protein (131) (Figure 2.15B). 
H1152 Y27632






Figure 2.16. The Sequence, structure and activation of ROCK. A) The sequences and domains of ROCK. ROCK1 
and ROCK2 are 92% similar in the Kinase Domain. B) ROCK can form homodimers via the coiled-coil region to 
release the kinase domain (in blue) from the auto-inhibition found in the monomeric form. C)ROCK can also be 
activated by binding of Rho GTPases to the Rho binding domain (RBS), exposing and thus activating the Kinase 
domain. Finally, ROCK can be activated by the cleavage of the inhibitory Pleckstrin Homology Domain by caspase 
3, thus freeing the kinase domain for catalytic activity. Figures adapted and redrawn with permission from (130,134) 
 
 
ROCK was first isolated and reported in 1995 (135) and in the following year shown to play a role in 
generating actin stress fibres in cells (136). Since then ROCK has been shown to play a fundamental 
role in regulating a wide variety of functions in the cell; from controlling the cells cycle (137,138), and in 
particular in controlling the cytoskeleton through its regulation of actomyosin contractility (136)(Figure 
2.17). The control of the cytoskeleton gives ROCK a fundamental role in regulating modes of cell 
migration (139). In work by Sanz-Moreno et al (140), it has been seen that the rounded morphology of 
melanoma cells are observed in histopathological sections of both primary tumours and metastasised 
tumours. Cells found at the invasive front of primary tumours and cells comprising metastases have a 
more rounded morphology than tumour cells found at the core of primary tumours (Figure 2.18)(139). 
Yamaguchi et al 2006
Riento and Ridley 2003
Redrawn from Nakagawa et al 1996, 
Riento, Ridley 2003

































































The mechanism by which ROCK regulates actomyosin contractility is both by the phosphorylation of 
Myosin Light Chain 2 (141) which promotes actomyosin contractility and also by the inhibitory 
phosphorylation of Myosin phosphatase (142) which further increases levels of actomyosin contractility. 
Levels of phosphorylated Myosin Light Chain 2 can be measured via Western blot or confocal 
microscopy as a marker to determine ROCK activity (Figure 2.18).  
 
Figure 2.17. ROCK regulation of Cellular Contractility. When activated, ROCK phosphorylates both myosin light 
chain and myosin phosphatase. In this way ROCK promotes both contractility and inhibits inhibition of contractility. 
Thus, ROCK increases the amount of phosphorylated myosin light chain, which is then available for binding to F-
actin and promoting actomyosin contractility.  
 
 
2.9.3 Rho/ROCK signalling as a Therapeutic Target of Melanoma 
The idea of targeting the Rho signalling pathway has been around for quite some time. The 
opportunities and challenges were reviewed by Eric Sahai and Chris Marshall in 2002 (125). As of 2015, 











great interest in targeting the Rho signalling pathway, effective small molecule inhibitors of Rho were 
only first reported in 2012 (144). In this regard targeting the downstream kinase ROCK has been a 
much more viable option as kinase inhibitors are a much more developed field of research. As of March 
2016, 27 kinase inhibitors have been approved for use by the FDA (145). This year, Feng et al reviewed 
171 ROCK inhibitors (145) demonstrating the abundance of research into ROCK as a therapeutic target 
not only in cancer but also in ocular diseases such as glaucoma, psoriasis, systemic lupus 
erythematosus, idiopathic pulmonary fibrosis and graft-vs-host disease (145). ROCK inhibitors have 
also been suggested to have neuroprotective effects (146) and play a role in cardiac remodelling (147). 
 
Figure 2.18. ROCK drives actomyosin contractility (A) and this can be observed in vitro through morphology in a 
rounded, amoeboid phenotype (B). C) In human melanomas tumour cells at the core of the primary tumour present 
mainly with and elongated phenotype, while at the invasive edge and at metastatic sites these cells present with a 
more rounded phenotype. The red arrow indicates the direction from the core of the primary tumour to the invasive 
front D) Quantification of data shown in (C). Cells in a spindle tumour body (TB) are more elongated than cells at 
the invasive front (IF). Images reproduced with permission from (95,140) 
 
 
Over 600 somatic coding mutations in ROCK have been identified in human cancer genomes, either 
cell lines or primary tumours (143), and many of these mutations described in ROCK lead to a more 
active kinase as auto-inhibition is eliminated. RhoA or ROCK is often overexpressed in many tumour 
types (125,148), although this may not correlate with a more active kinase in itself.  
Orgaz & Sanz-Moreno, 2013 Sanz-Moreno et al, 2011
Sanz-Moreno et al, 2011






Currently,  the ROCK inhibitor Fasudil is approved for clinical treatment of cerebral vasospasm in Japan 
and China (149). However, it has not been approved for use in Europe or the US and, as its initial patent 
expires in 2016 (150), the financial incentive to invest into clinical trials for Fasudil is non-existent.  
There are other examples of ROCK inhibitors being tested clinically. As the safety profiles of ROCK 
inhibitors are already established to a certain extent this makes it an attractive target for translation to 
other diseases such as cancer. 
Inhibition of ROCK activity has been shown to slow or inhibit tumour growth in prostate, glioma and 
human papilloma virus positive tumours (97). Routhier et al first showed that inhibition of ROCK activity 
by systemic delivery of the ROCK inhibitor Y27632 in mice could reduce melanoma tumour volume 
(97). Chris Marshall’s group in London has also shown that inhibition of ROCK can block melanoma 
cell migration and metastasis both in vitro and in vitro models of melanoma (3). In addition, they have 
also shown that ROCK1 and ROCK2 have redundant effects on melanoma growth in vitro. Kuemper et 
al demonstrated that the deletion of both ROCK1 and ROCK2 genes is required reduced cell 
proliferation and tumour growth in vitro (138). Individual knock-outs of either ROCK1 or ROCK2 did not 
lead to any significant reduction of tumour growth in their study. 
In parallel to this, ROCK has been proposed as a potential combinatorial drug target. Smit et al from 
the Pepper lab first proposed ROCK as a potential combinatorial drugs target in melanoma in their 2014 
paper (4). They show that a variety of BRAF inhibitor resistant cell lines became sensitised to BRAF 
inhibitors when used in combination with ROCK inhibitors. They also show that the proliferation of these 
resistant cells can be reduced just by using the ROCK inhibitors. They followed this study with another 
paper showing that inhibition of ROCK and MEK can also be effective with NRAS mutant melanomas 
(151).  
Despite all the data supporting the idea of blocking ROCK activity to inhibit cancer progression, there 
are a couple of considerations that have to be made when thinking of ROCK as a therapeutic target. 
First, there have been examples of ROCK inhibition having pro-tumorigenic effects in other cancer cell 
types. As reviewed in Wei et al (143) pancreatic (152) and colon cancer cells (153) have been observed 
to increase in cell proliferation after treatment with the classic ROCK inhibitor Y27632. Further 
inspection of these studies points to gaps in their studies that deserve consideration. In the study by 
Nakashima et al in pancreatic cancer, Y27632 was used at concentrations of 3 μM. Y27632 is much 
less specific for ROCK than other inhibitors such as H1152, Fasudil and GSK269962A (Table 2). They 
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do not observe the effects of Y27632 at higher doses. Further in the study they use Fasudil to study the 
phosphorylation targets of ROCK in colon cancer, but never demonstrate what effects Fasudil have on 
cell proliferation in the study, which is a curious omission. In the other study by Nakashima et al in colon 
cancer cell lines, Y27632 is used at doses of 10 μM, which is the standard dose used in several other 
studies (154,155). Further work would be required to fully validate the claims of these two studies. 
Nonetheless, these studies point both to potential tissue specific effects of ROCK in regulating cell 
proliferation and the need for further studies to be conducted prior to using ROCK inhibitors clinically. 
Secondly, as ROCK is a strong regulator of actomyosin and contractility in cells, one of the main side-
effects of systemic ROCK inhibition would be a dramatic drop in blood pressure in patients. In the 
pharmaceutical industry this challenge has had two effects: on one hand, this has driven research into 
novel ROCK inhibitors with differing levels of specificity and potency aimed at addressing this negative 
effect in patients, on the other hand, it has also made ROCK inhibitors an attractive candidate for 
treating erectile dysfunction (145).  
2.9.4 ROCK Regulation of Metabolism 
Much attention has been paid to the role of ROCK in regulating actomyosin contractility, and thus its 
effects on the cytoskeleton, proliferation, division, cell cycle control, migration and invasion. However, 
little attention has been paid to its role in regulating cellular metabolism. It has often been assumed that 
any effect on cellular metabolism may be a secondary indirect effect of ROCK rather than a direct 
regulation. However, there is some evidence that ROCK could be altering cellular metabolism, either 
directly or through its regulation of the cytoskeleton. It has been observed in adipocytes and myoblasts 
that ROCK regulates the transport of the glucose transporter GLUT4 to the membrane through actin 
cytoskeleton regulation (156). ROCK has also been studied in its role of regulating both insulin signalling 
as well as leptin signalling in the brain through its interactions with the insulin receptor and JAK/STAT 
signalling pathway respectively (157). 
There are currently only two published articles investigating the role Rho/ROCK signalling may have on 
cancer cell metabolism. The first, published by Zhang et al in 2010 (158), demonstrated how Rho 
dependent transformation of breast and lung cancer cells could be inhibited by blocking the 
mitochondrial glutaminase enzyme using their novel glutaminase inhibitor 968. They have recently 
followed up with a mechanistic explanation of the function of the 968 glutaminase inhibitor, which binds 
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to the monomeric form of mitochondrial glutaminase GAC, inhibiting the active glutaminase tetramer 
(159). 
The second paper. by Zhang et al (155). is a much more comprehensive paper that demonstrates how, 
in a variety of lung and breast cancer cell lines, and within a gain of function mutant p53 background, 
Rho/ROCK signalling drives the Warburg effect by promoting the trafficking of the glucose transporter 
GLUT1 to the plasma membrane. In this study they interfered with ROCK activity with shRhoA stable 
knockdowns, siRNA transient knockdowns of ROCK1/2 and with 10 μM treatments of the ROCK 
inhibitor Y27632. They hypothesise that this trafficking is done via ROCK’s promotion of actin filament 
formation, which allows GLUT1 to be trafficked to the plasma membrane. They also show that wild-type 
p53 represses the Warburg effect. Importantly it has been shown that loss of p53 promotes the 
Rho/ROCK dependent rounded-amoeboid type migration in A375P melanoma cells (160) and all of the 
work presented in this thesis has been performed in a p53 wildtype background. Secondly, they 
demonstrate these effects cell lines of epithelial origin, whereas melanomas are non-epithelial tumours. 
ROCK activity in metastatic melanoma has been shown to regulate a variety of cellular processes and 
to play a fundamental role in promoting melanoma proliferation and metastasis. The first part of this 
thesis aims to investigate how ROCK activity is affecting cellular metabolism. 
2.10 Conclusion 
This chapter set out to establish the background upon which this work is built. We have established that 
while clinically available treatments for melanoma have increased substantially in the last decade, there 
is still a great need to understand how melanomas metastasise in order to develop therapies for patients 
that either are non-responsive to currently available treatments or develop resistance to treatment. One 
approach to gain a deeper understanding of cancer metastasis is to study how cancer cells re-wire their 
metabolism. Metabolomic methods are now an established part of biomedical research and have come 
of age since the definition of the term metabolomics almost two decades ago (161). In particular, NMR 
metabolomics permits researchers to gain a broad biochemical understanding of the system of interest 
in a highly reproducible manner. The technical developments of mass spectrometry and NMR 
spectroscopy have resulted in a massive increase of data available to researchers, which has been 
accompanied by the development and application of multivariate statistics, pattern recognition and 
machine learning algorithms to make sense of the data. There is now a push to find methods to optimally 
integrate diverse -omics datasets through various statistical and mathematical modelling methods. 
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ROCK is a family of serine/threonine kinases that play an important role in regulating the actin 
cytoskeleton and thus cell growth, proliferation and migration, which comes with high energy demands. 
Recent pre-clinical data has suggested it may be a promising therapeutic target for metastatic 
melanoma and a phase one clinical trial targeting ROCK in metastatic melanoma is currently recruiting 
patients (clinical trial number: NCT01585701). While it is a thoroughly studied kinase, there is currently 
a gap in knowledge as to how it may regulate cancer cell metabolism. The work presented in this 
research project aims to address this gap in knowledge and conduct a 1D 1HHR-MAS NMR study of 
metastatic melanoma cells in vitro after interfering with either ROCK activity or expression in both 
human and murine melanoma. 
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Chapter 3 : Materials and Methods
3.1 Cell Culture and Molecular Biology 
3.1.1 Cell Culture 
A375M2 were cultured in Dulbecco’s Modified Media (DMEM from Sigma –Aldrich) supplemented with 
10% Foetal Bovine Serum (FBS) and 1% penicillin/streptomycin (P/S). B16F10 cells were cultured in 
RPMI-1640 (Life Technologies) with the same supplements. Cells were incubated at 37⁰C and at 10% 
CO2. Cell culture media was replaced every other day and passaged when the cells reached 80% 
confluency. Frozen cells were stored by suspending 106 cells in a solution comprising 90% cell culture 
media and 10% DMSO. Cells were the transferred into cryo-vials and kept at -80 ⁰C for 24 hours. Cells 
were then transferred to liquid nitrogen storage. To thaw cells, cryo-vials were put at 37⁰C and then 9 
ml of cell culture media was added. The suspension was centrifuged at 1200 rpm for 5 min at room 
temperature. The supernatant was discarded and the pellet was re-suspended in 3 ml of media and 
then transferred into a T25 cell culture flask.  
3.1.1.1 Cell Passage 
Cells were passaged using the warm trypsinization technique. The medium was aspirated followed by 
two phosphate buffered saline (PBS) (without Ca2+ and Mg2+) washes to remove any residual medium. 
Trypsin was added to the flasks (2 ml to the T75 flask and 5 ml to the T175 flask) containing the cells 
and incubated at 37⁰C for 5 minutes. Following incubation flasks were gently shaken and cells were 
observed under the microscope to ensure cell detachment. Trypsinization was stopped by addition of 
media (3 times the volume of trypsin). The cells were transferred to a falcon tube and pelleted down by 
centrifugation at 1200 rpm for 4 minutes. The supernatant was aspirated and the pellet was then re-
suspended in appropriate volume of fresh medium. 10 μl of the suspension was transferred to CASY 
counter and the number of cells/ml of the original suspension was determined. Cells were split 1/5 or 
1/10 depending on speed of cell proliferation. The final volume was filled up to 8 ml for the 10 cm plates 
and to 2 ml for the 6-well plates by using fresh medium. All melanoma cells were passaged a maximum 
of six times to ensure homogeneity between experiments.  
 50 
 
3.1.1.2 ROCK Knockout Mouse Melanoma sample preparation 
Mouse melanoma samples were kindly provided by Dr. Sandra Kuemper (Marshall lab, ICR, London). 
The mouse melanoma model uses BrafV600E as an oncogene induced by Cre expression in 
melanocytes (using Tyr-Cre-ERT2). Mice were treated with tamoxifen which activates Cre in the cells 
where tyrosinase expressed as Cre is expressed under the tyrosinase promoter and held inactive. 
Melanocytes become oncogenic and become melanomas after about 1-2 years (on a PTEN wildtype 
background). Cells from these primary tumours were cultured until melanoma cells grow out and 
fibroblasts in culture become senescent. Cells were then harvested for NMR experiments (described 
below) at passage number 4. 
3.1.2 siRNA Knock Downs with LAH4-L1 or LADap(Me)6-L1 Peptides 
Cells were seeded onto six-well plates at a concentration of 2 × 105 cells per well. 24 hours after seeding 
cells were transfected with siRNAs targeting the gene of interest. siRNAs were re-suspended to a final 
concentration of 20 μM according to manufacturer protocol. The ON-TARGETplus siControl non-
Targeting siRNA (Dharmacon, GE) was used as mock control. LAH4-L1 peptide was purchased from 
Pepceuticals Ltd (Nottingham, UK), LADap(Me)6-L1 was synthesised in house (162).  
Metabolomic experiments with siRNA knockdowns were performed with LAH4-L1 peptide transfections 
while siRNA screens were performed with LADap(ME)6-L1 peptide.  
Peptide transfection was performed according to protocol (163). For transfections final siRNA 
concentrations in wells was 50nM. The amount of peptide used was a 1:10 siRNA/peptide weight ratio. 
For transfections in a 6 well plate, siRNA and peptide were diluted in separate 1.5 ml Eppendorf tube 
with 50 μl Opti-Mem media and left to resuspend for 5 min. They were then mixed and allowed to 
complex at room temperature for 30 min. The complex was then diluted with additional Opti-Mem to a 
final volume of 500ul per well. The cells were washed with PBS (without Ca2+ and Mg2+) and the 
siRNA/peptide mixture was put into the wells. The cells were incubated with the siRNA/peptide complex 
at 37˚C for 4 hours. Opti-Mem was then aspirated from the wells and replaced with fresh cell culture 
media supplemented with 1% FBS.  
 For imaging and Western blotting 48 hours after transfection, cells were seeded onto collagen and after 
24 hours the media was changed to 1% FBS in DMEM. After another 48 hours cells were lysed or fixed 
for Western blotting and microscopy respectively. For NMR experiments cells were treated in an 
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identical fashion but were seeded onto 10 cm plates at a concentration of 2 × 106 cells/plate. 
Transfection reagent volumes were multiplied 6 fold compared to transfection in a 6 well plate. 
3.1.3 Western Blotting 
3.1.3.1 Protein extraction for Western blotting 
Molecular biology experiments: 200 μl of 1x Laemmli lysis buffer (with inhibitors: 1 μM DTT, 1 mM NaF, 
100 μM β-Glycerol phosphate, 5 μM PMSF and Protease inhibitor cocktail tablet from Roche) were 
added to the cells into the 12-well plates, followed by occasional gentle shaking for 5 min. Lysates were 
then collected, and used for the Western blot analysis. 
Metabolomics experiments: After scraping cells and transferring them into a 15ml tube, 1ml of 
suspension was transferred to a separate 1.5ml Eppendorf tube. The suspension was spun down at 
1400 rpm for 4 min at room temperature. The supernatant was discarded and the resulting pellet was 
snap frozen in liquid nitrogen for 3 min and stored at -80˚C until protein extraction. 150 μl Laemmli lysis 
buffer was then added to the sample and the resulting lysates were treated as below. 
The cell lysates obtained from the experiments performed on plastic and on collagen were thawed, 
boiled at 100°C for 5 min, sonicated for 15 seconds on ice (50% sonicator efficiency), centrifuged at 
13,000 rpm for 30 min at 4°C, supernatants were collected and prepared with 4X LDS loading buffer 
(Invitrogen). The samples were resolved using with 8-10% acrylamide gels or premade Nu-PAGETM 4-
12% Bis-Tris gels (1.5 mm, Invitrogen) at 100V in MES running buffer (Invitrogen) for up to 2 hours at 
room temperature. The gels were then electrophoretically transferred onto a PVDF membrane (0.45 
μm, ImmobilionTM) for 2 hours at 100V. Transfer tanks were surrounded by ice. Membranes were 
blocked with 5% BSA (PAA) in tris buffered saline containing 0.1% (v/v) Tween-20 (TBST) for 1 hours 
at room temperature. Membranes were then cut and incubated with primary antibodies diluted in 5% 
BSA-TBST overnight at 4°C. The next day membranes were washed for 3x 10 minutes in TBST, 
incubated with HRP (horseradish peroxidase) conjugated secondary antibody for 1 hour and then 
washed again with TBST for 3x 10 min. They were developed by using ECL or ECL Prime western 
blotting detection reagents (Amersham) and exposed to X-ray film in a dark room. Images were 
analysed with ImageJ. Briefly, a box was drawn around the bands of interest using the “rectangular 
selection” tools, the intensity profile of the bands was drawn (“Analyse” → “Gels” → “Plot lanes”) and 
 52 
 
the intensity of each peak (corresponding to a band) was measured using the “Wand” tool.  Data was 
collected and figures were made by using Excel, R, or OriginPro. 
3.1.4 Experiments on collagen 
3.1.4.1 Collagen 1 preparation 
Bovine skin collagen type I (PureCol, Nutacon BV, 5005-B, pepsinised, telopeptide free) was prepared 
to a final concentration of 1.8 mg/ml in 5x-DMEM (phenol red and serum free, from ICR) as per the 
following recipe (for 1 ml): 55.56% collagen, 20% 5 x DMEM, 21.35% H2O (MilliQ, sterile and filtered) 
and 3% 0.1M NaOH. Following degassing in a vacuum, 700 μl/well was placed in 12-well plates, 300 
μl/well in 24-well plates and 100 µl/well in a 96 well plate. Collagen was polymerised for 4 h at 37°C, 
10% CO2. Cells were seeded on top of the matrix in media (DMEM with 10% FBS and 1% Penn/S) at 
concentration of 8,000 cells/well in 96 well plates, 10,000 cell/well for 24-wells plate and 100,000 
cell/well for 12 well plates.   
3.1.4.2 Light microscope morphology assessment 
The 24-well plates were subjected to a wash with 1 ml of PBS (with Ca2+ and Mg2+) to each well, addition 
of 600 μl of 4 % formaldehyde. After 15 min, 1 ml of PBS (with Ca2+ and Mg2+) was added to each well, 
aspirated and added for the second time. Next, three pictures for each well were taken by QC Capture 
and the quantification of % elongation was conducted by using ImageJ.  
3.1.4.3 RNA extraction for qPCR 
RNA extraction was done by adding 900 µl Trizol (Invitrogen) per well for 5 minutes at room 
temperature. Lysates were then transferred to an Eppendorf tube and mixed with 200 μl chloroform for 
10 min at room temperature. Samples were then centrifuged at 12,000 rpm at 4 ⁰C for 15 min to separate 
RNA from the protein containing phase. The RNA containing phase presents as the aqueous phase in 
the upper part of the Eppendorf tube. The RNA containing phase was carefully transferred to a new 
tube to not disturb the opaque protein containing phase. 400 μl isopropanol was then added and the 
sample was spun at 12,000 rpm at 4 ⁰C for 10 min. The supernatant was then discarded and 400 μl 
75% ethanol in RNAse free water was added to the tube and spun at 12,000 rpm at 4 ⁰C for 10 min. the 
supernatant was discarded and the remaining pellet was dried for 10-30 min at room temperature 
followed by resuspension in 30 μl RNAse free water. The sample was then further purified from DNA 
by using the DNAse removal kit according to manufacturer’s instructions.  
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3.1.5 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
For qPCR experiments cells were seeded either onto bovine collagen 1 or plastic at concentration of 
40,000 cells/well in a 6 well plate. 24 hours after seeding cells were treated either with mock DMSO or 
ROCK inhibitor (5 µM H1152) for 24 or 48 hours.  
Quantitech Primer assay qPCR mRNA primers (Qiagen) were purchased for the respective genes. 
Primer sequences are proprietary information and so are not listed here. Primers were used at 
approximately 10 μM qPCR was performed using one-step Brilliant II SYBR Green qPCR kit (Agilent 
Technologies) and Stratagene MX 3005x qPCR system with MxPro software. RNA concentration was 
adjusted to 100 ng RNA/well for all samples: in addition, GAPDH was used as a loading control. 
Samples were loaded in qPCR plates and sealed with qPCR strips. Each sample was run in duplicate 
or triplicate. qPCR data was considered reliable if GAPDH measurements were between 15-20 cycles. 
Individual gene measurements were expected to fall between 15-30 cycles and measurements greater 
than 30 cycles were considered unreliable. Data was exported from the MxPro application as a text file 
containing the number of cycles for each well. Data from all the replicates was then analysed using the 
delta/delta method and normalised to GAPDH using Microsoft Excel.  
3.1.6 Light microscopy Morphology assessment 
Fibrillar bovine dermal collagen was prepared at 1.7 mg/ml according to the manufacturer's protocol at 
100 ml/well in T96 plates and 300ml/well in T24 plates. Cells were seeded on top at 7 × 103 cells/well 
in T96 plates and at 30 × 103 cells/well in T24 plates in 10% FBS medium. Cells were allowed to adhere 
for 24h and the medium was changed to 1% serum. Cells were subsequently imaged 24h. Cells were 
imaged with QImaging O1Q1 Click FM12 camera and Q-imaging software. The calculation of the 
number of elongated cells was carried out with ImageJ. For this calculation, cells were classified into 
two categories, ‘rounded’ or ‘elongated’ according to their morphology. 
3.1.7 Immunohistochemistry 
3.1.7.1 Sample preparation 
A375M2 human melanoma cells were seeded onto a thick layer of collagen in 96 well plates at 10,000 
cells/well. B16F10 mouse melanoma cells were plated onto a glass coverslip for microscopy. 
 At the conclusion of the experiment, cells were washed 3 times with PBS (with Ca2+ and Mg2+), fixed 
in 5% PFA for 10 min at room temperature, and permeabilised in 0.3% Triton in 4% BSA/PBS for 20 
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min at room temperature. Non-specific binding was blocked in 4% BSA/PBS for 1 hour at room 
temperature. Cells were then incubated overnight at 4℃ with primary antibody (see table below) diluted 
in 4% BSA/PBS. The next day cells were washed three times in PBS (with Ca2+ and Mg2+) and 
subsequently incubated at room temperature for 2h in secondary antibody (concentration 1:300) in 4% 
BSA/PBS. Cells were then washed and stained with Phalloidin 546 (Invitrogen) (1:200) and Hoechst 
0.5% for 5 min at room temperature. Finally, cells were washed with PBS and stored in PBS at 4˚C until 
imaging. For cells seeded onto a glass coverslip, DAKO was used to mount the coverslips onto glass 
slides for imaging.  
For imaging with collagen 1, the collagen was removed with tweezers and placed upside down on a 
glass bottom culture dish to ensure the cells at the top of the collagen layer were in close proximity to 
the microscope. Imaging was done with a LSM5 10META Zeiss confocal microscope and Zen software. 
Images were analysed with Zen software. Indirect quantification of immunofluorescence intensity was 
carried out with ImageJ. A perimeter was drawn around individual cells and the ‘measure’ (ctrl+m) 
function was used. The Raw integrated density was normalised by dividing by the area of the selected 
region.  
3.1.7.2 Image Capture and Morphology Analysis 
Cells were washed once with PBS followed by fixing in 4% paraformaldehyde (PFA) for 15 min. Cells 
were imaged at 40x magnification and images were counted and analysed with ImageJ. Cell rounding 
was assessed by manually tracing the perimeter of each cell and then calculating the ratio of the largest 
and smallest diameter. Therefore, a perfect circle would have a roundness index of 1.0 while a straight 
line would have a roundness index of 0.0. Data was collected analysed and visualised with Microsoft 
Excel (Microsoft), SPSS 20 (IBM), Graphpad Prism (Graphpad Software Inc.) and R with ‘ggplot2’ 
visualisation library.  
3.1.8 Statistics 
For pairwise comparisons, students t-test was performed. Multivariate analysis was performed with 1-




3.2.1 NMR samples preparation  
At the end of the experimental procedure cells were washed with 5 ml cold fresh 1x PBS (with Ca2+ and 
Mg2+). The wash was followed by addition of 6 ml of the same cold fresh 1x PBS (with Mg2+Ca2+). For 
metabolomics experiments trypsin-EDTA was not used to avoid potential leakage of metabolites (164). 
The cells were then mechanically scraped from the plates, transferred to a 15 ml Falcon tube and 
pelleted at 1400 rpm for 4 min at room temperature. The supernatant was discarded and cells were re-
suspended in 500 µl PBS (with Mg2+Ca2+) and transferred to 1.5 ml Eppendorf tubes and spun down at 
0.2 g for 5 min at 4⁰C. The supernatant was aspirated and the pellets were snap frozen by immersion 
in liquid nitrogen for 3 minutes. The samples were then lyophilized overnight and kept at -80°C until 
further use.   
The reliability of sample preparation for NMR metabolomics studies have previously been studied. In 
the Mason group, previous work has shown that the current method results in good quality spectra(65). 
Cells were mechanically scraped from the plate as trypsinisation has shown to lead to metabolite 
leakage that is an unacceptable loss for metabolomics studies (164). Additionally, it was chosen to 
snap-freeze cells in order to rupture 100% of the cell membranes. Other methods that do not rupture 
all cell membranes can lead to varying lipid profiles due to sample handling or spinning by MAS. This 
snap-freezing step in liquid nitrogen also serves to quench metabolism and preserve the metabolic 
state. A drawback is the matter that the cells are effectively washed in PBS three times prior to the 
snap-freezing step, which may be a source of metabolite leakage. 
For liquid state NMR, 1.5 ml of spent media was collected and transferred to an Eppendorf tube. 
Samples were centrifuged at 1400 rpm for 5 min to precipitate any debris and the spent media was 
transferred to a new Eppendorf tube. Samples were then lyophilised at -58 ºC overnight, and stored at 
-80°C. Prior to NMR acquisition, samples were re-suspended in 600 µl D2O.  
3.2.1.1 NMR spectra acquisition   
The lyophilized cell pellets were re-suspended in Kel-F inserts (Bruker, Rheinstetten, Germany with 30 
µl D2O (Sigma-Aldrich, St Louis, MO, USA) at room temperature 2 hours before the acquisition to 
provide a lock signal. This step was performed as shorter rehydration times lead to larger spectral 
linewidths. A potential downside to this rehydration step is the possibility of metabolite degradation 
during rehydration and during spinning, especially 2D NMR experiments which last several hours. 
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Figure 3.1 demonstrates an example of a 1H 1D NMR spectra acquired from A375 M2 human melanoma 
cells at the beginning and end of spinning for 2 hours at 298˚K. The metabolic profile is fairly stable, 
with decreases in the signal from lipid components, such as the CH2-CH2 resonance of lipids and 
phosphocholine, possibly due to degradation over time. There is also and a shift in the formic acid peak, 
which could be attributable to a change in pH over time. This highlights the need to handle the samples 
with very similar time frames to reduce the chance for the inclusion of variability in obtained data. 
 
Figure 3.1. The lipid profiles of human melanoma cells change over time with MAS. Representative 1D spectra of 
A375 M2 human melanoma cells at the beginning (blue) and end (red) of 2 hours spinning at 298˚K 5 kHz. Spectral 
regions shown highlight the lipid region (top left), glutamate (top right), choline bodes (bottom left) and aromatic 
regions (bottom right).   
 
Subsequently, the samples were placed in 4 mm Zirconia Magic Angle Spinning (MAS) rotor and 
preserved with Kel-F cap. For HR-MAS NMR, an Advance 1H 400 MHz spectrometer equipped with a 
4 mm 1H/13C HR-MAS probe (Bruker UK Limited, Coventry, UK) was used. 1D spectra were recorded 
using a standard a Carr-Purcell-Meiboom-Gill (CPMG) spin echo pulse of 190 μs with water pre-
saturation during recycle delay of 1 second. The spectral width was 16.02 ppm and 1H 90 pulse length 
was 7.81 μs. Two dummy scans were performed before recording acquisition data. Total acquisition 







additional 1 sec delay between scans. The number of complex points recorded was 32048 data points. 
Other experimental parameters were 4096 receiver gain, with a total recording time of 7 min 55 s and 
total of 128 scans were acquired. To achieve sufficient statistical power 9 samples were collected and 
recorded for each tested condition. The 9 samples were comprised of three experimental replicates and 
each experimental replicate was composed of three technical replicates. All the spectra were recorded 
at 310°K and the magic angle spinning frequency was 5000 Hz. 2D 1H-1H correlation spectroscopy 
(COSY), J-resolved and 1H-13C-Heteronuclear Single Quantum Correlation (HSQC) experiments were 
performed on a representative sample for each tested condition, using standard Bruker settings.  
For liquid state NMR, 1H NMR spectra were acquired under automation at 298 K and 700 MHz on a 
Bruker Advance II 700 NMR spectrometer (Bruker Biospin, Coventry, UK) equipped with a 5 mm QCI 
helium-cooled cryoprobe and a cooled SampleJet sample changer. The temperature was allowed to 
stabilise for 3 min after insertion into the magnet. Tuning, matching and shimming was performed for 
each sample and the 1H pulse length was calibrated on each sample and was typically around 12 µs. 
1D CPMG-presat (cpmgpr1d) experiments were acquired with 128 transients, a spectral width of 20.5 
ppm, 64 K data points, a mixing time of 10 ms, a relaxation delay of 4 s and a total echo delay of 78.7 
ms. 1D NOESY-presat (noesygppr1d) were also acquired, but with 32 transients. Free induction decays 
were multiplied with an exponential function (line broadening of 0.3 Hz), Fourier transformed and 
calibrated to a 2,2,3,3,-D4-3-(trimethylsilyl) propionic acid (TSP) reference signal at 0.0 ppm. 
The spectra were Fourier transformed, manually phased and automatically baseline corrected using 
standard Bruker commands to remove NMR artefacts and then calibrated with 2,2,3,3-D4-
3(Trimethylsilyl) propionic acid sodium salt (TMSP-2,2,3,3-D4) with reference signal at 0 ppm by using 
Bruker Topspin 3.0 Software. Occasionally manual baseline correction was performed in Topspin 3.0 
by defining baseline points and correcting the baseline using cubic spline. 
3.2.2 Data Analysis 
3.2.3 Data pre-processing and Software 
Spectral pre-processing, and the cross-validation and multivariate analysis were conducted using a 
combination of software developed in our laboratory for a previous study by Dr Louic Vermeer and the 
MVAPACK, an open source Octave library for NMR metabolomic data processing and analysis.  
The in-house script uses Python 2.7, a programming language which allows efficient integration of 
systems (PythonTM 2013) with the mathematical Numpy and SciPy extension, and Matplotlib to visualise 
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PCA and OPLS plots (65). The pre-processing methods were used to modify NMR spectra and reduce 
the variances and influences which are not of interest and might interfere during the data analysis. 
Therefore, the spectral regions below 0.58 ppm, between 4.70-4.53 ppm and above 8.63 ppm were 
excluded as these regions contained respectively the TSP reference peak, residual water peak or noise, 
which are not useful regions.  
Data was then exported from the in house software into the MVAPACK software as a .csv file. 
Spectral alignment and binning was done in the octave environment using the Icoshift alignment 
algorithm and the optimized binning algorithm respectively. Data was then transferred again into the 
Python environment. 
Data was normalized using probabilistic quotient normalization (PQN), based on the assumption that 
changes in concentrations of single analytes only influence sections of spectra, while overall 
concentrations dominate the influences on the complete spectrum (165). PQN normalisation is 
calculated in the following manger: first an initial integral normalisation of each spectrum is conducted. 
Then a reference spectrum is calculated (such as an average spectra). Then a for each variable the 
quotient between the test spectrum and reference spectrum is calculated. Once all the quotients are 
calculated the median quotient is estimated. Finally, each data point is divided by the median 
quotient(166). 
Pareto-scaling of the spectra was adopted to assign equal significance to both small and large peaks, 
leading to the amplification of low intensity signals. In pareto-scaling, individual data points are mean 
cantered and then divided by the square root of the standard deviation. This decreases the impact that 
large fold changes have on the dataset.  
3.2.4 Metabolomics analysis development 
The Mason lab has been making use of an in-house metabolomic data processing and analysis 
package developed by Louic Vermeer. It has been featured in several publications in the last five years 
(65,67,68). ‘Louic’s Metabolomics Thingy’ was developed using Python 2.7 programming language 
using the Scipy, Numpy, and Matplotlib packages. It is equipped with the PyQT front end Graphical 
User interface (GUI) that facilitates metabolomic data processing and analysis to non-experts. It allows 




Additional pre-processing and analyses were performed using MVAPACK (167) which is an open 
source software package developed by Worley and Powers at the University of Nebraska. It is built on 
Octave GNU, an open source mathematical programming language based on Matlab, to offer an 
exhaustive list of functions to streamline NMR metabolomic data processing and analysis. Once 
parameters and scripts are established, it can also handle the entire metabolomic analytical workflow 
with a few keystrokes. 
To facilitate data processing and analysis in our study we have used the icoshift and optimised binning 
algorithms available in the MVA pack toolbox to improve and accelerate our NMR data analysis (71,72).  
Multivariate pattern Analysis 
Spectra were analysed initially by principal component analysis (PCA) to identify clustering of spectra 
into groups and to identify potential outliers from experimental variability in the dataset. For this analysis, 
after normalization pareto-scaling was applied, where the mean-centered data is divided by the square 
root of the standard deviation.  
 
Figure 3.2. Representative cross-validated OPLS-DA output. Sample data is plotted in blue and permutated data 
where class labels are randomly assigned are plotted in grey. Data is taken from lentiviral stable knockdown of 
fatty acid synthase in PC3 human prostate cancer cell line. Top left: Scores plot from 2CV strategy. Individual 
points represent individual NMR samples and are potted according to their score of the predictive component (x-
axis) and orthogonal component (y-axis). This plot visualises the separation between classes when using features 
that can distinguish between classes. Control class is plotted in blue and treatment class is plotted in red. Top 
middle: Back scaled loading plot: the OPLS-DA data is back-scaled to the original variables (NMR ppm/hertz) and 
plotted according to the covariance associated with the class (y-axis) as well as the correlation weights, visualised 
by colour. This plot allows easy visualisation of which variables in the data have discriminatory importance in the 
data. Top right: histogram of the number of components used to create the OPLS-DA model with each iteration of 
cross-validation. Bottom left: Predicted Residual Sum of Squares (PRESS) dot-plot for sample and permutated 
data each samples in the dataset. Bottom middle: 𝑄2 histogram of generated OPLS-DA models comparing sample 
data (purple) and permutated data (grey). This allows for a comparison of OPLS-DA models of the data and random 
noise. Bottom Right: Predictions made per sample. This allows for easy visualisation of outlier samples and give a 
general overview of the predictive ability of the OPLS-DA models.  
 
 
𝑄2 = 0.862 +- 0.038
𝑄2 perm = -0.703 +- 0.714
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In order to provide a robust statistical analysis and assess the predictability of the OPLS-DA, a double 
cross validation strategy was used (79). A representative visual output of OPLS-DA cross-validation 
data is shown in Figure 3.2. 4-fold cross-validation was performed using Leave-One-Out Cross-
Validation (LOOCV), where one sample is left out of the training set and is used as the validation data 
(168). 75% of samples were used as a training set and the remaining 25% of the samples were used 
as a test set. This ensured that the number of samples in the test set was proportional to the total 
number of samples from each class (65). The training set was then used to obtain a classification model, 
and this model was then used to predict the classes of the samples in the test set. This analysis was 
repeated for each sample in the data set. At the end the cross-validation is given as a Q2 value.  
 
The maximum number of components for the model was between 6 and 10 and the component 
selection was selected by which model gave the best F1-score. Each of these models leads to a point 
on the scores plot while loadings and weights are presented as averages over all the models. The 
procedure was repeated 200-2000 times with randomly chosen samples in the training and test sets, 
this was to prevent bias due to an unlucky choice of validation. to assess whether the differences 
between classes occurred by chance as well as to give a reference value for Q2. In total 4 × 2000 
models was generated. In addition to the Q2 histogram, the data were plotted into the back-scaled 
loadings, the principal components histogram, the predicted residual error sum of squares 
(PRESS)/sample and the predictions per sample plots.  
3.2.5 Qualitative and Quantitative Metabolic Analysis  
Metabolite assignment was done by comparing peak chemical shifts to those found in the literature (60) 
and in metabolomic database: Human Metabolome Database (HMDB) (169), and Biological Magnetic 
Resonance Data Bank (BMRB) (170) and Chenomx Software. Representative 2D spectra were also 
obtained to support the assignment. The 2D experiments conducted were Heteronuclear single 
quantum coherence spectroscopy (HSQC), homonuclear correlation spectroscopy (COSY), and 
homonuclear J-resolved spectroscopy (J-RES) experiments were conducted. Representative figures of 
2D spectra with partial assignments and 1D assignment with Chenomx are shown in Appendix B. 
MultiExperiment Viewer (MeV) which is a part of the TM4 Microarray Software Suite (171) was used to 
quantify the variations in metabolite concentrations and generation of heat maps and Hierarchical 
cluster analysis (HCL). The Euclidian distance algorithm was used to compute the differences between 
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metabolite level changes and the average linkage method was used to define the distances. Additional 
Heat map generation and analysis was performed in R using the Heatmap2 library. 
The online software MetaboAnalyst 2.0 (172) and 3.0 (173) was to identify the metabolic pathways most 
likely to be involved in the treatment effects. The list of relevant metabolites was uploaded into the 
Pathway Analysis and human pathway library was selected. Hypergeometric test was used to determine 
whether a metabolite occurred more than by chance in a compound list, and relative-betweenness 
centrality was selected for metabolite importance determination by measuring in a graph network the 
number of shortest paths going through the node.  
3.3 Bioinformatics 
3.3.1 GSEA (Gene Set Enrichment Analysis) 
Gene Set Enrichment Analysis is a computational method that determine whether a pre-defined set of 
genes shows significant expression enrichment between two biological states. The sets of genes used 
with GSEA software are derived from a collection of annotated gene sets known as the Molecular 
Signatures Database (MSigDB). It is also possible to create gene sets for analysis. For statistical 
purposes GSEA compares the expression of the given gene set to a random walk. Shortly, the gene 
set enrichment analysis uses a given set of gene expression data and examines its overall correlation 
with a phenotype by progressing or ‘walking down’ the gene list. The Enrichment Score (ES) starts at 
zero and decreases gradually, when it encounters a gene expression correlates with the phenotype, 
the ES is increased proportional to the correlation between the individual gene and the phenotype. In 
this way a curve is obtained (seen in green in Figure 3.3).  Statistical significance is determined by 




Figure 3.3. A Representative GSEA output. GSEA calculates the enrichment score (ES) by progressing or ‘walking 
down’ a ranked list of given genes in a gene set (represented by black lines in figure). As the algorithm progresses, 
the ES decreases gradually. When a gene in the set correlates with the phenotype in question, the ES (shown as 
a green line) increases proportional to the correlation of the gene expression with the phenotype. Statistical 
significance is then determined by comparing the obtained ES to a permutated dataset which is used as the null-
hypothesis (174).  
 
3.3.2 Analysis of gene expression from human databases 
Gene expression data of human melanoma samples from published microarray studies was used to 
analyse gene expression in melanoma progression as in (154).  
3.3.3 Gene Expression Omnibus (GEO)  
The National Center for Biotechnology Information’s (NCBI) Gene Expression Omnibus (GEO) - a 
public, international repository of, amongst other datasets, gene expression profiles - was accessed as 
the source of five MIAME-compliant transcriptomic databases. These databases, signified by their GEO 
accession number, were: GSE29359; GSE3189; GSE8401; GSE46517; GSE7553 (supplementary to, 
respectively: Avery-Kiejda et al., 2011 (175); Talantov et al., 2005 (176); Xu et al., 2008 (177); Kabbarah 
et al., 2010 (178); Riker et al., 2008 (179)). Avery-Kiejda et al. focussed on a comparison of gene 
expression profiles between ‘melanocytes’ and ‘melanoma’ cells (n=8, n=92, respectively), whilst 
Talantov et al. focussed on a comparison between ‘normal’ and ‘malignant’ cells (n=7, n=45, 
respectively). Hereafter, these two comparative conditions will be defined as a comparison between 
‘normal’ cells (non-tumorous) and ‘primary’ cells (tumorous, non-metastatic). Xu et al., Kabbarah et al. 
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and Riker et al. each analysed ‘primary’ and ‘metastatic’ cells (n=31 and n=52; n=31 and n=73; n=14 
and n=40, respectively). 
Gene expression data was extracted from each of the 5 databases for the genes of interest. In each of 
these databases, initial gene selection for subsequent experimental analysis was based upon the 
exclusion criteria that the gene exhibited a significant (p<0.05) fold-change expression of 1.5 or greater 
in primary or metastatic cells with regards to normal or primary cells, respectively. This was determined 
by means of performing an unpaired t test for each of the comparisons for each gene. In the case that 
multiple primers were used for individual gene expression analyses in a single microarray, the datum 
representing the greatest fold-change expression was selected.  
3.3.4 The Cancer Genome Atlas (TCGA) and Survival Analysis 
Data from The Cancer Genome Atlas (TCGA) – a joint effort of the National Cancer Institute 
(NCI) and the National Human Genome Research Institute (NHGRI); both part of the US National 
Institutes of Health (NIH) which comprehensively catalogues a broad spectrum of expression profiles 
and tumorigenic mutations – was accessed from the cBioPortal for Cancer Genomics (180,181). In 
particular, data was obtained from the supplementary work of (182), detailing expression profiles in 257 
Skin Cutaneous Melanoma (SKCM) patients with complete sequencing and copy number alteration 
(CNA) data, from a total patient database of 470. 
Gene expression and patient survival data was extracted for the 94 genes previously detailed. Since 
individual survival times, both censored and uncensored were available for each patient, we utilised the 
Kaplan-Meier method of cumulative group survival determination. The Kaplan-Meier survival estimate 
of each of the genes was determined from survival curves using IBM SPSS Statistics 22 and Graphpad 
Prism 6. The vital statistic of each patient was defined and limited by an absolute time-frame of 10 years 
following initial diagnosis. 
gene exhibited a significant (p<0.05) association with negative prognosis in patients over the 10-year 
period of observation. 
3.3.5 Heatmap Generation 
Heatmaps were generated using the open source Multiple Experiment Viewer (MEV) software. Loading 
data from OPLS-DA models were used for Heatmap data at buckets selected for identified metabolites. 
To generate the heatmaps Euclidean distance was calculated with average linkage clustering. Both 





4-12% Bis-Tris polyacrylamide precast gels NuPage  Invitrogen 
AlexaFluor ® Phalloidin 546 Life Technologies 
Amersham ECL Prime GE Healthcare 
Amersham ECL Western 
Blotting Detection Reagent 
GE Healthcare 
Amersham Hyperfilm ECL GE Healthcare 
Amersham rainbow protein molecular marker GE Healthcare 
Atelopeptide  bovine collagen I, PureCol Advanced BioMatrix 
Bis – acrylamide 29:1 40% solution Fisher Scientific 
Cassettes 1.5 mm Life technologies 
Complete EDTA-free protease 
inhibitor cocktail tablets 
ROCHE 
Dimethyl sulfoxide (DMSO) Sigma 
Dulbecco’s Modified Eagle Medium (DMEM) Life Technologies 
Dulbecco’s Phosphate Buffered Saline (PBS) Life Technologies 
Glass bottom culture dish (35mm dish, 14 mm well) MatTek 
H1152 Calbiochem 
Hoescht 33258 Pentahydrate Invitrogen 
MOPS SDS running buffer Invitrogen 
NUPAGE ® LDS sample buffer Life Technologies 
NUPAGE® MES SDS running buffer Life Technologies 
Opti-MEM reduced serum media Life Technologies 
PCR microplate Thermo-Fast 96 well non-skirted white  Thermo Scientific 
Penicillin – Streptomycin Life Technologies 
RPMI Medium 1640 Life Technologies 
Serum Sigma 
Tetramethylethylenediamine (TEMED) Sigma 
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Tripsin 0.05% EDTA Life technologies 
Trizol Life technologies 
Ultra-clear cap strips from PCR microplates Thermo Scientific 
Water resistant marker pen DAKO 
Whatman 3MM chromatography paper Whatman 
Xylene Sigma 
Y27632 Tocris Bioscience 
CFM-2  
MK-801 (Diclozipine)  







Brilliant III SYBR Green QRT-PCR kit Agilent 
DNA-free™ DNA Removal Kit Life technologies 
 





Laemli buffer 0 .1 mM DTT + 1M glycerol phosphate + 0.5M sodium 
fluoride + 100 mM Sodium Vanadate  
+ 0.1 PMSF + phosphatase inhibitors 
PVDF membrane stripping solution 0.1M Guanadine hydrochloride pH 2.5 
Transfer buffer 100 ml TrisGlycine + 200 ml methanol  
+ 700 ml H20 
Acrylamide gel 10% gel: 2.5 ml 40% acrylamide + 2.5 ml TrisHcl pH 8.8 
+ 5 ml H2O + 66.7 μl APS + 13.3 TEMED 
Acrylamide stacking gel 0.98 ml 40% acrylamide + 2.5 ml Tris HCl pH 6.8  
+ 6.4 ml H2O + 100 μl APS + 20 μl TEMED 
3.7 Antibodies 
Antibody Species and concentration Use Supplier 
GAPDH Mouse, 1:10,000 WB Abcam (MAB374) 
MLC2 Rabbit, 1:500 WB Santa Cruz (sc-15370) 
GRIK2 Rabbit 1:100 WB Abcam (ab66440) 
ROCK1 Rabbit 1:1,200 WB BD Transduction 
Laboratories 
ROCK2 Rabbit 1:500 WB Abcam 
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pThr18/Ser19-MLC2 Rabbit, 1:500 WB Cell Signalling 
(#3674) 
pSer19-MLC2 Rabbit, 1:50 IF Cell Signalling 
(#3671) 




WB VWR International 
(NA931) 




WB VWR International 
(NA934) 
Anti-rabbit Igg secondary 




IF ThermoFisher Scientific 
(ab150077) 
Anti-rabbit Igg secondary 









siRNAs were purchased from Dharmacon (GE Healthcare). Genes and respective siRNA sequences 



























































































































































Chapter 4 : A Metabolomic Investigation of Rho/ROCK 




Melanomas are the deadliest form of skin cancer and despite great advances in the treatment of 
malignancy, there is still a need for alternative targeted therapies of disease that can address non-
response and resistance that arises in patients after receiving currently available therapies (183). Rho 
Kinase (ROCK) is an attractive target to treat metastatic melanoma as it has been shown to regulate 
both melanoma proliferation and the formation of metastasis in vitro models of melanoma (3,5). 
Targeting cancer metabolism represents another attractive area of research into potential cancer 
therapies as cancer cells often present with re-wired metabolism that allows for increased proliferation, 
resistance to apoptosis, and metabolic signalling (16). ROCK is principally studied for its role in 
regulating the actin cytoskeleton by promoting high levels of actomyosin contractility. ROCK has been 
shown to regulate cellular metabolism in non-cancer cells and its role in insulin response has been well 
established (130,157). There is also some evidence that ROCK may play a role in promoting altered 
metabolism in cancer cells (155,158,184), however, these studies are few relative to the interest that 
ROCK has received in recent years with regards to melanoma. ROCK may re-wire cellular metabolism 
to sustain high levels of cellular contractility along with proliferative and invasive potential. In this section 
of the thesis we aim to address this gap in knowledge by studying the metabolic profile of human and 
murine melanoma cells when ROCK activity or expression is ablated. 
4.1.1 Study Design 
We hypothesize that ROCK activity regulates melanoma cell metabolism and our principle objective is 
to investigate how ROCK activity and expression is regulating cellular metabolism.  An introduction to 
the study design follows.  
4.1.2 In vitro models of metastatic melanoma 
One of the principle functions of ROCK is to regulate the actin cytoskeleton and increase cellular 
contractility by phosphorylating myosin light chain (141). These effects are best measured in vitro with 
what is called a ‘2 ½ D’ cell culture system by which cultured cells are placed atop a thick layer of 
collagen 1, either bovine or rat tail (140,185). Cells can then be measured phenotypically by microscopic 
imaging measuring the ‘roundness index’ of the cells which is the ratio between the largest and smallest 
diameter. Cellular contractility is then measured biochemically by quantifying the amount of 
phosphorylated myosin light chain 2 (p-MLC). This can be done by Western blot, calculating the ratio 
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between p-MLC to total-MLC. Otherwise, contractility can be measured by immunohistochemistry and 
confocal imaging of fixed cells stained for p-MLC.  
For this thesis we principally use the A375M2 human metastatic melanoma cell line. This cell line is a 
derivative of the original A375 parental cell line, initially derived from a 54 year old female (186). The 
M2 variant was produced by two rounds of injection of A375P cells into the tail vein of mice, extracting 
and culturing the lung metastases. A375M2 cells have much higher levels of p-MLC compared to the 
parental cells and when cultured onto a thick collagen-1 layer present with 95% rounded cells when 
compared to the 50/50 round/elongated phenotype displayed by the A375P cells (154) (Figure 4.1).  
We also use the B16F10 mouse melanoma cells line which is a variant of the B16F0 cell line. B16F10 
cells were generated in a similar fashion to the A375M2 cells however with ten rounds of harvesting 
lung metastases (187) as opposed to the two rounds of A375M2 cells. 
 
Figure 4.1. A375M2 Human Melanoma Cells as an in vitro model of metastatic melanoma with high levels of 
actomyosin contractility and Rho/ROCK signalling. A) Cells are classified into binary categories of ‘round’ or 
‘elongated’. A375M2 cells are 95% rounded when seeded on a collagen 1 matrix compared to the 50/50 
rounded/elongated of A375 Parental cells.  B) Roundness can also be quantified by finding the roundness index; 
the ratio between the largest diameter and the shortest diameter, where a perfect circle is 1 and a straight line is 
0. Cells with high roundness levels also present with blebbing.  C) A375M2 cells have high levels of actomyosin 
contractility, seen by increased levels of double phosphorylated myosin light chain 2 (p-MLC) show in western blot. 
Figure adapted from (154). 
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In this chapter, we have chosen to interfere with ROCK activity using three different strategies. They 
are: 1) small molecule inhibition of ROCK, 2) interference of ROCK expression by use of small 
interfering RNAs (siRNA) technology, 3) genetic knock out (KO) of ROCK in a murine model of 
malignant melanoma.  
Each method proposed has its advantages and disadvantages when it comes to targeting ROCK. Small 
molecules have a very rapid mode of action and can take effect within very small time frames. However, 
kinases are inherently very similar topologically and therefore small molecules looking to block the 
kinase activity can have off-target effects by blocking alternative kinases. It is known that ROCK 
inhibitors can bind to a variety of other kinases, such as AKT2, PKA, PKC, PKG, CAMK2 and MLCK 
(Table 2). 
 
Table 2. ROCK inhibitors and binding specificities. There are hundreds of ROCK inhibitors available for research 
however few have been used in vitro. Here listed are the ROCK inhibitors most widely used. The specificity of 
ROCK inhibitors are vastly different and have binding specificities for other kinases as well. Fasudil is the only 





For our study we have chosen to test three ROCK inhibitors. We make use of two classic inhibitors, 
H1152-p and Y27632, which are well evaluated in the literature (3,95,140,184). In addition, we make 
use of a newer generation of ROCK inhibitor, GSK269962A (GSK269), first developed in 2007(188). 
GSK269 has more than double the binding affinity to ROCK2 compared to H1152 and more than 7-fold 
increased binding affinity to ROCK1 compared to H1152 (Table 2). 
For our studies we will be using H1152 at a concentration of 5 µM and Y27632 at concentrations of 10 
and 20 µM. These concentrations were chosen to allow us to compare our results to those from previous 
studies in the Sanz-Moreno group (140,154,184,189). GSK269 will be used at a concentration of 0.1 
µM, as it has been previously shown that 0.1 µM GSK269 is sufficient to induce significant 






Figure 4.2. 0.1 µM GSK269 is sufficient to significantly alter A375M2 human melanoma cell morphology. A-D) Light 
microscopy images of A375M2 cells seeded onto collagen 1 show that 0.1 µM GSK269 is sufficient to induce an 
elongated phenotype. A) 5 µM DMSO control treated cells B) 5 µM H1152 treated cells C) 0.1 µM DMSO control 
treated cells D) 0.1 µM GSK269 treated cells. Below: quantification of the percentage of elongated cells after 
treatment with 0.05, 0.1, and 0.5 µM GSK269. *** -p<0.001. Data and figure generated by Francesca Di Giuseppe. 
 
 
To address the potential off target effects, from ROCK inhibitors of varying specificity, that could impact 
this study we will also make use of siRNA targeting ROCK1 and ROCK2. Gene silencing is a more 
specific way to target individual genes and observe their effects on the system, however it is rare if not 
impossible to obtain a full knockdown of gene expression by siRNA. Additionally, the full effects of the 
knockdown take several days to materialise. There is the additional challenge that we will need to 
deliver twice as many oligonucleotides to knockdown the expression of two genes simultaneously.  
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Finally, we have been graciously provided cultured murine melanoma cells where ROCK is genetically 
deleted from Dr. Sandra Kuemper in Chris Marshall’s lab. These cells were generated from a 
spontaneous murine model of melanoma where the ROCK genes were knocked out by Cre-Lox 
Recombinase technology (Dr. Sandra Kuemper, Personal communication, Figure 4.3, Figure 4.4). This 
strategy has the additional strength of being a sustained knockdown of gene expression. On the other 
hand, as these samples are of a different species care must be taken not to over interpret results. 
 
Figure 4.3. Schematic of Murine melanoma model generation. Mice harbouring the V600E BRAF mutation and the 
CRE recombinase gene spontaneously generate melanomas. These mice are bred with mice with ROCK1 and/or 
ROCK2 genes surrounded by flox/flox sites. 25% of the progeny of these mice contain all three mutations. When 
the F1 are administered tamoxifen, the expressed CRE-recombinase is activated and cuts out the ROCK genes.  
 
 
It is hoped that with three different strategies of targeting ROCK activity we may be able to identify 
common features correlating with ROCK activity that can be used as a platform for further investigation.  
ROCK activity and expression will be altered by small molecule inhibition, siRNAs targeting ROCK and 
in a murine model of melanoma where the ROCK genes are knocked out (KO).  
In our studies, the metabolomes of these cells will be studied with HR-MAS NMR, which is a highly 
reproducible metabolomic method that removes the need for labour intensive extraction protocols. 
Liquid NMR metabolomics will also be conducted to study how melanoma cells consume and secrete 
metabolites in control settings and after interfering with ROCK activity/expression. Finally, network 







Figure 4.4. Cultured murine melanoma cells of with ROCK knocked out (KO) show a more elongated phenotype 
compared to wild type cells.  A) Light microscopy images of wild-type, ROCK1 KO, ROCK2 KO and double KO 
melanoma cells. B) Western blot confirming KO and lowered levels of p-MLC compared to total-MLC. As double 
ROCK KO mice did not develop melanomas, the other isoform was knocked down in vitro for our studies. Figures 










4.2.1 Small molecule inhibition of ROCK decreases actomyosin contractility and Cell Roundness  
When seeded onto a thick layer of bovine collagen 1 and treated with ROCK inhibitors H1152-p, Y27632 
or GSK269, melanoma cells elongate significantly (Figure 4.5A) and have a reduction in p-MLC (Figure 
4.5B). H1152 showed mean 86% reduction in p-MLC compared to control while Y27632 at 10 µM 
showed a 75% reduction in p-MLC (Figure 4.5C).  
 
Figure 4.5.ROCK inhibition regulates phosphorylated-myosin light chain and cell morphology. A) Representative 
light microscopy images of A375M2 human melanoma cells seeded on a collagen 1 matrix treated with DMSO as 
control or H1152 ROCK inhibitor. B) Western Blot showing double phosphorylated myosin light chain 2 (pp-MLC) 
(pT18, pS19) compared to total myosin light chain 2 (t-MLC). GAPDH used as loading control. C)Quantification of 
pp-MLC/t-MLC by western blot (n=3). Bar chart shows mean +/- SEM error bars. **** -p<0.0001. 
 
 
4.2.2 ROCK knockdown decreases actomyosin contractility in mouse melanoma cell line B16F10 and 
decreases proliferation in vitro. 
Additional work was conducted with a murine melanoma cell line B16F10. Treating B16F10 mouse 
melanoma cells with the ROCK inhibitor H1152 at 5 µM led to a large decrease in contractility seen 
through a reduction in p-MLC (Figure 4.6A). We could also confirm that ROCK inhibition blocked cell 



















Figure 4.6. Inhibiting ROCK activity and Expression in B16F10 melanoma cells reduces cellular contractility and 
cell proliferation. A) Western blot and quantification of p-MLC levels after rock inhibition with H1152. B) Cell 
proliferation assay of B16F10 murine melanoma cells after rock inhibition. C) immunostaining and confocal imaging 
of B16F10 cells after rock knockdown show increased number of protrusions and lower p-MLC levels. D) Western 
blot confirming knockdown of ROCK2 and ROCK1 in B16F10 cells and quantification of p-MLC levels from confocal 




































When blocking ROCK expression in vitro we again observed that transient siRNA knockdowns of 
ROCK1 and ROCK2 simultaneously led to a reduction in contractility measured by p-MLC (Figure 4.6A) 
and cell morphology where more long actin protrusions were present (Figure 4.6C). 
4.2.3 1H HR-MAS NMR spectra of the human melanoma cell line A375M2 
Figure 4.7 shows mean normalised HR-MAS NMR spectra of control A375M2 cells (blue) and cells 
treated with 5 µM H1152 for 24 hours (red). Spectra were obtained on a 400 MHz NMR spectrometer. 
Assignments of metabolites associated with peaks are also showed in Figure 4.7 and can be used as 
a reference for the back scaled loadings and NMR spectra shown in this work. 24 individual metabolites 
were confidently assigned. In the HR-MAS spectra, the amino acids valine, leucine, isoleucine, 
glutamate, glutamine, alanine, tyrosine, phenylalanine was identifiable. Glutamine and glutamate were 
individually identifiable by their resonances at 2.36 ppm and 2.46 ppm respectively. Lipid components 
such as CH2-CH2 and CH3 groups were observable in HR-MAS spectra, choline, phosphocholine and 
glycerophosphocholine were also distinguishable. At higher regions, cytidine, uracil, adenine, inosine 
and uracil were observed. Taurine and creatine and myo-inositol were also observable. Residual DMSO 




Figure 4.7. Mean PQN Normalised HR-MAS NMR spectra of whole A375M2 Cells treated with DMSO control (blue) 
and 5 µM H1152-p (red) for 24 hours. Averaged spectra are composed of 9 samples each. Spectra were recorded 
on a 400 MHz Bruker Magnet. Identified metabolites are assigned in figure. A) Full spectrum with zoomed inset of 
high ppm region. B) zoom of low ppm region with assigned metabolites. The water region between 4.5 and 5.2 




























4.2.4 Small Molecule Inhibition of ROCK alters the cellular metabolome 
Each treatment of ROCK inhibitors led to a significant shift in the cellular metabolome of A375M2 cells 
(Figure 4.9). H1152 showed a shifted in metabolism at concentrations of 5 µM (Q² =0.246) while Y27632 
was tested at both 10 µM (Q² =0.156) and 20 µM (Q² =0.193). With regards to GSK269, cells were 
tested with both 0.1 µM and 5 µM concentrations (Q² = 0.607 and Q² = 0.521 respectively). This was 
done as initially 0.1 µM GSK269 was seen to be sufficient induce morphological changes in A375M2 
cells (Figure 4.2). Further work was performed with 5 µM doses to observe the metabolic profile of cells 
concentrations that induced anti-proliferative effects similar to those seen with H1152 and Y27362 
(Figure 4.8). In both cases significant changes in metabolic profiles and 0.1 µM was sufficient to see a 
large significant change in the metabolome. 
 
Figure 4.8. 5uM GSK269 is required for anti-proliferative effects in A375M2 human melanoma. A375M2 cells were 
treated with different doses of GSK269 for 48 hours and then cells were counted. Doses used were 0.5 µM, 1 µM, 




This data suggests ROCK play a significant role in rewiring the cellular metabolome. We observed 
significant metabolic changes at doses of ROCK inhibitors that do no limit cell proliferation, suggesting 
these changes may be independent of the anti-proliferative effects and may be tied to the morphological 
effects. The performance of the OPLS-DA models also suggests that the stronger binding affinities of 






Figure 4.9. ROCK inhibition significantly alters the metabolic profiles of A375M2 human melanoma cells. A,B,C) 
Scores plots, back scaled loadings and mean PQN normalised spectra of HR-MAS NMR data from small molecule 
inhibition of ROCK. A) H1152 5 μM B) Y27362 at 20 μM C) GSK269 5 μM. Every experiment was conducted n=3 




Hierarchical clustering of the NMR data of assigned metabolites also suggest that specificity of ROCK 
inhibitors can be reflected phenotypically in the cellular metabolome. Euclidean distance mapping show 
that the metabolic profiles induced by H1152 and GSK269 cluster more closely than Y27632 (Figure 
4.9, Figure 4.18). 
There were several consistent metabolic changes observed across treatments. We observed significant 












large role in regulating cell morphology, it would be interesting for future work to study the fluidity of 
melanoma cell membranes after ROCK inhibition. 
There were also significant decreases in choline, glycerophosphocholine, phosphocholine and 
glutamate. Myo-inositol decreased sharply in H1152 and GSK269 treated cells however increased in 
Y27632 treated cells.  
4.2.5  Glutamine, glutamate and glutathione are initially depleted in melanoma cells treated with 
GSK269 followed by recovery at 24 hours 
It has previously been observed that small molecule inhibition of ROCK leads to changes in the 
cytoskeleton within a few hours of treatment. Therefore, we were interested in understanding how the 
cellular metabolome may be changing within a shorter time frame than in previous experiments. Cells 
were treated with 5 µM GSK269 and harvested at 4, 8 and 24 hours. It was seen that after 4 hours there 
was already an observable change in the metabolome (Q² =0.298) which then became much larger at 
8 hours (Q² =0.761) (Figure 4.10B, C, Figure 4.11A). It seems the cells attempt to recover the initial 
challenge which is reflected in the smaller separation between classes at 24 hours (Q² =0.521) (Figure 




Figure 4.10. GSK269 alters melanoma metabolism within 4 hours and has sustained effects on metabolism at 24 
hours. A) Addition of the ROCK inhibitor GSK269 leads to increased number of protrusions and elongated 
phenotype of A375M2 cells on plastic. Representative light microscopy images of A375M2 cells on plastic at 4 and 
24 hours treatment of 5 μM GSK269. B,C,D) Scores plots, Q² values and Back-scaled loadings of OPLS-DA models 
at 4,8 and 24-hour time points. Every experiment was conducted n=3 times, and each experimental replicate 




















An initial decreased in saturated lipids at 4 hours was observed, however, it reversed into an increase 
in at 8 hours that was sustained after 24 hours (Figure 4.10C, D, Figure 4.11A). The decreases in 
choline and phosphocholine are already observable at 4 hours and are sustained at 24 hours while 





Figure 4.11. Time-course analysis with 5uM GSK269 at 4, 8 and 24hours. A) Heat map of A375M2 cells treated 
with 5µM GSK269 for 4, 8 and 24 hours. Hierarchical clustering was performed calculating Euclidean distance and 
average linkage. Colours represent covariance associated with treatment with lower covariance in green and higher 
covariance in red. B) Line chart showing fold change of glutamine, glutamate and glutathione at different time-






Glutamate and Glutathione decreased steadily until 8 hours and then recover slightly at 24 hours (Figure 
4.10C, D, Figure 4.11B). Glutathione is the major antioxidant in cells and it is known that high levels of 
ROCK signalling can inhibit reactive oxygen species (184). It could be explained that initial ROCK 
inhibition leads to a depletion of glutathione as cells respond to oxidative stress. In longer time points, 
cells start to replenish glutathione by switching on synthetic pathways.  
4.2.6 Sequential Knockdown of ROCK2 then ROCK1 gives optimal gene silencing 
Silencing ROCK expression with siRNAs will reveal which metabolic changes observed in the small 
molecule experiments are specific to ROCK and could identify which effects are due to off target effects 
of the small molecule inhibitors. Work was conducted to achieve an optimal silencing of ROCK with 
consideration to the added difficult of silencing two genes at once. The standard protocol (163) was 
conducted simultaneously delivering ROCK1 and ROCK2 siRNA (2 µl ROCK1 and 2 µl ROCK2 siRNA 
complexed with 3.5 µl LAH4-L1 peptide). The ‘Double’ protocol saw 4 µl ROCK1 and 4 µl ROCK2 siRNA 
complexed with 3.5 µl peptide followed by simultaneous delivery. Sequential knockdowns were also 
tested, with either siROCK1 or siROCK2 being delivered on the first day and siROCK2 or siROCk1 




Figure 4.12. Optimisation of siRNA knockdowns of ROCK1 and ROCK2 in A37M2 cells. A) Representative 
Immunostaining and confocal imaging of A375M2 human melanoma cells after sequential knockdown of first 
ROCK2 then ROCK1. B) Quantification of p-MLC levels from confocal imaging data C) Quantification of roundness 
of melanoma cells after rock knockdowns with different siRNA delivery strategies D) validation of knockdown of 
ROCK by qPCR E) Validation of knockdown of ROCK by western blot. Bar charts show mean value and error bars 
represent standard error of the mean. All experiments are n=3. * p<0.05, ** p<0.01 ***p<0.001. 
 
 
Ctrl Standard Double ROCK1(2) ROCK2(1)
ROCK1 1.00 0.68 0.65 0.33 0.37





















































** *** *** ***





siCtrl Standard Double ROCK1(2) ROCK2(1)
ROCK1 1.00 0.81 0.72 0.55 0.54








































The sequential knockdown of ROCK2 then ROCK1 was observed to give the most efficient knockdown 
when checking p-MLC levels in immunofluorescence (Figure 4.12B). It was also similar to the ROCK1 
then ROCK2 sequential knockdown in terms of RNA and Protein levels (Figure 4.12D, E). The 
sequential knockdown of ROCK2 then ROCK1 was also significantly more effective than the standard 
protocol showing a 33.9% +/- 5.6% less p-MLC (Figure 4.12C). For these reasons, the sequential 
knockdown of ROCK2 then ROCK1 was chosen as the protocol used for treating cells prior to NMR 
analysis. 
4.2.7 Effects of the delivery peptide LAH4-1 on cellular metabolism 
Challenging cells with a peptide/RNA complex could in itself alter the cellular metabolome and induce 
different stress responses. It has been shown previously that choline containing metabolites increase 
after transfection, probably due to membrane disruption during siRNA delivery(190). Delivery of other 
nanoparticles has also been observed to induce stress responses in cells(191). Metabolomic studies 
were conducted and OPLS-DA was performed between untreated A375M2 cells and those treated with 
non-targeting siRNA. A significant shift in the metabolome of the cells was observed (Q² = 0.795 vs 
random Q² =-0.405) (Figure 4.13A). There is a decrease of the methyl groups of lipids in the cells 
accompanied by an increase in unsaturated lipids (Figure 4.13B). We also observed an increase in 
glutamate, glutamine and glutathione. Finally, there was an increase in phosphocholine while choline 
and glycerophosphocholine decreased slightly. These observed changes are in accordance with 
previous observations(190) and demonstrate how not only DNA plasmid transfection but siRNA 
oligonucleotides can disrupt the cell membrane. This also demonstrates the importance of using non-





Figure 4.13. Metabolomic changes observed in A375M2 cells after transfection with LAH4-L1 Peptide/siRNA 
complex. A) scores plot showing statistical separation between treatment (blue) and control (red). Q² histogram 
showing Q² distribution of OPLS-DA models (blue) and OPLS-DA models of data with permutated classes (grey). 
B) back scale loadings plot and mean normalised HR-MAS NMR spectra illustrating difference in metabolome after 
treatment with peptide/RNA complex. Experiments were conducted n=3 times, and each experimental replicate 
containing three technical replicates, for a total of 9 samples per experimental condition. 
 
 
4.2.8 ROCK1/2 Knockdown significantly alters Cellular metabolism 
A clear separation between cell treated with non-targeting siRNA and cells treated with ROCK double 
knockdown was observed (Q² =0.747 vs. random Q² =-0.293, Figure 4.14A).  
Increases in the CH2-CH2 bonds of lipids was observed, similar to that seen in the small molecule 
treatments. This was accompanied by a decrease in unsaturated lipids as well as decreases in 
glutamate and glutathione, which is also consistent with the small molecule treatments (Figure 4.14B). 
An increase in myo-inositol was observed in the siRNA treatments which is opposite when compared 



































Figure 4.14. Metabolic changes observed in A375M2 cells after silencing ROCK1 and ROCK2 when compared to 
non-targeting siRNA. A) scores plot showing statistical separation between treatment (blue) and control (red). Q² 
histogram showing Q² distribution of OPLS-DA models (blue) and OPLS-DA models of data with permutated 
classes (grey). B) Back scaled loadings and mean normalised spectra highlighting differences between siCtrl 
treated A375M2 cells and siROCK treated cells. Experiments were conducted n=3 times, and each experimental 
replicate containing three technical replicates, for a total of 9 samples per experimental condition. 
 
 
4.2.9 Cultured Melanomas Extracted from ROCK KO mice reveal differing metabolic profiles between 
ROCK1 and ROCK2 single KOs and ROCK1/2 KO mice. 
In this section we study an ex vivo model of murine melanoma where ROCK is genetically deleted. 
Murine melanoma samples were generated, profiled and provided for metabolomic studies by Dr. 
Sandra Kuemper. Previously reported data demonstrate that ROCK1 and ROCK2 play redundant roles 
in sustaining melanoma proliferation (5) and to stop proliferation both isoforms must be knocked out.  
As discussed in the introduction of this chapter, murine melanoma samples where ROCK was knocked 
out either individually or together, were compared to wild-type melanomas (Figure 4.3). ROCK KOs 


































MLC (Figure 4.4B). Knock out of both ROCKs in the murine model lead to no melanoma formation, 
therefore to study the metabolome of a double ROCK depletion individual ROCK KO melanomas were 
extracted, cultured and the other isoform of ROCK was knocked out in vitro. In every studied case 
significant changes in the metabolome were seen (ROCK1 Q² = 0.628, ROCK2 Q² = 0.779, ROCK1/2 
Q² = 0.678) (Figure 4.15).  
Individual KOs of ROCK show distinct metabolic profiles. ROCK1 KO melanomas showed increases in 
the CH2-CH2 bonds of lipids and phosphocholine while there was a decrease in alanine and myo-
inositol (Figure 4.15A, Figure 4.16). ROCK2 KO had increases in valine, alanine, glutamine, myo-
inositol and the methyl groups of lipids (Figure 4.15B, Figure 4.16). There was a decrease in choline 




Figure 4.15. Back scale loadings plots with scores plots in-set of ROCK knocked murine melanomas. A) ROCK1 
KO B) ROCK2 KO B) ROCK1/ROCK2 double KO Experiments were conducted n=3 times, and each experimental 
replicate containing three technical replicates, for a total of 9 samples per experimental condition. 
 
The Double ROCK KO showed large increases in the methyl resonance of lipids and the CH2-CH2 
resonance of lipids which is similar to that seen in the small molecule treatments and siRNA treated 
cells (Figure 4.15C, Figure 4.16). There was an increase in choline and a decrease in phosphocholine 
and glycerophosphocholine. The decrease in glutamate observed in the previous experiments targeting 









ROCKs play redundant roles in glutamate metabolism (Figure 4.16). There was also an increase in 
creatine in the double KO not observed in the individual KOs  
 
Figure 4.16. Heatmap of Mouse melanoma metabolic profiles. Hierarchical clustering of both metabolites and 
treatments was performed calculating Euclidean distance and average linkage. Colours represent covariance 
associated with treatment with lower covariance in green and higher covariance in red. Glutamate is circled in red 
to show functional redundancy of ROCk1 and ROCK2 in regulating intracellular glutamate levels. In the single KOs 
there is no change in glutamate, however in the double KO there is a reduction in glutamate levels. 
 
 
There was an observed decrease glutamine and alanine in the ROCK1 KO while they were increased 
in the ROCK2 KO. In the double ROCK KO there is no change in either glutamine or alanine compared 
to wild-type (Figure 4.16). This suggests that ROCK1 and ROCK2 play opposing roles in regulating 
glutamine and alanine metabolism. However, as glutamine and glutamate are so tightly intertwined in 
their metabolic regulation these findings will have to be further explored. Alanine is also tied to glutamine 
metabolism, it has been shown in glioblastoma that 60% of glutamine is secreted as lactate and alanine 
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(192). Future work could further investigate glutamine utilisation in melanomas using labelled 
metabolites. 
ROCKs play redundant roles in regulating melanoma proliferation(5). How the individual isoforms 
regulate metabolism may shed light into potential mechanisms ROCK dependent regulation of 
proliferation. Metabolites that have subtle changes in individual KO while having larger changes in the 
double KO may suggest metabolic pathways that are redundantly regulated by both isoforms and 
suggest pathways critical to sustain melanoma proliferation. On the other hand, metabolites that show 
large changes in the individual KO suggest metabolites and pathways that are not critical to melanoma 
proliferation. In this set of experiments, glutamate stands out as there is no observed change in 





H1152 5 μM 0.246 -0.500 
Y27632 10 μM 0.156 -0.487 
Y27632 20 μM 0.193 -0.474 
GSK269 0.1 μM 0.607 -0.355 
GSK269 5 μM 0.554 -0.660 




Table 3. Q² values of Metabolomics Experiments presented in this chapter. 
 
 
4.2.10 Silencing of ROCK1 and ROCK2 in A375M2 melanoma cells show similar metabolic profiles  
Based on the results from the murine models of ROCK KO melanomas (Figure 4.15, Figure 4.16), 
similar experiments were conducted in A375M2 human melanomas to see if results could be replicated 
in a model of human melanoma. ROCK1 or ROCK2 expression was transiently silenced with siRNA 
and their metabolic profiles were studied. 
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It was observed that the individual knockdowns of ROCK1 and ROCK2 both had good separation of 
metabolic profiles when compared to siCtrl treated A375M2 cells (siROCK1 Q² = 0.679, siROCK2 Q² 
=0.535). Both conditions had very similar metabolic profiles to each other when compared to non-
targeting siRNA treated cells (Figure 4.17A, B). In both comparisons, the majority of the separation 
between classes seems to be attributed to a reduction the CH2-CH2 and CH3 resonances of lipids. 




Figure 4.17. Back scaled loadings plots with scores plots and mean Q² values inset of OPLS-DA models of (A) 
siCtrl vs. siROCK1 (B) siCtrl vs. siROCK2 and (C) siROCK1 vs. siROCK2 A375M2 melanoma cells. Experiments 
were conducted n=3 times, and each experimental replicate containing three technical replicates, for a total of 9 













A comparison between siROCK1 treated cells and siROCK2 treated cells was also performed and 
showed separation between classes (Q² = 0.406). The back scaled loading plot from this comparison 
shows a decrease in most metabolites in the siROCK2 condition compared to the siROCK1 condition 
with the exception of saturated lipids (Figure 4.17C). The data suggests that in A375M2 cells the 
changes in metabolism responsible by ROCK are mainly a factor of magnitude rather than of differential 
regulation of metabolism, with ROCK1 being more responsible for saturated lipids while ROCK2 driving 
increases in most other metabolites. This observation is partially consistent with what was observe in 
the murine models of ROCK KO melanoma. In those experiments it was seen that ROCK1 KO led to 
increases in saturated lipids while ROCK2 KO had no change in saturated lipids. The difference is that 
these changes in CH2-CH2 bonds of lipids were observed in the comparison with wild type melanomas 
while the changes observed in this section only became apparent when comparing siROCK1 and 
siROCK2 treated melanoma cells. In the comparison with siCtrl treated cells, there was a general 
decrease in lipids.  
When comparing siROCK1 and siROCK2 treated human melanoma cells, we still observed a significant 
difference in the metabolic profiles (Figure 4.17C). This is very different to the effects observed in the 
murine model shown in section 4.2.9 (Figure 4.15, Figure 4.16), where we observed that individual KOs 
of ROCK in the murine models led to very different metabolic profiles. Compared to wild-type 
melanoma. 
The difference between results could be due to weak silencing of ROCK1 and ROCK2 expression; data 
validating the knockdown of ROCK1 and ROCK2 are not currently available. It could also be explained 
by the very different systems of murine melanomas and human melanoma cells lines used.  
4.2.11 Hierarchical clustering of metabolomics data strongly correlates with IC50 data of ROCK SMI 
Hierarchical cluster analysis of the generated metabolomic data show that the metabolic profile of the 
cells treated with the more specific ROCK inhibitor GSK269, clusters more closely to the genetic 
alterations of ROCK than the metabolic profile of cells treated with the less specific inhibitors H1152 
and Y27362 (Figure 4.18). The siRNA ROCK treatment clustered closest with the GSK269 treatment. 
Together they then formed a cluster with the ROCK double KO in the murine melanoma cells. It is 
interesting to note that the metabolic profiles of the treatments correlate so closely despite coming from 
different species. Finally, H1152 and Y27362 clustered furthest from the other treatments which is in 
agreement with the smaller metabolic changes observed in the OPLS-DA comparisons. 
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Studying the ratios of some critical metabolites can also reveal information about the underlying biology 
taking place in the cells. For example, the alanine/lactate (ala/lac) ratio is known as a marker for the 
redox state of cells as both alanine and lactate are produced form pyruvate and are coupled with NAD+ 
and NADH (193). From our data, only H1152 alters ala/lac (Figure 7.5 in Appendix B).  
Another example is the glycerophosphocholine/phosphocholine (GPC/PC) ratio, which uses the 
knowledge that malignant tissues contain more phosphocholine with an accompanying decrease in 
(194). From our studies, we did not observe great changes in GPC/PC after ROCK inhibitor treatments, 
however there was a decrease in GPC/PC in mouse melanoma cells were ROCK was knocked out 
(Figure 7.6 in Appendix B). In the time course experiments with GSK269, we observed there was an 
initial increase of GPC and decrease of PC at 4 and 8 hours, while at 24 hours this change had stabilised 
(Figure 4.11). These changes in GPC and PC after ROCK inhibition on a short time scale are consistent 
with the hypothesis that ROCK activity is tied to a malignant phenotype. The fact that this is not observed 
at 24 hours in the time-course experiments with GSK269 could also explain the lack of changes in 
GPC/PC observed in other ROCK inhibitors experiments at 24 hours.  
From Figure 4.18 we can observe that most conditions correlated with a decrease in glutamate 
concentrations, which becomes the rationale for further investigation into glutamine and glutamate 
metabolism in melanoma in the following chapters. Full spectral overlays of the NMR spectra of 





Figure 4.18. Heat map of all ROCK cellular metabolomic data with hierarchical clustering. Hierarchical clustering 




4.2.12 Metabolomics of Spent media reveal Consumption patterns of melanoma cells in culture 
Thus far, work has been conducted looking solely at the intracellular metabolites. We observed 
significant and consistent changes in metabolism of melanoma cells after altering ROCK activity and 
expression. To gain a broader picture of the metabolism of the cells we studied the spent media of 
A375M2 cells after ROCK inhibition or silencing. Work was conducted aiming to understand how ROCK 
activity might affect how melanoma cells are using the cell culture media and secreting metabolites into 
the spent media. It has been seen that melanomas secrete glutamate into the tumour microenvironment 







Figure 4.19. Representative NMR Spectra comparing fresh and spent cell culture media after siRNA transfection. 
Top) Spent DMEM cell culture media from A375M2 human melanoma cells after transfection. The large acetate 
peak is due to the counter-ion from the cationic peptide transfection vector used in the transfection process. Bottom) 
Fresh DMEM cell culture media.  
 
 
4.2.13 Melanoma Cells consume more glucose, secrete more lactate and secrete less glutamate after 
ROCK inhibition 
An initial observation of the NMR spectra generated from fresh cell culture media compared to spent 
cell culture media reveal that A375M2 melanoma cells secrete large amounts of lactic acid, and to a 
lesser extent alanine and glutamate (Figure 4.19). In the figure there is a substantial acetate peak which 
is a residual from the transfection protocol. The transfection vector LAH4-L1 is dissolved in acetic acid 
to displace trifluoroacetic acid as a counter ion priori to lyophilisation and the acetate is present in 
solution when the peptide-siRNA complexes are produced. 
An issue that becomes apparent when working with spent cell culture media is that glutamine cyclises 
into pyroglutamate. This has been reported in other metabolomic work with blood serum (198) and has 
been suggested to be due to as of yet unidentified factors in serum. The reasons for this phenomenon 
has not been explained as of yet. The cell culture media used in these studies contained between 1%-
10% FBS. To compensate for the effects of glutamine cyclisation of glutamine in NMR studies Nagana 











a fair view on glutamine levels in the presence of serum. In this work this step has not been taken with 
the spent media studies, however this phenomenon is taken into account when discussing future 
results. Analysis of fresh media used in our experiments showed that there was 0.39 mM pyroglutamate 
present in the media before starting experiments. This demonstrates the need in future work to add 
fresh glutamine just prior to experiments in the cell culture experiments rather than relying on media 
supplemented with glutamine. A table of assignments made from the cell culture NMR spectra can be 
found in Appendix B. 
For more in depth statistical analysis of the metabolites consumed as well as secreted, nine replicates 
from cells treated with DMSO and cells treated with GSK269 at 5 µM were collected and analysed by 





Figure 4.20. NMR Metabolomics of spent cell culture media shows the ROCK inhibitor GSK269 induces significant 
changes in glucose and glutamate metabolism in A375M2 cells. OPLS-DA of spent 1% FBS DMEM cell culture 
media after ROCK inhibition with GSK269. A) Scores plot and Q² histogram of OPLS-DA models of spent media 
comparing control to GSK269 treated cells. B) back scale loadings plot and mean normalised spectra C) box plots 
for the median normalised peak intensity of select metabolites (Lactate, Glucose and Glutamate) showing 
significant changes in metabolite consumption and secretion patterns. Experiments were conducted n=3 times, 
and each experimental replicate containing three technical replicates, for a total of 9 samples per experimental 
condition. 
 
OPLS-DA of Spent media from cells treated with DMSO vehicle control and ROCK inhibitor GSK269 5 
μM for 24 hours showed that there is a clear separation between the two treatments (Q² = 0.637 Figure 
4.20A, B). There was a residual DMSO peak present in the NMR spectra at 2.71 ppm as GSK269 is 
dissolved in DMSO. The residual peak was excluded from the analysis along with the residual water 
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glucose, meaning the cells were taking up more glucose after ROCK inhibition. There was also a 
reduction in the amount of glutamate present in the spectra (Figure 4.20C). Univariate analysis of the 
peak intensity corresponding to glucose, lactate and glutamate respectively show a mean 20.68% 
decrease, 26.49% increase and 27.5% decrease (Figure 4.20C). There is a 3-fold increase in the 
lactate/glucose ratio of GSK269 treated cells compared to control (mean lac/glc ratio control = 4.99, 
GSK269 = 14.54). 
 
Figure 4.21. Melanoma cells treated with ROCK inhibitors secrete more lactic acid. Cell culture plates containing 
A375M2 cells after 24-hour treatment of either DMSO control (left) or 5 μM GSK269 (right). The pH sensor Phenol 
red turns yellow in acidic environments and it is seen that the cell culture media of ROCK inhibitor treated cells is 
a markedly different colour from control cells. 
 
These are striking findings as the proliferative potential of melanoma cells are blocked by ROCK 
inhibition, yet they are upregulating their dependence on glucose fermentation as an energy source 
compared to control cells. These findings were also confirmed as the pH of the spent cell culture media 
was reduced due to the increased secretion of lactic acid (Figure 4.21). This could be a part of the 
response to ROCK inhibition. The reduction in the amount of glutamate in the media is more difficult to 
justify. It is borderline significant (p = 0.0541) and the change in glutamate could be explained either as 
an effect of ROCK inhibition or could simply be due to the reduced cell number seen after 24 hours of 
ROCK inhibition (Figure 4.24A).  




Figure 4.22. Spent cell culture media experiments were repeated at high growth conditions of 10% FBS and show 
similar findings to 1% FBS conditions. OPLS-DA of spent 10% FBS DMEM cell culture media after ROCK inhibition 
with GSK269. A) back scale loadings plot and mean PQN normalised spectra with the OPLS-DA scores plot 
inlayed. B) Zoom of mean normalised spectra on the resonances of Glucose (left) and lactate (right). Mean spectra 
(average spectra) with standard deviation (shaded) is plotted for DMSO treated cells (blue) compared to GSK269 
treated cells (red). Experiments were conducted n=3 times, and each experimental replicate containing three 
technical replicates, for a total of 9 samples per experimental condition. 
 
NMR metabolomics were repeated at the higher growth condition of 10% FBS (Figure 4.22) and showed 
that at high growth conditions this pattern was even greater than experiments conducted at 1% FBS 
conditions. We again observed increased consumption of glucose and increased secretion of lactate 
into the spent cell culture media in GSK269 treated cells compared to DMSO control treated cells 
(Figure 4.22B). Estimations of the concentrations of lactate and glucose in the spent media performed 
with Chenomx showed an average of 5.82 mM glucose in control conditions compared to 3.71 mM 
glucose in GSK269 treated conditions, a 36.3% reduction in the uptake of glucose. Likewise, there were 
11.76 mM lactate in control conditions compared to 27.90 mM lactate in GSK269 treated conditions, an 







glucose and 1 mM glutamine. The mean lactate/glucose ratio in control conditions was 2.67 while in 
GSK269 treated conditions mean lac/glc was 7.73. Additionally, the relative rate of lactate production 
over glucose consumption ([Lactate]/([Glucose in fresh media] –[Final Glucose]) was 2.81 for control 
treated cells and increased 1.5-fold in GSK treated cells to 4.44. This again points to a shift in the 
Warburg effect after ROCK inhibition. 
4.2.14 Network Analysis of NMR metabolomics and transcriptome data suggest Glutamine/Glutamate 
pathways as most significantly regulated by ROCK activity 
To conclude this section of work and to generate a hypothesis for future work, we aimed to understand 
which metabolic pathways were most altered based on the data collected thus far. We were aided by 
the data presented in the study by Sanz-Moreno et al (140). In this work they performed a microarray 
analysis of A375M2 cells seeded onto a thick collagen matrix and studied the transcriptomic profile of 
cells after ROCK inhibition by H1152 for 16 hours. To obtain a deeper understanding of the cross-talk 
between metabolism and gene expression in our systems we made use of the publicly available data 
(GSM586484–GSM586501) to integrate transcriptome data with the generated NMR metabolomic data. 
 
Figure 4.23. Pathway Analysis of metabolic pathways most regulated by ROCK activity from metabolomic and 
transcriptomic data. Pathways are ranked in descending order by enrichment score shown in blue. Also shown is 





Integrated pathway analysis was performed using the Metaboanalyst 3.0 web tool (173)(Figure 4.23). 
All genes that were downregulated after H1152 treatment along with downregulated metabolites after 
treatment in the same conditions were used for analysis. Metabolites were selected from the OPLS-DA 
back-scaled loadings plot The metabolites selected for pathway analysis were Aspartate, Choline, 
Glucose, Glutamate, Glutamine, Glycerophosphocholine, Inosine, Myo-inositol, Phosphocholine, and 
Isoleucine. Glyceryl in Triglycerides, which was also downregulated in after H1152 treatment, was not 
recognised in Metaboanalyst and was thus excluded from pathway analysis. 
 
The hypergeometric test and degree centrality analysis was selected for enrichment analysis and 
topology analysis respectively.  
Pathway analysis reveal that glutamine/glutamate metabolism was the most regulated metabolic 
pathway by ROCK activity from our dataset. This was followed by glyoxylate and dicarboxylate 
metabolism, glycine, serine and threonine metabolism, glycerophsopholipid metabolism and arginine 
and proline metabolism (Figure 4.23). This suggested to use that glutamine/glutamate metabolism is 
the most regulated metabolic pathway by ROCK activity and formed the hypothesis upon which future 
work was based. 
4.2.15 ROCK activity and exogenous glutamine is required for melanoma cell proliferation in human 
and mouse melanoma 
With the information that ROCK could be regulating glutamine and glutamate metabolism we then 
studied how A375M2 human melanoma cells proliferate in absence of exogenous glutamine. It was 
seen that after 24 hours there is already a trend of less proliferation which becomes more pronounced 




Figure 4.24. ROCK and exogenous glutamine are required for A375M2 melanoma proliferation in vitro. A) A375M2 
cells treated every 24 hours with 5 μM H1152 over 5 days show near complete termination of proliferation. B) Cells 
cultured in glutamine free media also completely halt proliferation. experiments done in triplicate. data points are 














In this chapter we aimed to understand if and how ROCK regulates melanoma cell metabolism. We 
studied the metabolic profiles of cells after interfering with ROCK activity or expression in human and 
mouse melanomas. We observe that ROCK does alter the metabolic profiles of cells in each condition 
studied. There were many metabolic changes observed ranging from lipid metabolism, amino acid 
metabolism and carbohydrate metabolism. In this section we will discuss the presented data, aiming to 
give context to our findings and suggest future research directions. 
4.3.1 ROCK as a therapeutic target of melanoma 
In recent years ROCK has been suggested to be a potential therapeutic target for malignant melanoma 
either alone or in combination with currently available treatments such as BRAF inhibitors (3,4,199). 
Interfering with ROCK activity has been shown to block melanoma proliferation (5) and metastasis in in 
vitro models of melanoma (3). While there are a couple of studies implicating Rho/ROCK signalling in 
cellular metabolism (156) and cell transformation (158), to date there has been no -omic level study as 
to whether ROCK regulates melanoma metabolism. 
In this chapter we sought to investigate if and how ROCK re-wires cellular metabolism. We designed 
our study to investigate the cellular metabolome using three different strategies in order to account for 
short-comings with each experimental system such as off target effects of small molecule inhibitors and 
of genetic alterations of ROCK expression by siRNA (200,201). Understanding the differences between 
targeting strategies could also have implications for future studies. Additionally, transient knockdowns 
by siRNA do not perfectly ablate protein expression and therefore phenotypic studies must be taken 
with caution. Studies were also conducted on genetic KOs of ROCK in models of spontaneously 
developed murine melanomas. The data collected from this study show surprisingly similar results to 
those found in the transient knockdowns in A375M2 human melanoma cell line. Hierarchical clustering 
of the data demonstrates it clustering more closely to GSK269 and the siRNA knockdown than the data 
from older ROCK inhibitors (Figure 4.18).  
In all cases studied where ROCK activity or expression was blocked we observed significant changes 
in the metabolic profile of melanoma cells. Consistent changes observed in each experimental set up 




Gaining a deeper understanding of the biochemistry of melanoma cells driven by Rho/ROCK signalling 
can point to additional opportunities in terms of designing therapies for melanoma. In particular 
glutamine and glutamate metabolism may be an attractive target for future cancer therapies.  
4.3.2 Glutamine/glutamate metabolism 
Pathway and network analysis from our studies suggest that glutamine/glutamate metabolism is the 
metabolic pathway most affected by ROCK. This was demonstrated both when analysing metabolomic 
data alone and when integrated with transcriptomic data from experiments in similar conditions. 
Glutamine is generally a non-essential amino-acid although in various cancer types a requirement for 
exogenous glutamine to sustain proliferation has been observed. This phenomenon is call ‘glutamine 
addiction’ (22,202) and has been established for a variety of cancer types, including melanoma (203). 
Glutamine is the key nitrogen donor for the de-novo synthesis of a variety of macromolecules, such as 
most amino-acids excluding proline (Figure 4.25). It has also been suggested that reliance on glutamine 
may serve as a mechanism for acid-resistance in the case of increased lactate secretion seen in cancer 
cells displaying the Warburg effect (204). Glutamine addiction in melanomas was investigated by 
Ratnikov et al (195) who demonstrated that melanomas mainly used glutamine through the TCA cycle 
and produced aspartate as melanoma had limited ability to use exogenous aspartate. In addition, 
melanocytes could grow without exogenous glutamine.  
 
Figure 4.25. Glutamine metabolism in cancer and its role in maintaining amino acid pools and antioxidant 
homeostasis. Exogenous glutamine is essential for many cancer cells to sustain growth and proliferation. Figure 




Rho signalling has already been linked to glutamine metabolism as Rho dependent transformation of 
fibroblasts and the growth of breast and B cell lymphomas(158), however a mechanism was never 
proposed.  
There is some evidence that metabolites may influence not only cell proliferation but morphology and 
migration as well. Fu et al (206) studied how amino acid restriction of melanoma cell lines affect cell 
attachment and actin cytoskeletal remodelling. They observed in A375 human melanoma cells that 
restriction of glutamine did not affect attachment, while restriction of phenylalanine (Phe) or tyrosine 
(Tyr) significantly reduced cell attachment to laminin and fibronectin. They also observed that cell 
morphology was affected by Gln/Phe/Tyr restriction by affecting the expression of Integrin α5. 
In our work we saw that intracellular glutamate was consistently regulated by ROCK, in addition, we 
observed that glutamate was secreted by melanoma cells into the extracellular environment. In the 
murine melanomas cells studied, we observed that glutamate was unchanged in the individual KOs 
while having dramatic changes in the double KO. This suggests that glutamate is redundantly regulated 
by the different ROCK isoforms and could play an important role in proliferation. Glutamate is also a 
very important signalling molecule and both glutamine and glutamate are also essential precursors to 
glutathione synthesis which is discussed below. 
4.3.3 Glutamate Signalling in Melanoma? 
Glutamate has been observed to be altered by ROCK activity both in our whole cell studies as well as 
in the spent media studies. Glutamate is not only an essential part of the process of using glutamine as 
an energy source but is a very important signalling molecule as well. Cancer cell metabolism has also 
been known to use metabolites such as glutamate and lactate for paracrine or autocrine signalling 
(16,207). Glutamate is the primary excitatory neurotransmitter involved in a variety of neural functions 
such as memory and synaptic plasticity (208). 
Glutamate signalling is mediated by transmembrane proteins known as glutamate receptors (208) 




Figure 4.26. Structure and function of glutamate receptors. Top – metabotropic glutamate receptors are G-protein 
coupled receptors activated by glutamate binding. Activation by glutamate leads to downstream signalling. Bottom 
– ionotropic glutamate receptors are ion channels activated by glutamate. They are classically known to be involved 
in calcium signalling. Figure adapted from (208) under the Creative Commons Attribution (CC-BY-NC) License. 
 
 
External glutamate binds to these receptors and induces downstream signalling. Glutamate receptors 
are divided into two major classes according to their signalling pathways. Metabotropic glutamate 
receptors (mGluRs), are G-protein coupled receptors while Ionotropic glutamate receptors (iGlurRs). 
mGluRs are ion channels (Figure 4.27).Ionotropic receptors are subdivided into three groups according 
to the original agonists that were found to have specific binding (209): NMDA, AMPA and kainate. AMPA 
and NMDA receptors are better understood while less is known about kainate receptors (210). 
There is strong evidence that glutamate signalling may play a role in melanomas and other cancers. 
Metabotropic glutamate receptors were the first to be identified as potential therapeutic targets in 
cancer. The GRM1 gene, which codes for metabotropic glutamate receptor subtype 1 (mGluR-1) has 
been shown to be essential for the growth and migration of murine and human  melanoma (211,212), 
it has been seen that mice with GRM1 overexpression spontaneously develop melanoma (213) and 
there has even been an initial clinical trial investigating the feasibility of using a glutamate activated 
sodium channel blocker (Riuzole) in patients with resectable stage 3 and 4 melanoma (214). The 
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expression of GRM5, another metabotropic glutamate receptor, has also been observed to lead to the 
development of melanoma in mice (215). 
 
Figure 4.27. Glutamate receptor families.  Glutamate receptors are divided into metabotropic receptors, which are 
g-protein coupled receptors, and ionotropic receptors which are ion channels. both metabotropic and ionotropic 
glutamate receptors are subdivided into three sub-groups; group 1, group 2, group 3 for metabotropic receptors 
and NMDA, AMPA and kainate receptors for ionotropic receptors. 
 
 
Studies into the role of ionotropic receptors have mainly been focussed on their role in glioma as 
glutamate receptors play an important role in synaptic signalling in the CNS. It has been seen that 
blockage of AMPA receptors (GRIA family of genes), which reduces calcium permeability in cells, 
reduced migration and induced apoptosis in human glioblastoma (216) and later that AMPA receptors 
also regulate growth of human glioblastoma via Akt (217). There is evidence also that the expression 
of AMPA receptors allows glioblastoma to survive in a glutamate-rich environment which is otherwise 
cytotoxic (218). Building on this idea, Beretta et al demonstrated that GRIA2 is more expressed in slow 
growing and low grade tumours while less expressed in fast growing tumours (219). Piao et al showed 
that overexpression of GRIA1 enhanced glioma cell migration by increasing beta-1 integrin surface 
expression and thus increasing the number of focal adhesions. 
Outside of the brain, GRIA3 (AMPA type receptor) expression has been shown to be correlated with 
pancreatic cancer cell proliferation and migration while inversely correlated with apoptosis (220). Very 
recently the NMDA receptor antagonist MK-801 has also been shown to be effective at reducing cell 
proliferation in combination with tamoxifen in vitro (221). Kainate receptors to date have been 
overlooked at potential therapeutic targets, partially due to the lack of sufficiently specific drugs.  
Glutamate receptors have been shown to play an important role in melanoma genesis. The NMDA type 
receptor GRIN2A has been suggested to have a tumour suppressive role in melanoma (222), Depletion 
of endogenous wild-type GRIN2A lead to an increase in proliferation and migration in melanoma cell 
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lines.  In other studies, overexpression of the metabotropic glutamate receptor GRM1 in mice was 
sufficient for the spontaneous generation of uveal melanomas (223,224) and promotes pro-angiogenic 
signalling in melanoma (225). GRM5 glutamate receptor over-expression was also sufficient to induce 
melanomas in mice(226), and it seems that GRM1 and GRM5 can act independently of each other to 
induce melanomas(227). 
In the next chapters, we will examine how glutamate receptors may play a role in melanomas and if 
altering glutamate signalling can regulate cell proliferation and morphology in our system. 
4.3.4 Increased Warburg effect after ROCK inhibition 
A375M2 melanoma cells where ROCK was inhibited showed significant alterations in the consumption 
and secretion patterns when compared to control cells. Principally we observed that cells increase the 
consumption rate of glucose and secretion of lactic acid after 24 hours. The real effect is probably even 
more drastic as there are fewer cells following ROCK inhibition cells compared with the control.  
This is an interesting finding as we know that ROCK is essential for melanoma proliferation both from 
published data (97,138) and from our data (Figure 4.24). Additionally, both exogenous glucose and 
glutamine are essential to sustain melanoma proliferation. This upregulation of the Warburg effect after 
ROCK inhibition may be a stress response to ROCK inhibition or attempt of the cells to compensate for 
the challenge. It has been proposed that the Warburg effect can play a role in balancing oxidative stress 
(228,229). It has already been shown that inhibition of ROCK in melanomas leads to increase levels of 
ROS (184). Therefore, it would be reasonable to assume that during ROCK inhibition melanoma cells 
may upregulate the Warburg effect as a response to the increased oxidative stress. This would also 
help to explain how our results contradict those found in Zhang et al’s work which explores how mutant 
p53 drives the Warburg effect via Rho/ROCK signalling (155). They found that in H1299 lung cancer 
cells, SKBR3 and MDA-MB-463 breast cancer cells ROCK inhibition with Y27632 led to a reduction of 
the Warburg effect. There are additional possible explanations for this discrepancy. The GOF mutant 
p53 studied in their paper led to increased levels of RhoA and thus ROCK activity background while 
A375M2 cells used in our system are wild-type p53 but still have relatively high levels of Rho/ROCK 
signalling.  Finally, it may be a tissue specific effect as Zhang et al saw the opposite effects in two breast 
cancer cell lines (SKBR3 and MDA-MB0463), and one lung cancer cell line (H1299), all of which are of 
epithelial origin. Our work was performed in malignant melanomas which are of neural crest origin and 
not of epithelial origin. The study of spent media should be replicated in a tumour of epithelial origin to 
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see if the work of Zhang et al can be replicated. Our study of spent media was replicated at both 1% 
FBS and 10% FBS conditions to show different levels of growth factor stimulation and in both situations 
we saw an almost identical metabolic profile of the spent media.  
Our findings should also be viewed within the context of recently published data investigating BRAF 
mutant melanoma, BRAF inhibitor resistant melanomas and combinatorial therapies of melanoma. 
Baenke et al (230) recently demonstrated that melanomas resistant to BRAF inhibition switch to 
mitochondrial oxidative metabolism, produce less lactic acid and become more dependent on 
exogenous glutamine than melanomas sensitive to BRAF inhibition. They also demonstrate that 
blocking glutaminase activity with BPTES can re-sensitise melanomas to BRAF inhibition. Additionally, 
it has been shown that inhibition of ROCK activity can re-sensitise resistant melanomas to BRAF 
inhibitors (4). One possible explanation could be that ROCK inhibition in BRAF inhibitor resistant 
melanomas could also be switching these cells from the TCA cycle and forcing them back into a 
glycolytic state. Studying the metabolism of BRAF resistant melanomas after ROCK inhibition would be 
another avenue of research worth pursuing and may shed new light into how ROCK activity drive 
melanoma metabolism, proliferation, and drug resistance.   
There are also many potential indirect ways of ROCK regulating metabolism. ROCK has multiple 
confirmed and proposed downstream targets. Many of these targets related to cytoskeletal functions, 
such as Lim Kinase (LIMK), Adducin, ERM, NHE1, CRMP2, Vimentin (130). There have recently been 
phosphor-proteomic studies proposing more than 100 potential substrates for ROCK (231). Among the 
proposed targets of ROCK, Nishioka et al observed binding between ROCK and 6-phosphofructo-2-
kinase (PFKFB2) peptide, again suggesting a role in the regulation of glucose metabolism by ROCK. 
While in this study they observed binding between ROCK and PFKFB2, they did not confirm a direct 
phosphorylation, so this data still needs confirmation. 
4.3.5 Glutathione and ROS in melanoma 
Glutathione is the main anti-oxidant present in mammalian cells to counter-act the damage that reactive 
oxygen species can cause to cells, namely DNA damage that leads to oncogenic mutations. It has 
commonly been thought that anti-oxidant treatment could be used as a preventative measure for cancer 
(232) or as a cancer treatment (233), although this view is currently being challenged (184,234,235). 
As reviewed in (234) several groups have demonstrated that anti-oxidants can actually favour 
tumorigenesis and metastasis. Herraiz et al (184) demonstrated that inhibition of ROCK activity and 
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actomyosin contractility led to an increase in intracellular ROS and an increase in RAC1 activity. RAC1 
then led to an increased expression of the tumour-suppressor TP53, which can in turn promote pro-
apoptotic pathways. 
In our study we have observed that inhibition of ROCK activity leads to an initial decrease of glutathione 
in A375M2 melanoma cells, this could be explained by how in the short term ROCK inhibition leads to 
an increase in intracellular ROS which consumes the available GSH in the cells. At 24 hours we observe 
that GSH concentrations start to recover. This data is consistent with 13C flux GC-MS studies currently 
being conducted in the Sanz-Moreno group (unpublished Data) as well as previously published work 
showing that ROCK inhibition leads to increased DNA damage in melanomas via reactive oxygen 
species(184). Future work should also elucidate the long term effects of ROCK inhibition on anti-oxidant 
levels in melanomas. 
4.3.6 Myo-inositol  
Myo-inositol was observed to decrease in all the small molecule treatments, however we observed an 
increase in myo-inositol concentrations in the siROCK treated cells. In the KO model of ROCK in 
melanoma, we observed that myo-inositol was decreased in the double ROCK KO only.  
myo-inositol is an extremely important signalling molecule, with a diverse set of phosphates and lipids 
added to the myo-inositol building block to form a series of second messenger (236), that have been 
shown to regulate metabolism, aging, oxidative stress, DNA repair, and autophagy/cell death (237).  
Myo-inositol has previously been implicated as a biomarker for prostate cancer (238) On the other hand, 
dietary supplements of myo-inositol been seen to reduce tumour growth in murine models of mammary 
gland, colon and lung cancer (239,240) and has even been tested in humans as a potential chemo 
preventative agent for lung cancer (241). In primary glioblastoma multiform (GBM) patients, proton MR 
spectroscopy of the affected hemisphere revealed an increase in the concentrations of myo-inositol and 
glutamine, relative to control subjects. Myo-inositol has been characterized as a specific marker of 
astrocytes in the adult brain, providing preliminary evidence of the abnormally higher astrocytic cell 
density in GBM (242). Furthermore, myo-inositol has been reported to increase in colon 
adenocarcinoma, schwannomas, ovarian carcinoma, astrocytoma and endometrial cells (243) and 
decrease in breast tumours (244). This suggests it may play very different roles in cancers dependent 
on the tissue of origin. We have observed high levels of myo-inositol in melanomas. Melanomas 
originate from melanocytes which are neural crest derivatives. One could hypothesise that melanomas 
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might have similarities with glioblastomas, compared to cancers of epithelial origin such as breast 
cancers. In work not presented in this thesis, MCF7 breast cancer cells had a very low or absent signal 
for myo-inositol.  
In melanomas it was observed that supplementing B16 mouse melanoma cells with myo-inositol 
partially reversed the anti-proliferative effects of lithium chloride, suggesting LiCl affects 
phosphatidylinositol metabolism in melanomas (245). The fact that we observed certain alterations of 
ROCK activity in melanoma also regulated myo-inositol levels suggests ROCK could also be affecting 
these pathways.  
4.3.7 Lipids/Choline 
It is well established that cancer cells have drastically different lipid profiles to normal tissue (246,247). 
The understanding of lipid metabolism in cancer has reached the point where real-time analysis of 
tissue lipid profiles are being tested clinically to aid surgeons in the resection of tumours (248). In our 
studies we have observed that there is a consistent increase in CH2-CH2 bonds of lipid chains after 
ROCK inhibition/ablation. ROCK is an important regulator of cell morphology so it is not surprising that 
we observe changes in the lipid profiles of cells after ROCK inhibition. Cells with high ROCK signalling 
are much more contractile and rounded when in a three dimensional environment. ROCK can also be 
activated by binding to lipids such as arachidonic acid (148). We observed that in short time scales 
saturated lipids decrease initially at 4 hours before increasing at 8 hours and this increase is sustained 
at 24 hours. 
Observations of changes in Choline metabolism has been a staple of metabolomic studies and has 
been correlated with malignant progression in a large number of studies as reviewed by Griffin and 
Shockor(249). In our work we observed that small molecule inhibition of ROCK in melanomas led to a 
decrease in choline while silencing through siRNA or genetic KOs led to an increase in choline. This 
could be explained either through off-target effects of either treatment or due to the very different 
timescale of each experiment. Drug treatments studies were halted after 24 hours while the siRNA 
knockdowns were conducted over 96 hours. In the ROCK KOs of murine melanoma cells were 
passaged five times after extraction from mice to allow senescence of fibroblasts to take place. These 
factors could contribute to the differences observed between different experimental procedures.  
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4.3.8 Different Roles for ROCK1 and ROCK2 in regulating melanoma metabolism? 
We observed that individual KOs of ROCK1 or ROCK2 led to distinct metabolic profiles and suggest 
they play different roles in regulating cellular metabolism. We observed that in amino acid metabolism 
(leucine, glutamine, valine and alanine) ROCK1 promotes increases in concentration while ROCK2 
decreases concentration in ROCK KO models of murine melanoma. When we examined ROCK1 and 
ROCK2 in the human melanoma cells A375M2 we also observed slight differences in metabolism 
between ROCK1 and ROCK2 knockdowns. The data suggested to us that changes in metabolism 
responsible by ROCK1 and ROCK2 are mainly a factor of magnitude rather than of differential 
regulation of metabolism. It appears ROCK1 is responsible for saturated lipids while ROCK2 drives an 
increase in most other metabolites. Further experiments should be conducted to further understand not 
just the differences between ROCK isoforms but also to understand the differences between the two 
models of melanoma to better understand how to advance research of ROCK driven melanoma 
metabolism. 
ROCK1 and ROCK2 are very similar and it has been demonstrated that ROCKs play redundant roles 
in sustaining melanoma proliferation (5). There are studies into differential effects they may have on 
cellular function. It has been seen that ROCK1 and ROCK2 play different roles in keratinocyte 
differentiation (250), myosin 2 activity (251), leukocyte recruitment (252) and cell detachment (253). 
Related to cell metabolism, however it has been shown in adipocytes and myoblasts that ROCK1 and 
not ROCK2 regulated glucose transport and insulin response (156). Further work could be conducted 
to investigate how the individual isoforms of ROCK regulate metabolism and whether metabolite 
restriction differentially affect isoform specific KOs. 
4.3.9 ROCK promoting stem cell like features in melanoma metabolism? 
Melanomas are derived from melanocytes, which are themselves neural-crest derived cells in embryo 
development. This has led several groups to consider the theory that melanoma behaviour could be 
explained through the view of the cancer stem cell theory (88,89,254,255). It has also been shown that 
cells with high ROCK signalling and demonstrate amoeboid-like features are associated with stem-likes 
features of melanoma cells (256). In our work we have described the metabolic profiles of cells 
displaying amoeboid like features. One possible avenue for further research is into glutamate as a 
signalling molecule that promotes contractility. It could be that these neural crest derived cells maybe 
rewiring themselves to take advantage of the glutamate signalling pathways that are often used in 
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neural tissue. There is evidence that glutamate signalling may play an important role in melanoma 
proliferation and migration as discussed in section 1154.3.3 and will be explored further in the following 
chapters.  
4.3.10 Limitations of study 
The limitations of this study range from the limitations of the sampling, experimental and analytical 
methods. 
The sample preparation methods the metabolomic studies required long time periods of 10-15 min per 
sample, which is a long time for metabolomic studies. This was addressed by mechanical detachment 
of cells from plates, however other methods of quenching, such as cold methanol may be preferable for 
future work. 
While HR-MAS NMR allows a removal of the extraction steps in most metabolomic experiments, there 
downside is the decreased resolution of the NMR spectra due to overlapping signals from polar and 
non-polar compounds. 
Spectra were allowed to suspend at room temperature for 2 hours prior to insertion into the magnet and 
were then heated to 310˚K and kept at temperature for several minutes to stabilise. There is the 
probability of sample degradation during this timeframe which would influence the data obtained. 
Further work should address these experimental limitations. 
While much work on cell morphology was conducted on a thick collagen 1 layer, it was impossible to 
create experimental conditions NMR metabolomics in a collagen environment. Therefore, all NMR 
metabolomic experiments were conducted on plastic. It is well known that the matrix on which cells are 
cultured can significantly alter the transcriptomic profile of cells (257). In addition, our studies were 
conducted over very different time-scales due to the requirements of each experimental system. Drug 
treatments were conducted at 24-hour time points while siRNA silencing was done at 96 hours and the 
murine melanoma cells were passaged four times in culture after extraction to allow fibroblasts to 
senesce. While this can be seen as a shortcoming, it also demonstrates that the metabolic changes 
observed are sustained over time. In our studies we conducted transient knock-downs to study gene 
expression. Other available gene editing methods such as short-hairpin RNAs or CRISPR/Cas9 could 




In this chapter we aimed to study how ROCK activity and expression may rewire the metabolic profiles 
of melanoma cells. We have demonstrated through whole cell HR-MAS NMR melanoma cells with high 
ROCK activity is correlated with increased levels of glutamate and myo-inositol. Network analysis 
suggests that glutamine/glutamate metabolism is the pathway most regulated by ROCK activity. Cells 
with high ROCK activity and thus a rounded morphology have decreased levels of saturated lipids. 
These observations offer interesting starting points for future research and should be further 
characterised in future work.  
We have also demonstrated with 1D liquid NMR that melanoma cells where ROCK activity was inhibited 
switched increased the rate of glycolysis. Increased consumption of glucose and increased secretion 
of lactate after ROCK inhibition suggest cells become more dependent on glucose for their energy 
demands despite the anti-proliferative effects of ROCK inhibitors.  
Examining the effects of ROCK inhibitors over shorter time frames also revealed that glutathione is 
initially depleted and then starts to recover after 24 hours. This fits data published in the literature that 
ROCK inhibitors cause increased oxidative stress in melanoma cells (184). 
Finally, we observed that individual KOs of ROCK have distinct metabolic profiles suggesting they have 
distinct roles in regulating cellular metabolism. This does not lead to a difference in proliferative ability, 
and therefore suggests that only certain metabolites, such as glutamate is much more important in 
sustaining proliferation. 
Further work in this thesis will attempt to further characterise glutamine and glutamate metabolism in 






Chapter 5 : A BIOINFORMATICS INVESTIGATION OF 
GLUTAMINE AND GLUTAMATE METABOLISM AND 




In the previous chapter the metabolic profiles of melanoma cells were studied while perturbing either 
ROCK activity or expression. It was seen that glutamine/glutamate metabolism was the most 
consistently regulated metabolic pathway by ROCK. Other major changes observed were in 
glutathione, myo-inositol and lipid metabolism. In the exometabolome it was seen that ROCK inhibition 
led to increased Warburg effect. It was also seen that melanoma cell secrete glutamate, suggesting a 
role for glutamate signalling in melanoma.  
This work was performed with several melanoma cell lines; the A375M2 human melanoma cell line, the 
B16F10 mouse melanoma cell line, and a murine model of melanoma in which the ROCK genes were 
deleted. In vitro studies with cell lines are powerful models to study disease as it allows researchers to 
conduct experiments on genetically identical systems in controlled experimental environments where 
senescence is not an issue(258). However, the strictly controlled nature of cell lines can be a great 
weakness as well. Human tumours are very heterogeneous and also exhibit intra-tumoral heterogeneity 
that cannot be replicated with individual cell lines (259). Interactions between the stroma and tumours 
are not taken into account in research using only cell lines (260). Even more importantly the interactions 
between tumours and the immune system, which have proved to provide clinical benefit when targeted, 
require more sophisticated models than most in vitro work provides(261). For these reasons, among 
others, cell line experiments run the risk of being poorly generalisable to a clinical setting. This issue 
has arisen as some cell lines are better models of disease than others along with issues of the cell 
culture environment, namely growing cells on plastic in highly oxygenated environments, selects for 
vastly different subpopulations of cells compared to tumours grown in vitro (262).  
In our studies we have attempted to address these issues by studying the role of ROCK in several 
models of metastatic melanoma. We have used the A375M2 human melanoma cell line as opposed to 
the parental A375P cell line. A375M2 cells were chosen due to their high metastatic potential along with 
increased expression of RhoC/ROCK signalling compared to A375P cells (154). This decision was 
made due to our interest in metastatic melanoma. They have also been used in key studies making the 
foundation of this thesis (3,140,184,263). In this chapter we make use of microarray data from (140). In 
that study, A375M2 human melanoma cells were treated with ROCK inhibitors to identify genes whose 
expression was correlated with ROCK activity and thus rounded-amoeboid type migration. In this 
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chapter we make use of this data set to analyse the expression of metabolic genes in the context of 
ROCK activity.  
While in vitro studies of metastatic melanoma cell lines are important models enabling the role of ROCK 
to be more accurately defined, it is important to understand what relevance these findings have to the 
wider melanoma patient population. We can then understand whether future interventions can be 
developed from our in vitro studies and be applicable in the much more heterogeneous environment of 
the clinical setting. Consequently, in this chapter we have conducted a bioinformatics screen of genes 
related to glutamine/glutamate metabolism and glutamate signalling. By harnessing publicly available 
gene expression data of patients at different stages of disease, metabolic targets of disease associated 
with disease progression may be identified, related to our experimental findings described in the 
previous chapter.  This information can then fed be back into in vitro studies of melanoma in an attempt 
to gain further mechanistic insight. 
It is fairly well established that glutamine metabolism is important for sustaining melanoma proliferation 
(3-5,97) and the link with ROCK signalling, described in the previous chapter, adds a new perspective 
on the potential mechanisms of how ROCK regulates melanoma proliferation and metastasis. An 
additional question is how glutamine and glutamate metabolism may support not only melanoma 
proliferation but metastatic potential as well. We also observed that ROCK may supress the Warburg 
effect in melanoma, or possibly that ROCK inhibition may lead to an upregulation in Warburg effect to 
counteract an increase in oxidative stress.  
The first aim of this chapter therefore is to investigate whether there is any evidence in publicly 
accessible databases of increased glutamine/glutamate metabolism and/or suppressed Warburg effect 
in metastatic as opposed to non-metastatic melanomas.  
The second aim is to identify whether increased or decreased expression of any genes is associated 
with the expression of ROCK1 and/or ROCK2 and whether these genes may be related to 
glutamine/glutamate metabolism or suppression of the Warburg effect. A short discussion on glutamine 
and glutamate metabolism follows.  
Glucose and glutamine are the essential sources of carbon for many cancer types and this holds true 
for melanomas. Ratnikov et al demonstrated that all of the 9 melanoma cell lines investigated were 
dependent on at least 1 mM glutamine in the cell culture media to sustain proliferation (195). The 
findings in this study led to a review by Ratnikov et al (264) where they discuss the roles glucose and 
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glutamine metabolism play in melanoma progression (Figure 5.1). Glutamine is the most abundant 
amino acid present in serum and the phenomenon of glutamine addiction in many cancer types has 
been described in the literature (22,23,202,205,264-266) and observed in our experimental system. 
Glutamine is a major precursor for the TCA/Krebs cycle. It is converted to glutamate and subsequently 
α-ketoglutarate which then feeds into to the TCA cycle, eventually leading to the generation of ATP via 
oxidative phosphorylation. The first catabolic step in glutamine metabolism (glutaminolysis) is the 
reaction catalysed by the glutaminase enzyme (GLS) which generates glutamate from glutamine. 
Glutamine is also a major source of nitrogen source for the synthesis of most other amino acids. It is 
also essential for the production of glutathione, which is the most abundant anti-oxidant molecule that 
plays a crucial role in cell survival in the face of oxidative stress. (205,264), Figure 5.1). 
Several aspects of glutamine/glutamate metabolism have been implicated as potential therapeutic 
targets in melanoma. One example is glutaminase: Inhibition of glutaminase via small molecule 
inhibitors has been shown to inhibit RhoA dependent transformation in fibroblasts (158) and has also 




Figure 5.1. Glutamine and Glucose Metabolism are re-wired in melanoma. Melanomas are dependent on 
exogenous glutamine and glutamine metabolism can be re-wired by oncogenes such as Myc and mutated BRAF 
to drive increased glutamine transport and glutamine metabolism. Figure adapted from.(264).  
 
 
Another example are the solute carriers responsible for glutamine and glutamate transport as 
melanomas require exogenous glutamine to grow and proliferate. The study of solute carriers, the family 
of proteins responsible for amino acid transport has been understudied (161,267), showing the 
importance of further research.  
Glutamate is also another area of interest for targeted therapies. Glutamate is not only a major 
metabolite involved in the various cellular processes described above, but it is a major signalling 
molecule as discussed in Chapter 4. We observed that A375M2 cells secrete glutamate and it has also 
been observed in the literature. For example,  Ratnikov et al showed not only that melanomas secrete 
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glutamate, but also that 30-50% of the glutamate secreted from the 9 melanoma cell lines studied were 
derived from the TCA cycle in their 𝐂𝟏𝟑  tracer studies of glutamine metabolism in melanoma (195). 
Glucose metabolism is also another attractive therapeutic target in cancer (268) and the Warburg effect 
was the first metabolic rewiring observed in cancers (20). In our studies in the previous chapter we 
observed that inhibition of ROCK activity led to an increase in the Warburg effect. This could either be 
a compensatory mechanism to reduced proliferation or to increase lactate production as a response to 
increased oxidative stress. Several studies have shown that melanomas make use of both glucose and 
glutamine as energy sources to maintain flexibility in sustaining proliferation (269). However, Ratnikov 
et al showed that 8 of the 9 melanoma cell lines studied could sustain proliferation without glucose 
(195). Additionally, it has recently been shown that melanomas resistant to BRAF inhibition with 
vermurafenib, the current first line treatment for BRAF mutant melanomas, switch to glutamine 
dependence (230,270) rather than glucose. This suggests that while glucose and glutamine are both 
important for melanomas, they may become more dependent on glutamine at later stages of the 
disease. In unpublished work by the Sanz-Moreno group, it has been seen that A375M2 cells require 
glucose to sustain proliferation. 
In this chapter we aim to identify potential therapeutic targets of malignant melanoma involved in 
glutamine/glutamate metabolism and glutamate signalling based on the metabolomic pathway analysis 
conducted in the previous chapter. The study proposed here is a conceptual level of -omic data 
integration discussed in chapter 1, namely we aim to use the generated metabolomic data to inform our 
studies of gene expression in a panel of melanoma patients. The data shown in the previous chapter 
identified that glutamine/glutamate metabolism is significantly altered after interfering with ROCK 
signalling. We will now investigate if these findings related to glutamine, glutamate and ROCK have 
broader applications to clinical data. 
Genes related to glutamine, glutamate and glucose transport and metabolism as well as glutamate 
signalling will be identified. We will explore the regulation of these genes through post-hoc analysis of 
a previously published microarray study in A375M2 human melanoma cells where ROCK activity was 
inhibited with the small molecule inhibitors H1152 and Y27632 for 16 hours (140). This may give an 
indication if the expression of the genes of interest are under control of ROCK.  
Additionally, six publically available databases containing microarray data of melanoma patients at 
different stages of disease are also identified and the change in expression of these genes will be 
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studied by comparing both primary melanoma against normal tissue and comparing metastatic 
melanomas to primary melanomas. This will allow us to identify if any genes of interest may be more 
broadly implicated in melanoma clinically. Where available survival analysis based on these genes 
expression will also be studied to find if any genes may have prognostic value.  
We will be looking at several melanoma databases and there is a large heterogeneity between studies 
and individual patients, therefore, we will be looking for qualitative indications that metabolic pathways 
may be altered in primary melanomas and metastatic melanomas through gene set enrichment analysis 
(GSEA).   
A next step will be to investigate if ROCK signalling regulates these candidate targets. This could shed 
light mechanistically as to how ROCK regulates cellular metabolism seen in the previous chapter. Linear 
correlations of the expression of ROCK and candidate genes will be explored through post-hoc analyses 
of publicly available databases of melanoma patient microarrays containing data about both primary 
and metastasized melanomas.  
We will conclude this chapter by returning to in vitro studies to examine the findings from our 
bioinformatics work. We will select a sample of the genes studied and confirm if ROCK activity regulates 
gene expression by RT-qPCR. Finally, an siRNA screen of a selection of genes from each metabolic 
pathway studied will investigate the effects of these genes on proliferation and cell morphology on 
collagen. This will bring the clinical data collected in this chapter back into an in vitro setting where we 




5.2 Methods  
5.2.1 Initial gene selection 
The identification of candidate genes takes two different strategies. One is searching of the Human 
Metabolome Database (HMDB) for candidate genes using the keyword ‘glut*’. This strategy will allow 
identification of targets not just for glutamine and glutamate, but also include terms such as glutathione. 
The downside is this may identify genes not of interest to our pathways and thus depower our study. 
 
Figure 5.2. Search Strategy for Candidate Genes from Glutamine and Glutamate related genes. The Genes were 
searched for in an un-biased manner through keyword search for genes was conducted by both searching in the 
Human Metabolome Database for (HMDB). This search was then supplemented with manually searching other 
databases and the keyword glut* as well as a literature search, KEGG for genes belonging to different metabolic 
pathways, and wikipathways databases for genes involved in glucose metabolism, glutamine, glutamate 
metabolism, glucose and glutamine transport and glutamate receptor signalling. 
 
 
To supplement this strategy, we are also including a literature and database search of candidate genes 
involved in glucose, glutamine and glutamate metabolism, transport, and glutamate signalling.  
5.2.2 Generation of candidate library 
Searching the HMDB for genes and descriptors including the search term ‘glut*’ gave a list of 106 genes 
(listed in Appendix A) in November 2013. Genes found in the HMDB search were integrated with genes 
selected through literature search and KEGG pathways databases. Genes included for analysis were 
involved in glutaminolysis, TCA cycle, glycolysis, glutamine/glutamate transport and glutamate 
HMDB enzyme search







• Glu signaling Receptors
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receptors. Searches were conducted in the literature KEGG pathways and wikipathways databases 
leading to a final library of 181 unique genes. The genes and their pathways are detailed in Table 4. 
Whole gene lists can be seen in Appendix A. 













106 31 30 26 21 181 
Table 4. Metabolic pathways and search terms used to select genes for screening. 
 
 
5.2.3 A375 Melanoma microarray 
The data generated by Sanz-Moreno et al (2011)(140) (accession numbers GSM586484–GSM586501) 
was selected for analysis in this chapter. In this study, they conducted a transcriptome analysis of A375 
and A375M2 human melanoma cells seeded on a thick collagen 1 layer and observed the transcriptome 
changes after ROCK inhibition with H1152 and Y27632.  
5.2.4 Analysis of gene expression from human databases 
Publicly available melanoma patient transcriptome databases that comply with the minimum information 
about a microarray experiment (MIAME) standards (271) were searched for in the The National Center 
for Biotechnology Information’s (NCBI) Gene Expression Omnibus (GEO), as performed in (154). The 
GEO-NCBI is a public international repository of, amongst other datasets, gene expression profiles. 
Databases selected for post-hoc analysis were selected for having high sample purity (>95% 
melanocytic cells), enough patient samples to perform statistical comparisons (n>40) and include 
normal tissue samples. Samples from these studies were reported to have >95% 
melanocytic/melanoma cells and no mixed histology. 
These databases, signified by their GEO accession number, were: GSE29359; GSE3189; GSE8401; 
GSE46517; GSE7553 corresponding to the following publications: Avery-Kiejda et al, (2011)(175); 
Talantov et al, (2005)(176); Xu et al, (2008)(177); Kabbarah et al, (2010); Riker et al, (2008)(179).  The 
databases and number of samples are shown in Table 5. Avery-Kiejda et al focussed on a comparison 
of gene expression profiles between ‘melanocytes’ and ‘melanoma’ cells (n=8, n=92, respectively), 
whilst Talantov et al focussed on a comparison between ‘nevus’ and ‘malignant’ cells (n=7, n=45, 
respectively). These two conditions will be defined as a comparison between ‘normal’ cells (non-
tumorous) and ‘primary’ cells (tumorous, non-metastatic). Xu et al, Kabbarah et al and Riker et al each 
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analysed ‘primary’ and ‘metastatic’ melanoma cells (n=31 and n=52; n=31 and n=73; n=14 and n=40, 
respectively) (Table 5). Gene expression data was extracted from each of the 5 databases for the 181 
genes previously detailed. In the case of more than one primer being present in the microarray data, 
the primer with highest mean expression was selected.  























Table 5. Melanoma databases used in study and number of samples in each study. 
 
 
A final data set was obtained from The Cancer Genome Atlas (TCGA), which is a collaboration between 
the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI); both 
part of the US National Institutes of Health (NIH). It aims to comprehensively catalogue a broad 
spectrum of expression profiles and tumorigenic mutations. Data was accessed from the cBioPortal for 
Cancer Genomics (180,181). In particular, data was obtained from the supplementary work of Guan et 
al (2015)(182), detailing expression profiles in 354 Skin Cutaneous Melanoma (SKCM) patients with 
complete sequencing and copy number alteration (CNA) data, from a total patient database of 470. 
5.2.5 Data Analysis 
In each of these databases, initial gene selection for subsequent experimental analysis was based upon 
the exclusion criteria that the gene exhibited a significant (FDR adjusted p value<0.05) and a fold-
change expression >1.5 or a fold-change expression < 0.66 in primary or metastatic cells with regards 
to normal or primary cells, respectively. 
5.2.6 GSEA (Gene Set Enrichment Analysis) 
GSEA is a computational method that determine whether a pre-defined set of genes shows significant 
expression enrichment between two biological states (174). The sets of genes used with GSEA software 
are derived from a collection of annotated gene sets known as the Molecular Signatures Database 
(MSigDB). It is also possible to create ad hoc gene sets for analysis.  
 
 
The statistical test given in GSEA is the ‘enrichment score’ (ES). This is calculated by ‘walking down’ a 
rank ordered list of genes within the gene set and incrementing the ES according to how much a gene’s 
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expression correlates with the given phenotype (Figure 3.3). Significance tests are then run against a 
permutated dataset used as the null hypothesis and nominal p-values are false-discovery rate (FDR) 
adjusted as the multiple test correction (174). GSEA was performed using the desktop app available 
from the Broad Institute website. A representative output of GSEA is visualised in Figure 3.3. 
Seven gene sets were constructed based on metabolic pathways of interest. These are: 
 Glycolysis 
 TCA Cycle 
 Glutaminolysis 
 Gln/Glu transport 
 Ionotropic Glu Receptors 
 Metabotropic Glu Receptors 
 Glucose Transport 
Full gene lists can be seen in Appendix A. 
5.2.7 Survival Analysis 
Survival analysis is the statistical estimation of the time taken until an event. In the case of this work, 
the event is death. Survival analysis was performed in R using the ‘survival’, ‘ggplot2’, and ‘ggsurv’ 
packages in the R Studio interactive development environment (IDE). Z-score normalised gene 
expression data was used for the analysis. and patients were divided into ‘low’ and ‘high’ expression 
groups according to a cut-off of z-score =0. The z-score is the number of standard deviations a 





Where X Is the original expression value, 𝝁 is the mean expression for the gene of interest, and 𝝈 is 
the standard deviation of the gene of interest. The cut-off was selected as the z-score is the number of 
standard deviations from the mean, therefore z =0 is the mean expression value for the gene of interest. 
Kaplan Meier plots were generated for each gene of interest using the ‘ggsurv’ R package, which is 
built using both the ‘survival’ and the ‘ggplot2’ package in R. Log-rank tests were performed for each 
gene of interest and nominal p-values were FDR adjusted for multiple-test corrections. 
5.2.8 Gene Expression Correlations 
Gene expression networks are highly variable, non-linear and complex. While advanced network-based 
differential gene analysis tools are available (272-275), they fall outside the scope of this work. 
Correlations between gene expressions were analysed to reveal patterns between ROCK expression 
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and the expression of metabolic genes. Expression data over the five databases was normalised by 
calculating the z-scores each gene in each database. This gave a final dataset comprised of 804 
melanoma patients. Spearman rank correlations were calculated for the 181 genes of interest and both 
ROCKs. The Spearman rank correlation was chosen instead of the Pearson correlation because we 
are not assuming a normal distribution of gene expression. Only genes that had a Spearman R² > 0.25 
or R² <-0.25 were considered.  p-values were FDR adjusted to account for multiple testing. 
Data was processed and analysed in python 3.5 using the numpy, scipy.stats, statsmodels and pandas 
packages. Data was visualised using matplotlib, pandas, and seaborn. 
5.2.9 RT-qPCR 




A summary of the genes that passed the exclusion criteria is show in Table 6. The full list of genes that 
passed exclusion criteria is shown in Appendix A. The diverse data sets showed very different numbers 
of genes that passed the exclusion criteria, with the Talantov data set having 48 of the 150 examined 
genes pass the exclusion criteria while on the other end the Riker dataset only had 3 of the 172 genes 
examined pass exclusion criteria. This cannot be explained by the total number of patients enrolled in 
the studies as Talantov contained 52 total samples while Riker contained 54 total samples. It can be 
explained however by the number of samples per group. The Talantov data set only contained 7 normal 
tissue samples, while Riker had double the number of primary samples. The small sample size of normal 
tissue in Talantov could enhance be attributed to the large number of genes that passed the exclusion 
criteria. This highlights the need for multiple data sets to increase confidence in our analysis. 
  
 NORMAL VS. 
PRIMARY 
METATASIS VS. PRIMARY 
MELANOMA 
 Avery Talantov Kabbarah Riker Xu TCGA 
INITIAL GENE SELECTION 181 181 181 181 181 181 
GENES FOUND IN ARRAY 164 150 150 172 150 177 
GENES PASSING SIGNIFICANCE 
THRESHOLD 
15 76 38 4 63 10 
GENES PASSING FOLD CHANGE 
THRESHOLD 
15 48 14 3 32 7 
GENES WITH HIGHER EXPRESSION 1 29 8 0 22 4 
GENES WITH LOWER EXPRESSION 14 26 6 2 10 3 
Table 6. Number of Genes that pass the exclusion criteria of >1.5-fold change in expression or <0.66-fold change 
in expression in each of the six melanoma patient databases. A full list of the genes that were up- or down-regulated 
in each database can be seen in Appendix A. 
 
 
5.3.1 SLC2A3 (GLUT3) is overexpressed in primary melanomas 
In both databases (Avery and Talantov) where comparisons were made between normal tissue/nevi 
and primary melanomas only SLC2A3 was observed to be overexpressed (Figure 5.3A, C). The 
SLC2A3 gene codes for the GLUT3 glucose transporter. It has been shown to be involved in promoting 
epithelial to mesenchymal transition in non-small cell lung cancer (276), proliferation of  breast cancer 
(277), and is correlated with increased aerobic glycolysis in colon cancer (278). There were no other 
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genes that were found to be overexpressed in the Avery data set however the Talantov data set showed 
28 other genes that were overexpressed in primary melanomas (Table 6, Figure 5.3A). Among these 
there were genes involved in glycolysis (ENO1, ENO2, OGDH, PFKL, PFKP, TPI1) additionally 
supporting the role of increased glycolysis in primary tumours. Glutamine transporters (SLC1A5, 
SLC7A5) and glutamate receptors (GRIK1, GRIK2, GRIN2D) were also seen to be overexpressed in 
primary tumours.  
Ornithine aminotransferase (OAT) and Phosphoserine aminotransferase (PSAT1) were observed to be 
less expressed in primary melanomas compared to normal tissue in both data sets (Figure 5.3B). OAT 
functions within the pathway that converts arginine and ornithine into glutamate and GABA. It has also 
been shown to be under-expressed in prostate cancer (279) which leads to an accumulation of 
putrescine. PSAT1 encodes for an aminotransferase which is part of the serine biosynthesis pathway, 
it catalyses a reaction which consumes α-ketoglutarate and produces glutamate as a by-product hence 
its inclusion in our studies. PSAT1 has previously been shown to be overexpressed in colon cancers 
and overexpression in SW480 human colon cancer cells increased cell proliferation and 
chemoresistance (280).  
In individual data sets it was seen that several genes involved in the glutaminolysis and the TCA cycle 
were under-expressed in primary tumours (CS, IDH1, SDH1, SDHC, ACO1, GLS2, GLUD2, IDH2, ME1, 
ME2), while only a few glycolysis genes were under expressed (PKFM, GAPDHS, GPT, GCLM) (Figure 
5.3B).  Finally, several transglutaminases were also observed to be under-expressed in primary 





Figure 5.3. SLC2A3 is overexpressed in Primary Melanoma Samples. A) Only SLC2A3 was observed to be 
significantly overexpressed in both datasets with normal tissue vs. primary melanoma samples. Venn diagram of 
the two databases with metastatic and primary melanoma samples. Genes shown passed criteria of having fold 
change expression <1.5 and FDR adjusted p <0.05 B) OAT and PSAT1 are less expressed in primary melanomas 
compared to normal tissue. Venn diagram of the two databases with metastatic and primary melanoma samples. 
Genes shown passed criteria of having fold change expression <0.66 and FDR adjusted p <0.05. Highlighted in 
red are genes that show to be both overexpressed and under expressed in databases. C) Box and whisker plots 
SLC2A3 expression in the Avery and Talantov Databases. Boxplots show median expression along with upper and 
lower quartiles. Whiskers show 95% confidence interval. ** p<0.01 ***p<0.001 and Fold Change in Expression and 
FDR adjusted p-values for fold change in expression between primary melanoma samples and Nevus or 
Melanocyte samples in the respective databases.  
  











































































Figure 5.4. The transglutaminase TGM2 is more expressed in metastatic melanomas compared to primary 
melanomas. Venn diagram of the four databases with metastatic and primary melanoma samples. Genes shown 




5.3.2 TGM2 is overexpressed in metastatic melanoma samples compared to primary melanoma 
samples while TGM1 expression is down regulated in metastatic samples compared to primary 
melanomas 
Transglutaminase 2 (TGM2) is more highly expressed in all the databases analysed comparing 
metastatic melanoma samples compared to primary melanoma samples. TGM2 was included in the 
screen not only for its catalytic activity as a transglutaminase, but it has also been shown to regulate 
RhoA signalling. Transglutaminase binds to an transamidates RhoA which leads to a constitutively 
active GTPase. This can then lead to increased activity of ROCK(282-284). Across the four databases 
examined, it showed a mean 3.35-fold increase in expression in metastatic samples vs. primary 
samples and had a significant change in three of the four databases (Figure 5.4). In the Riker database 
the change in expression was not statistically significant (p = 0.19), however the trend is consistent with 
the other databases as a 2.05-fold increase in expression was observed (Figure 5.5). TGM2 encodes 


























amino group of a lysine residue and a γ-carboxamide group of a glutamine residue. It can be found both 
intracellularly and in the extracellular matrix (285).  
 
Figure 5.5. TGM2 is overexpressed in metastatic melanoma compared to primary melanomas. A) box and whisker 
plots illustrating the expression of TGM2 in the datasets analysed. Boxplots show median expression along with 
upper and lower quartiles. Whiskers show 95% confidence interval. ** p<0.01 ***p<0.001 B) Table of fold change 




TGM1 and other transglutaminases such as TGM3 and TGM5 showed lower expression when 
comparing expression between metastatic samples compare to primary samples (Figure 5.6A). TGM1 
was found to be less expressed in metastatic melanomas compared to primary melanomas in all four 
databases (Figure 5.6B). 
 
 


























Figure 5.6. Several Transglutaminase family members are less expressed in metastatic melanomas compared to 
primary melanomas. Venn diagram of the four databases with metastatic and primary melanoma samples. Genes 




5.3.3 GSEA reveal melanomas upregulate glycolysis and downregulate the TCA cycle in tumorigenesis 
while switching to glutamine metabolism in metastasis 
Gene Set Enrichment Analysis is a computational tool to assess whether a set or group of genes is 
overrepresented in a disease state. This non-threshold bioinformatics technique can reveal if a set of 
genes is being globally regulated, in this case in metastatic melanoma or in ROCK inhibition. The genes 
comprising the gene sets can be seen in Appendix A. Gene sets that were selected (Table 4) were run 
through GSEA against each database. 
In terms of Primary melanomas, The TCA cycle gene set was found to be significantly overexpressed 
in melanocytes when compared to melanomas in the Avery dataset (Nominal p-value = 0.036, FDR q-
























respiration during tumorigenesis, consistent with the Warburg effect observed in melanomas. GSEA 
analysis of the Talantov dataset shows that Gln/Glu transporters and glycolysis are significantly 
overexpressed in melanomas when compared to benign nevi (FDR q-value = 0.021 and 0.041 
respectively, Figure 5.7). 
When comparing metastatic melanomas to primary melanomas, there was a trend for the Gln/Glut 
transport gene set being overexpressed in metastatic melanomas compared to primary melanomas in 
the Kabbarah dataset (nominal p= 0.038, FDR q-value = 0.132, Figure 5.7). In the Xu dataset there was 
a trend for the TCA cycle gene set being overexpressed in metastatic samples when compared to 
primary samples (nominal p-value = 0.036, FDR q-value = 0.098, Figure 5.7).  
This data presented here suggests that in tumorigenesis cancer cells switch away from aerobic 
respiration and upregulated glycolysis while in metastasis they may upregulate glutamine metabolism 




Figure 5.7. Melanoma cells upregulate glycolysis and downregulate aerobic respiration in tumorigenesis and switch 
to glutamine metabolism during metastasis. GSEA data from Analysis of patient databases. Gene sets were made 
for diverse metabolic pathways involved in glutamine/glutamate metabolism. Full gene sets are shown in the 















5.3.4 ROCK expression positively correlates with glutamine metabolism and the TCA cycle while it 
negatively correlates with glycolysis 
It was observed that ROCK expression is not normally distributed in melanoma patients, ROCK1 shows 
expression that is left-skewed (Figure 5.8A), with most patients having expression below the median. 
ROCK2 shows a potential bimodal distribution (Figure 5.8A). While beyond the scope of this work, 
future work studying the subpopulations of patients expressing different levels of ROCK may reveal 
other factors regulating tumour progression in melanomas. 
Linear correlations of the metabolic genes analysed show that genes involved in glutamine metabolism 
are positively correlated with ROCK expression (GLS1, SUCLG2, ME2, and SDHD. Table 7). This 
supports the hypothesis that ROCK can regulate glutamine/glutamate metabolism and the TCA cycle 
such as. The correlation between ROCK1 and Glutaminase 1 (GLS1) is shown in Figure 5.8B as an 
illustration.  
ROCK expression is also positively correlated with genes involved in glutathione synthesis such as, 
GCLC and GCLM (Table 7). This also suggests ROCK plays a role in supressing reactive oxygen 




Figure 5.8. Linear regression between z-scores of A) ROCK1 and ROCK2 B) ROCK1 and GLS1 and C) ROCK2 
and IDH3G across the five human melanoma databases (n=804). Covariance test is Spearman’s rank correlation 
and 95% confidence interval is imaged around the linear fit. The margins of the scatter plots show histograms of 








Linear correlation analysis of ROCK expression show that ROCK expression is negatively correlated 
with a range of glycolysis genes such as PFKL, TPI1, PKM, PFKL, and GAPDH (Table 8). It has been 
seen that cells with inhibited ROCK have increased Warburg effect and this supports the data found in 
the previous chapter. However, it should be noted that there are TCA cycle genes that also negatively 
correlate with ROCK, such as IDH3G and PC. 
5.3.5 ROCK1 correlates with different metabolic enzymes compared to ROCK2  
An interesting pattern appears when looking at the genes that pass the cut-off criteria. While ROCK1 
and ROCK2 expression are strongly correlated (Spearman r = 0.4744, Table 7), there is a difference in 
which other genes their expression correlates. ROCK1 expression positively correlates with several 
TCA cycle genes while ROCK2 does not (Table 7). On the other hand, both ROCK1 and ROCK2 
expression is positively correlated with genes involved in glutathione synthesis and nucleotide synthesis 
(PPAT) (Table 7).
 
ROCK1 Pathway SpearmanR ROCK2 Pathway SpearmanR 
ROCK2 Rho/ROCK 0.4745 ROCK1 Rho/ROCK 0.4745 
GLS Glutaminolysis 0.3646 GFPT1 Glutamate Metabolism 0.2832 
SUCLG2 TCA Cycle 0.3518 EPRS t-RNA synthesis 0.2817 
ME2 TCA Cycle 0.3441 PPAT Purine synthesis 0.2590 
GCLM Glutathione Synthesis 0.3129 ENPEP Renin-angiotensin 
system 
0.2589 
PPAT Purine synthesis 0.2989 GCLC Glutathione Synthesis 0.2526 
GCLC Glutathione Synthesis 0.2974 AASS Lysine Degradation 0.2524 
SDHD TCA Cycle 0.2943 RIMKLB Glutathione Synthesis 0.2500 
GFPT1 Glutamate metabolism 0.2781    
EPRS t-RNA synthesis 0.2779    
 
Table 7. Genes involved in the TCA cycle and glutamine synthesis positively correlated with ROCK expression. 
Genes, metabolic pathways and Spearman rank correlations shown for genes where 𝑹𝟐 > 𝟎. 𝟐𝟓 
 
 
ROCK2 is positively correlated with genes involved in the TCA cycle (ACO1, SUCLG2) and glutamate 
synthesis (ENPEP). It is negatively correlated with glutamine secretion (SLC7A5, SLC3A2), and 
individual genes in the TCA cycle and glycolysis (IDH3G and PFKL respectively).  
Both SLC3A2 and SLC7A5 are genes that are involved in glutamine transport. SLC3A2 codes for the 
42F cell-surface antigen heavy chain protein (4F2HC) while SLC7A5 codes for the Large neutral amino 
acids transporter small subunit1 (LAT1). When SLC3A2 and SLC7A5 associate they form the 
heterodimer CD98, also called LAT1. LAT1 is involved in the transport of not only glutamine, but also 
 148 
 
branch-chained amino acids such as valine, leucine, isoleucine as well as aromatic amino acids like 
tryptophan and tyrosine. 
While ROCK1 and ROCK2 expression positively correlate together (Spearman r = 0.4744, Table 7) it 
is interesting to find that they still correlate a few different genes. This data connects with the results 
shown in the previous chapter; we observed that ROCK1 and ROCK2 have different metabolic profiles 
in murine models of melanoma where ROCK is knocked out.  It was suggested that individual isoforms 
of ROCK redundantly regulate glutamate concentrations. From the expression correlation analysis, we 
could suggest further that ROCK1 promotes the processing of glutamine/glutamate through the TCA 
cycle while ROCK2 may play a lesser role in promoting oxidative phosphorylation. ROCK may also 
suppress the expression of glycolytic enzymes, which is supported by our data showing that inhibiting 
ROCK activity leads to increased glycolysis in melanoma in the previous chapter. 
 
ROCK1 Pathway SpearmanR ROCK2 Pathway SpearmanR 
IDH3G TCA Cycle -0.4799 IDH3G TCA Cycle -0.4144 
PFKL Glycolysis -0.4090 GATB t-RNA synthesis -0.3608 
GSS Glutathione Synthesis -0.3712 SLC3A2 Glutamine Transport -0.3440 
OGDH Glycolysis -0.3450 PFKL Glycolysis -0.3381 
SLC3A2 Glutamine Transport -0.3445 SLC7A5 Glutamine Transport -0.3198 
BCAT2 Branched chain amino 
acid synthesis 
-0.3439 PKM Glycolysis -0.2995 
TPI1 Glycolysis -0.3334 GOT2 Glutaminolysis -0.2647 
PKM Glycolysis -0.3300 
PC TCA cycle -0.3266    
ALDH4A1 Glutamate synthesis -0.3104    
GATB t-RNA synthesis -0.2960    
QARS t-RNA synthesis -0.2904    
GAPDH Glycolysis -0.2871    
SLC7A5 Glutamine Transport -0.2849    
SLC25A22 Mitochondrial 
glutamate transport 
-0.2676    
EARS2 t-RNA synthesis -0.2523    
 
Table 8. Genes involved in glycolysis and glutamine efflux negatively correlated with ROCK expression. Genes, 






Figure 5.9. ROCK expression is positively correlated with glutamine metabolism and the TCA cycle while negatively 
correlated with glycolysis. Representative figure demonstrating metabolic pathways where ROCK expression was 
positively correlated (red) and negatively correlated (blue) with genes. Metabolites are shown in grey. Genes that 
did not pass threshold criteria are excluded for illustrative purpose. 
 
 
The picture that forms from this analysis is that ROCK expression is positively correlated with glutamine 
metabolism and part of the TCA cycle while it is negatively correlated with glycolysis and the release of 
glutamine via SLC7A5 (Figure 5.9).
 
5.3.6 Genes from several metabolic pathways correlated with patient outcomes  
The TCGA dataset had the added benefit of having overall survival data along with RNA-set gene 
expression data which allowed an investigation of how gene expression correlates with patient 
outcomes. This survival dataset contains a majority of patient data from metastatic melanomas (296 of 
354 samples) and therefore is highly biased toward poor prognosis in patients. Despite this, survival 






































Figure 5.10.Survival Analysis of TCGA melanoma data show several genes correlate with overall survival (OS) at 
10 years. A) Representative Kaplan-Meier survival curve of Citrate Synthase (CS) demonstrating lower survival of 
patients with expression of CS higher than median expression. CS curve shown for illustrative purposes. B) Table 
of genes that showed significant correlation with patient outcomes after multiple test corrections. 
 
 
After False Discovery Rate (FDR, Benjamini-Hochberg method (286)) multiple test correction, seven 
genes were significantly correlated with better or poorer patient outcomes (Figure 5.10B). GRIN3A 
correlated with better prognosis in patients. GRIN3A encodes for the glutamate receptor NMDA type 
subunit 3A. The other six genes (PFAS, GOT2, CTPS1, GGT6, PGAM1 and CS) all correlated with 
poor prognosis (Figure 5.10B). The genes that correlated with poor prognosis are genes involved in the 
TCA cycle, glycolysis, glutaminolysis, and both lipid and nucleotide synthesis. There does not seem to 
be a clear pattern from this data; it may suggest that highly energetic melanoma cells that cause poor 
Gene Pathway q-value Diff Median OS (Years)
CS TCA Cycle 0.0262 -5.14
PGAM1 Glycolysis 0.0262 -4.95
GOT2 Glutaminolysis 0.0100 -4.75
CTPS1 Phospholipid and nucleic acid 
synthesis
0.0140 -4.72
PFAS Purine synthesis 0.0054 -4.72
GGT6 Glutathione synthesis 0.0155 -3.71






























prognosis and require increased expression of metabolic genes. ROCK1 and ROCK2 were also tested 
and did not correlate with patient outcomes. However, as noted in section 5.3.4, the expression of 
ROCK is non-normally distributed. Future work would look sub-groups of patients with different 
expression profiles of ROCK. This shows that the relevance of ROCK in metastatic melanoma may go 
beyond expression and instead is related to its activities.  
5.3.7 Summary of bioinformatics 
To summarize the analysis done in this chapter; we aimed to assess if the metabolomic findings in 
chapter 4 could be more broadly applicable to clinical data of melanoma patients. 181 genes related to 
glucose transport/metabolism, glutamine/glutamate transport/metabolism, TCA cycle and Glutamate 
signalling were selected to analyse gene expression at different stages of melanoma, correlations with 
ROCK expression and correlations with patient prognosis. Univariate analysis was performed to 
understand the change in expression of these genes in primary melanomas and in metastasized 
melanomas. It was seen that expression of the glucose transporter SLC2A3 was upregulated in primary 
tumour samples while the transglutaminase TGM2 was upregulated in metastatic samples. This 
supports the hypothesis that the Warburg effect is important in primary tumour formation and is partially 
replaced by glutamine metabolism in the metastatic disease. Gene set enrichment analysis was also 
performed, suggesting that melanomas upregulate glycolysis and downregulate the TCA cycle in 
primary tumour formation while switching to glutamine metabolism during metastasis. Correlations of 
gene expression were analysed compared with ROCK and it was seen that ROCK is negatively 
correlated with a number of genes responsible for glycolytic enzymes while being positively correlated 
with a number of TCA cycle genes. This further supports a role for ROCK in promoting metastasis via 
its regulation of metabolism. The glutamate receptor GRIN3A correlated with better patient prognosis 
while a number of genes involved in a variety of pathways such as glutaminolysis, glutathione synthesis, 
glycolysis and the TCA cycle correlated with poor prognosis.  
It was also observed that ROCK expression is not normally distributed which would suggest that future 
analysis of gene expression and patient data should take into account the bimodal distribution ROCK2 
expression. This may reveal additional information on gene expression patterns and potentially 
prognosis in sub-groups of melanoma patients. 
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5.3.8 qPCR validation of genes identified from microarray 
Thus far analyse have been conducted in patient databases of melanomas. We were further interested 
in examining the microarray data presented by Sanz-Moreno et al (140) from the view of 
glutamine/glutamate metabolism because their study closely resembles the experimental conditions 
conducted in our in vitro work. 
Microarray data on A375M2 cells treated with the ROCK inhibitor H1152 for 16 hours was obtained 
from (140). The largest change in gene expression observed from the microarray was that the 
expression of glutaminase (GLS1) decreased 8.2% after treatment with H1152 compared to control 
(FDR adjusted p value = 0.0012). interestingly, there is also a 13.4% reduction in GLS1 expression in 
A375 parental cells compared to A375M2, which further suggests that glutamine metabolism may be 
important in promoting metastatic potential in melanoma. However, this suggests that the gene 
expression changes observed from this microarray are quite subtle. 
As a final part of this work, we aimed to identify potential gene targets in related to glutamine and 
glutamate metabolism in A375M2 to then further study their roles in cell proliferation and morphology. 
We used the 106 genes taken from the HMDB gene set described in Figure 5.2 and looked at 
expression of these genes in the microarray data. The top 20 genes that appeared to be positively 
regulated by ROCK activity the microarray were then selected to further validate if their expression is 
regulated by ROCK activity. Primers were validated and optimised (Figure 5.11) prior to gene 
expression analysis by qPCR. The titration curves for TGM2 are shown in Figure 5.11A as an 
illustration. Primers were optimised in A375M2 cells seeded on bovine collagen 1 using 100, 10, 1 and 
0 ng of extracted RNA (Figure 5.11B). From the optimisation it was decided that 100 ng of RNA would 
be used per qPCR well.  
Several genes showed very low expression and ct values were not distinguishable between wells with 
100 ng RNA and those without cellular RNA. This made quantification by qPCR impossible for genes 
such as GRIA1, SLC25A18, and GRIK1 (Figure 5.12). Other genes showed relatively high expression 
in A375M2 cells and gave confidence to studies in the transcriptional regulation of these genes during 




Figure 5.11. Titration of qPCR primers from metabolic genes of interest. A) Representative plot of curves generated 
from the primer targeting TGM2. B) Table of mean ct values for the primers tested at 0, 1, 10, and 100ng. RNA 
was taken from A375M2 cells seeded onto Collagen 1 for 24 hours at 1% FBS supplemented media. 
 
 
The expression of the 20 genes was assessed by qPCR. RNA from A375M2 cells plated on collagen 1 
was extracted and quantified for the 20 genes of interest. It was seen that there are several genes with 
relatively high expression compared to GAPDH. PPAT, SLC7A11, OAT, GRIK2, and GLS1 were the 
Titration curves qPCR - TGM2
Gene ct_100ng ct_10ng ct_1ng ct_0ng
GAPDH 12.72 15.45 18.47 29.33
GRIK2 18.64 24.14 27.01 34.54
GFPT1 19.09 22.01 25.4 31.58
EPRS 19.55 22.4 25.69 32.42
PPAT 19.91 23.15 26.61 34.33
GCLC 19.96 23.17 26.47 31.34
SLC7A11 20.23 23.05 26.24 34.9
GLUD1 20.5 23.48 26.86 32.37
GLS1 21.09 27.36 31.33 32.05
GLUD2 21.63 22.68 25.19 28.66
OAT 21.83 24.96 28.43 36.69
AASS 24.41 27.71 31.11 36.83
ABAT 25.79 28.31 31.64 36.11
SLC1A1 26.03 28.77 30.31 30.79
SLC7A8 26.41 29.42 32.91 36.99
TGM2 26.65 30.43 32.03 32.67
GLUL 26.84 31.56 35.72 37.18
NAGS 27.92 28.3 30.73 32.72
GRIA1 29.29 30.32 31.99 32.87
SLC25A18 29.79 32.45 34.42 35.82
FOLH1 29.96 31.14 33.83 39.64





most expressed genes from this screen. Of the 20 genes tested, PPAT and SLC7A11 showed the 
highest expression, with an expression level ~40% that of GAPDH (Figure 5.12A). PPAT encodes for 
Phosphoribosyl Pyrophosphate Amidotransferase (PUR1 at protein level) which is the enzyme involved 
in the first step of de novo purine synthesis (287). SLC7A11 encodes for the glutamate-cysteine 
exchange transporter protein xCT. It will be further studied in the next chapter due to its relevance to 
glutamate transport and high expression levels in A375M2 cells. The ionotropic glutamate receptor 
GRIK2 was also relatively highly expressed in A375M2 cells, with even higher expression glutaminolytic 
genes such as GLS1 and GLUD1 (Figure 5.12B). These findings also suggest that glutamate secretion 





Figure 5.12. Expression of select metabolic genes in A375M2 human melanoma cells. A) Representative images 
of selected genes in A375M2 human melanoma cells and quantification of gene expression relative to GAPDH of 
A375M2 cells when seeded on collagen 1. Genes shown in descending order. B) Quantification of gene expression 
by qPCR relative to GAPDH shown on a Log 10 scale.  
 
 
We then assessed if the expression of these genes is regulated by ROCK activity as was observed by 
the previous microarray. Cells plated on collagen were treated with DMSO as control or H1152 for 24 
hours. RNA from these cells was extracted and gene expression was quantified by qPCR. The results 
show that many of the genes did not have a strong regulation of expression by ROCK activity. Initially 
TGM2, FOLH1 and GFPT1 RNA levels appeared to decrease after ROCK inhibition (Figure 5.13A). 
Additional repeats show TGM2 expression is significantly regulated by ROCK activity (Figure 5.13B). 
Replicates however showed this effect was much less stated (Figure 5.13B). This is particularly 
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interesting as we observed in 5.3.2 that TGM2 is overexpressed in metastatic melanomas when 
compared to primary melanomas. This points to the possibility that ROCK activity is regulating TGM2 
expression in metastatic melanoma.  
The results suggest that only TGM2 expression is regulated by ROCK activity from the 20 genes initially 
selected for analysis. This also suggested that the microarray used was not sufficient to draw any 
conclusions regarding the control of metabolic genes expression by ROCK. 
 
Figure 5.13. TGM2 expression is regulated by ROCK activity. Gene expression after 24h ROCK inhibition. A) n=1 
screen of gene expression of A375M2 cells on collagen 1 treated with DMSO control and H1152 ROCK inhibitor 
for 24 hours. Genes shown in ascending order of expression after ROCK inhibition. Each sample was tested in 
triplicate B) Based on initial screen genes were selected for repeat screens. Gene expression relative to control 




5.3.9 In vitro Screens of metabolic targets reveal differential regulation of melanoma morphology and 
cell proliferation 
The candidate did not generate the following data shown in this section. Data presented here was 
generated by Dr. Eva Crosas-Molit from the Sanz-Moreno group and Ms. Beatriz Padilla from the Mason 
group. It is presented here to help create a larger context for discussion.  
 
Data generated from the metabolomic data in the previous chapter along with the bioinformatics 
analysis of glucose metabolism, glutamine metabolism and glutamate signalling was used to inform the 
generation of a candidate library with which to perform and in vitro screen of how these pathways 
contribute to melanoma proliferation and cell morphology. A total of 21 genes were selected for 
screening. These were: 
 5 TCA cycle genes (IDH3A, IDH3B, IDH3G, MDH1) 
 4 glutaminolysis genes (GOT1, GOT2, GLS1, SLC7A8) 
 7 glycolytic genes (OGDH, GPI, HK3, ACO2, ENO1, ENO2) 
 2 glutamate receptors (GRIN3A, GRIK2) 
 4 genes identified from the HMDB search which had potential regulation by ROCK. (TGM2, 
FOLH1, PPAT, EPRS) 




Figure 5.14. Screen of metabolic enzymes show glutamine and glycolysis are required for both cell proliferation 
and amoeboid phenotype. A) siROCK1/2 is shown in red as a positive control for both cell proliferation and cell 
morphology. Genes that were selected as have ‘strong’ regulation of morphology coloured in purple. Other genes 
with significant regulation of cell morphology are coloured in blue. All experiments were n=3, plots show mean +/- 
SEM of measured values. B) Representative Western Blot Confirming Knockdowns of genes from screen. Data 
and figures generated by Dr. Eva Crosas Molist and Ms. Beatriz Padilla 
 
  






















































































In the screen it was observed that blocking glycolysis (GPI, OGDH), the TCA cycle (IDH3B), or 
nucleotide synthesis (PPAT) led to a significant decrease in proliferation in melanoma cells, similar to 
or even exceeding that found in the ROCK1/2 knockdown. In addition, it was seen that knockdown of 
these gene led to a significant elongation of cells, comparable but less pronounced than those found in 
ROCK knockdowns. 
The results from this screen demonstrate that melanoma cells require both glycolysis and oxidative 
respiration to sustain both proliferation and a rounded morphology. It is sufficient to block one pathway 
to see a reduced ability of these cells to sustain proliferation and morphology. 
Among other targets selected in the bioinformatics screen, TGM2 was studied in the first screen and 
the knockdown a non-significant elongation of cells and a significant reduction in proliferation, however 
not to the extent of the principle hits found above. Genes involved in glutamine metabolism and 
transport, such as GLS1 and SLC7A8, had no on cell morphology while leading to a considerable 
reduction in cell proliferation. 
Interestingly, among the three isoforms of Isocitrate dehydrogenase 3 (IDH3) studied, IDH3B showed 
to have the largest effect on cell morphology while IDH3G had the largest effect on cell proliferation. 
IDH3G was also observe to be negatively correlated with ROCK expression. IDH3 catalyses the 
enzymatic reaction of isocitrate to α-ketoglutarate in the TCA cycle. It could be assumed that the 
isoforms could compensate for the depletion of one isoform, however it was observed that it was 
sufficient to target an individual isoform to reduce cell proliferation. IDH1 and IDH2 have been 
extensively implicated in cancer (288) and while no mutations of IDH3 have been observed in cancer 
(289) aberrant signalling of IDH3A via HIF1α has recently been seen to promote proliferation in lung 
cancer cell lines (290). 
Two glutamate receptors were also screened, the NMDA receptor GRIN3A and the kainate receptor 
GRIK2. Silencing GRIN3A had no significant effects on either cell proliferation or morphology while 
GRIK2 had a significant effect on cell morphology while having no effect on cell proliferation. This 
contrasts with the vast majority of genes silenced in the screen and shows it is possible to alter 





This chapter builds upon the metabolomic work in Chapter 4 by investigating the role of 
glucose/glutamine/glutamate metabolism, transport and signalling in melanoma metastasis in a large 
set of melanoma patient transcriptome data. This was done to determine whether the experimental data 
found in chapter 4 is more broadly applicable to a clinical setting.  
Gene expression at different disease stages was analysed suggesting differing roles for glycolysis and 
the TCA cycle in melanoma tumorigenesis and progression respectively. Gene expression was 
investigated both at an individual level and at the level of gene sets. Glycolysis and in particular SLC2A3 
was seen to be overexpressed in the process of primary tumour formation while the TCA cycle was 
seen to be downregulated in primary tumour samples when compared normal skin/melanocyte. Several 
genes were found to have potential therapeutic value as their expression was correlated with poor 
prognosis in patients.  
Finally, the link between ROCK and these metabolic pathways was further investigated by examining 
the correlation in expression between ROCK and the metabolic genes. It was seen that ROCK1 
expression positively correlates with TCA cycle genes and negatively correlates with a number of 
glycolytic enzymes. In the previous chapter we observed that inhibition of ROCK activity led to increases 
in the consumption of glucose and lactate production. It has also been shown that ROCK1 regulates 
the trafficking of the glucose transporter GLUT3 to the plasma membrane (156). It may be that, in future, 
this link could be further established at a transcriptional level for both ROCK signalling and glycolysis.  
Post-hoc analysis of previously published micro-array data (140) suggested several metabolic enzymes 
that may be transcriptionally regulated by ROCK signalling. Further investigation of the micro-array data 
along with validation of these results by qPCR demonstrate the difficulty observing relatively small 
changes in gene expression.  
5.4.1 Transglutaminases are differentially expressed in melanomas 
Tissue transglutaminase 2 (TGM2) was observed to be significantly overexpressed in three of the four 
patient databases examined comparing metastatic melanoma samples to primary melanoma samples 
(Figure 5.5) but that this expression pattern does not correlate with either ROCK1 or ROCK2. 
Nevertheless, we observed in vitro that TGM2 expression was modestly but significantly downregulated 




metastasis and could be directly regulated by ROCK activity. Furthermore, knockdown of TGM2 had a 
modest but significant effect on both melanoma cell proliferation and morphology (Figure 5.14). in 
contrast, TGM1 was seen to be less expressed in all four of the databases (Figure 5.6) while TGM3 
and TGM5 we also observed to be less expressed in metastatic melanomas; again this pattern did not 
correlate with ROCK1 or ROCK2 expression. As briefly touched upon in the results section (5.3.2), 
transglutaminases have been shown to regulate the activity of both RhoA (284)and ROCK2 (283). It 
has been seen that transglutaminases can transamidate RhoA which leads to a constitutively active 
GTPase which can then lead to increased activity of ROCK. It is interesting that we observe a regulation 
of TGM2 expression by ROCK as this suggest a regulatory loop between TGM2 and ROCK. 
TG2 is a complex and multifunctional enzyme involved in catalysing the formation of an isopeptide bond 
between a free amine group and acyl group, peptide cross-linking and post-translational modifying 
transamidation, deamidation, as well as a host of other functions such as the ability to serve as a kinase 
and atypical ATP/GTPase. These numerous roles within the cell have implicated TGM2 in cellular 
adhesion, migration, growth and survival as well as regulating apoptosis, differentiation, and ECM 
organization. As a result of these processes, TGM2 is associated with not only tumour growth and 
metastasis, but wound healing, inflammation, neurodegeneration and tissue fibrosis (285). However, 
the particular role played by TGM2 in tumorigenesis and metastasis is not well defined and appears 
likely to be influenced and altered by a number of factors. TGM2 has been shown to have opposing 
effects in anti- and pro-apoptotic effects on cancer cells depending on its multifunctional activity and 
conformational changes dependent on the local environment, in addition to the genetic background of 
the system of study(291).  
In the context of metastasis, it has been shown that both the absence of TGM2 in secondary site cells 
and overexpression in primary site cells is essential for successful melanoma metastasis (292). Further 
complicating the matter, melanoma tumour growth and invasion has been shown to be inhibited by an 
atypical GPCR, GPR56, of which TG2 is a major binding partner (293). Nevertheless, there does appear 
to be ample reason to believe that TGM2 plays a tangible role in tumour development and metastasis 
in renal cell carcinoma (294), colorectal cancer (295) and breast cancer (296). It seems highly likely 
that the particular function and potential pathogenicity of TGM2 is highly tissue-dependent (297,298). 
Our data supports not only the idea that TGM2 could promote metastasis, but that changes in ROCK 




We also observed that other members of the transglutaminase family such as TGM1 and TGM5 were 
downregulated both in primary melanomas and in metastatic melanoma. There is much less literature 
available regarding other the other transglutaminase family members observed in our study. TGM1 has 
been shown to stabilise endothelial and keratinocyte cell junctions (299) therefore it would be possible 
that invading cancer cells would downregulate TGM1. TGM5 also seems to play a role in maintaining 
the structural integrity of the epidermis; mutations in TGM5 lead to acral peeling skin syndrome, a rare 
autosomal recessive disorder which is characterised by blistering and peeling of the skin (300). This 
will present challenges for further research as it will be important to understand if TGM2 has a role in 
promoting metastasis. Further work should be conducted to understand to what extent ROCK is 
regulating TGM2 expression and/or activity. 
5.4.2 Glutamine/glutamate transporters 
5.4.2.1 SLC1A5 and SLC7A5 
We observed that ROCK2 expression is negatively correlated with SLC3A2 and SLC7A5. SLC3A2 
(CD98hc) and SLC7A5 (LAT1) dimerize to form the active amino acid transporter LAT1 (301). SLC3A2 
is of particular interest as it is required for the active transporters not only of LAT1, but of several other 
amino acid transporters such as LAT2 glutamine transporter (SLC7A8) and xCT (SLC7A11) 
glutamate/cysteine exchange (302). This fits well with the data presented in Chapter 4 as the LAT1 
heterodimer is involved in glutamine efflux coupled with leucine intake (303). In the study by Nicklin et 
al (303), they demonstrated that SCL7A5 (LAT1) is coupled to SLC1A5 (ASCT2) in activating the mTOR 
pathway as ASCT2 regulates glutamine uptake coupled with sodium efflux while LAT1 then exchanges 
intracellular glutamine for extracellular leucine. While in our work we have focussed on glutamine and 
glutamate, it should be noted that leucine also regulates melanoma proliferation and autophagy via 
mTORC signalling (303). Autophagy is a self-destructive process which allows cells to adapt to nutrient 
deprivation (304). It has been shown that under low pH conditions, melanomas undergo autophagy as 
a protective mechanism (305). More recently, Jewell et al showed that depriving melanomas of leucine 
inhibited autophagy and lead to apoptosis in four melanoma cell lines(306). This suggests that LAT1 
could potentially play a role in these pathways as it is also involved in leucine uptake. In our studies we 
observed that when ROCK is inhibited, melanoma cells secrete lactate, which would thus reduce the 




more leucine to support autophagy. This could partially explain the inverse correlation in expression 
between ROCK2 and SLC3A2/SLC7A5. 
Additionally, CD98hc (SLC3A2) has been shown to bind and regulate β1 Integrin, which itself is 
responsible for regulating Rac, PI3K and AKT signalling (307,308), suggesting a role for amino acid 
transporters not only in direct metabolism, but also in signalling pathways involved in cell proliferation 
and migration.  
ASCT2 and LAT1 are the two most well studied glutamine transporters. ASCT2 has been shown to play 
a role in sustaining the proliferation of cervical cancer, osteosarcoma, clear-cell renal carcinoma, triple 
negative breast cancer, non-small cell lung cancer, prostate cancers, colorectal cancers, and 
hepatomas (309-319). With regards to melanoma, SLC7A5 has already been proposed to be an 
independent prognostic marker for melanoma in a study of 30 melanoma patients (318). In a study by 
Wang et al, targeting ASCT2 reduced proliferation, however targeting LAT1 with the small molecule 
inhibitor BCH did not reduce melanoma proliferation (203). As has been previously suggested, this 
could be explained by the opposing but coupled roles of ASCT2 and LAT1 in regulating glutamine 
transport. 
5.4.2.2 SLC7A8 
Data from this chapter points to SLC7A5 as being of particular importance in melanoma patients. 
Additionally, there was some initial indication that SLC7A8 may also be of interest as in the microarray 
data in the previous chapter we observed that SLC7A8 expression could be regulated by ROCK activity. 
However, further work showed it is very weakly expressed in A375M2 cells and there was no observed 
regulation of SLC7A8 by ROCK activity. Furthermore, it was observed to be both over and under 
expressed in primary melanomas compared to normal tissue and it was not seen to be overexpressed 
in metastatic melanomas.  
SLC7A5 and SLC7A8 are both members of the cationic amino acid transporter/glycoprotein associated 
family of solute carriers (SLC). Both of these light chain subunits associate with SLC3A2 (4F2hc/CD98), 
the heavy chain subunit, to form functional channels, LAT1 and LAT2 respectively. Each are associated 
with the transport of large, neutral amino acids, or in the case of LAT2, occasionally various cationic 
amino acids. LAT1 preferentially transports large neutral amino acids, for instance, L-phenylalanine, L-
tryptophan, L-leucine and L-tyrosine. The selectivity of LAT2 appears to be broader whilst the affinity 




physiological concentrations (320). LAT2 has been implicated in arginine/glutamine exchange, with 
glutamine influx being heavily favoured over efflux (321). The transport of amino-acids is essential for 
a variety of nutrient-based cellular functions such as growth, proliferation and cell integrity and 
maintenance.  
While SLC7A5 expression has been consistently associated with a number of cancerous conditions, 
SLC7A8 has rarely been observed in tumour cells, whilst shown to be ubiquitously expressed in non-
tumour cells. Thakkar and colleagues (322) demonstrated activation of SLC7A8 in breast cancer cell 
lines overexpressing the oestrogen receptor, suggesting its involvement in mitogenic signalling. 
Expression of SLC7A8 in ovarian cancer has shown to be unchanged while SLC7A5 was 
overexpressed (323), or even negatively associated with tumorigenesis (324). Expression of SLC7A5 
was associated with the development of malignant glioma (325), breast cancer (320), colorectal 
adenocarcinoma (326) and gastric carcinoma (327). On the other hand, the expression and activity of 
SLC7A8 in each of these cancers was either unchanged or negatively correlated. Furthermore, SLC7A5 
was found to be associated with tumorigenesis, migration, invasion and metastasis in renal cell 
carcinoma (328) and cholangiocarcinoma (329). Again in these studies the impact of SLC7A8 was seen 
to be non-significant.  
It is well established that melanoma is a highly plastic cancer and can shift between different invasive 
phenotypes with rapid succession. In some systems such as astrocytes LAT2 (SLC7A8) rather than 
LAT1 (SLC7A5) is the principle transporter of glutamine and is primarily involved in its influx (330). It 
does not appear to play an important role in melanomas or other tumour types however and SLC7A5 
is taking a more central role in sustaining tumour proliferation and invasion.  
5.4.2.3 SLC7A11 
SLC7A11 encodes for the xCT protein and is a cysteine/glutamate exchange transporter which in 
principally known for importing extracellular cysteine while exporting glutamate. We observed that 
SLC7A11 is highly expressed in A375M2 human melanoma cells. The importance of xCT has typically 
been thought to be the import of cysteine whose presence is the rate limiting amino acid in the synthesis 
of glutathione (331,332). It has been suggested to be a useful target for cancer therapy since 2005 
(332). Its additional role in glutamate release, also makes it an attractive target. As stated earlier, 




Glutamate signalling has been shown to promote glioma cell invasion (333), decrease cell adhesion in 
melanocytes (334), and promote invasion in bone metastasis (197). It has been suggested to be a 
therapeutic target in triple negative breast cancer (335) and targeting xCT has shown to induce tumour 
regression in HIV-associated lymphoma (336,337). It binds to CD44, an important antigen that regulates 
cell migration and adhesion (338). SLC7A11 expression correlates with patient prognosis in 
glioblastoma (339), hepatocellular carcinoma(340), squamous cell carcinoma (341) and malignant 
gliomas (342), suggesting its importance in a variety of cancer types. 
5.4.3 Glutamate Receptors 
Glutamate receptors play an important role in pre- and post-synaptic signalling in neurons. Glutamate 
receptors are divided into two major groups: metabotropic receptors, which are G-Protein coupled 
receptors activated by the binding of glutamate, and ionotropic receptors, which are classically 
understood to be ion channels and activated by glutamate binding. This strict view of the function of 
ionotropic receptors is being challenged by evidence that they may have metabotropic functions as well 
(343). 
In our work we observed that high GRIN3A expression was seen to be associated with better patient 
prognosis. GRIN3A encodes for NMDA receptor subunit 3A (GluN3A). While initially it may seem 
curious to see that a specific subunit of glutamate receptors correlates with better prognosis in patients, 
there is a possible explanation that can be garnered from the literature. the GluN3A subunit of NMDA 
receptors forms atypical NMDA receptors which have been proposed to be dominant negative and 
antagonise the function of classical NMDA receptors (344). NMDA receptors containing a GluN3A 
subunit have lower 𝐂𝐚𝟐+ permeability and produce smaller glutamate-evoked whole-cell currents in the 
central nervous system (344). When viewed in the context of glutamate signalling promoting metastatic 
potential in melanoma, this is more evidence that glutamate signalling may be playing a role in 
promoting melanoma progression. GRIN3A was screened for its effects on cell proliferation and 
morphology and it was observed that silencing GRIN3A has no effects on cell proliferation or 
morphology (Figure 5.14) and this again supports the view that GRIN3A may be playing a different role 
from other glutamate receptors, such as GRIK2, which was seen to significantly affect cell morphology 
after silencing. 
Other evidence is provided by GRIN2A, which forms classical NMDA Receptors. It has been shown to 




patients (346). In our work we observed that GRIN2A is mutated in 25% of the 287 melanomas in the 
TCGA dataset with mutation and copy number variant data. It did not however correlate with patient 






In chapter 4 we identified that glutamine/glutamate metabolism maybe involved in promoting melanoma 
proliferation or an amoeboid phenotype via ROCK signalling. In this chapter we assessed the roles that 
these metabolic pathways play in melanoma patient databases to understand if the results found in vitro 
may have relevance in a clinical setting. A picture arose from the data analysis which points to glutamine 
and glutamate transport being upregulated during metastasis in melanoma. Links were also established 
between ROCK expression and glutamine metabolism, with ROCK1 positively correlating with 
glutamine metabolism and negatively correlating with glycolysis. Additionally, ROCK2 negatively 
correlated with glutamine secretion and leucine uptake again supporting the hypothesis that ROCK 
drives glutamine metabolism.  
Transcriptome data from A375M2 melanoma cells where ROCK activity was inhibited by small molecule 
inhibitors was also analysed in the view of glutamine/glutamate metabolism. It was observed that genes 
involved in glutamate secretion and glutamate signalling are highly expressed in A375M2 melanomas. 
Finally, a selection of metabolic genes from the microarray data was screened for their effects on 
melanoma proliferation and morphology. This screen demonstrated that there is a relationship between 
cell proliferation and morphology and suggests that melanoma cells require energy from both glycolysis 
and the TCA cycle to sustain high levels of both. Additionally, glutamate signalling was also observed 
to play a role in regulating melanoma morphology.  
In the next chapter we have shown that the results found in chapter 4, namely that ROCK activity drives 
melanoma metastasis via regulation of glutamine/glutamate metabolism, may be applicable to the 
broader, more heterogeneous clinical setting of melanoma. In the next chapter we will return to an in 




Chapter 6 : An in vitro investigation of Glutamine 






In the previous chapters, we observed that ROCK activity drives higher levels of intracellular glutamine, 
glutamate and glutathione. In addition, inhibition of ROCK activity led to increase anaerobic respiration 
in the presences of oxygen. Glutamine and glutamate metabolism was investigated through patient 
microarray data and it was seen that enzymes involved in glycolysis are upregulated in primary 
melanomas while genes involved in glutamine metabolism are upregulated in melanoma metastasis. 
Furthermore, ROCK expression correlated with glutamine metabolism and the TCA cycle while being 
inversely correlated with glycolytic enzymes. The collected data together suggests that metastatic 
melanomas become less dependent on the Warburg effect and utilise glutamine/glutamate metabolism 
to sustain high levels of proliferation in metastatic potential. In short, we have also found evidence that 
ROCK may promote glutamine metabolism in metastatic melanoma, both through the metabolomic 
studies conducted as well as through our bioinformatics analysis.  
6.1.1 Glutamine/Glutamate transport in melanoma cell proliferation and morphology 
Based on the work in the previous chapters we have built a hypothesis that ROCK is promoting 
melanoma metastasis via the regulation of glutamine/glutamate metabolism and glutamate signalling. 
In this chapter we aim to test this hypothesis and further understand how glutamine/glutamate 
metabolism affects the proliferation and morphology of metastatic melanoma and if there is evidence 
for how this is direct regulated by ROCK. Toward this aim we have two principle objectives: First, we 
will conduct studies of how interfering with glutamine/glutamate metabolism and signalling regulates 
melanoma proliferation, melanoma cell morphology and their metabolic profiles. Secondly we aim to 
link regulation of glutamine/glutamate metabolism and/or glutamate signalling to ROCK expression or 
activity.  
Several amino acid transporters are of interest to us as we observed that the expression of enzymes 
responsible for glutamine/leucine exchanges (SLC7A5/SLC3A2) negatively correlates with ROCK 
expression in melanoma patients. Additionally, SLC7A11 which encodes for xCT, responsible for 
glutamate cysteine exchange, was seen to be highly expressed in A375M2 melanoma cells. As 
discussed in the previous chapter, gln/glu transport has garnered interest in cancer research due to the 




(348). For this chapter, six genes involved in gln/glu transport were selected, either on the basis of their 
potential significance in metastatic melanoma, identified in the previous chapter (SLC1A5, SLC3A2, 
SLC7A5, and SLC7A11), or their putative ability to affect uptake of glutamine from cell culture media 
(SLC38A1 and SLC16A19). In a similar fashion to the RNAi screen shown in the previous chapter, we 
are interested in understanding if these genes associated with glutamine/glutamate transport play roles 
in regulating cell proliferation and/or cell morphology. We will then investigate if the metabolic profiles 
of melanoma cells where the expression of gln/glu transporters are silenced replicates the profiles of 
cells where ROCK activity or expression is inhibited. 
6.1.2 Glutamate signalling in melanoma cell proliferation and morphology 
In the previous chapters we observed that glutamate is secreted by melanoma cells and glutamate 
signalling may also be playing a role in regulating cell proliferation or morphology. Glutamate signalling 
is mediated by transmembrane proteins that bind to and are activated by glutamate. There are two 
major groups of glutamate receptors divided according to their downstream signalling; metabotropic 
receptors are G-protein coupled receptors while ionotropic receptors are ion channels. Glutamate 
signalling has already been implicated to be important in melanoma. It has been seen that 
overexpression of the metabotropic receptors GRM1 and GRM5 are sufficient to induce melanoma in 
mouse models of melanoma (224,226). Additionally, ionotropic receptors such as GRIN2A have been 
seen to be often mutated in melanoma (222) and mutant GRIN2A may supports tumour cell survival. 
Evidence from the previous chapter as well as the literature all support our hypothesis that glutamate 
signalling plays a role in promoting melanoma proliferation and metastasis. 
There is additional evidence that glutamate signalling may play a role in promoting melanoma 
progression. TCGA data shows that the 26 glutamate receptors genes are mutated in 80.1% out of 287 
melanomas from the largest dataset of melanoma sequencing data present on the TCGA (Figure 6.2) 
(180,181). GRIN2A is mutated in 25% of cases followed by GRID2 which is mutated in 19% of 
melanomas (Figure 6.3). The data found in the TCGA database supports other published literature 
which has found GRIN2A to be mutated in 22-33% of melanomas (222,345), and has been suggested 
to have prognostic value (346).  
This evidence is further bolstered when compared to the total mutation data in the TCGA. There are 




rate of these genes is 4.67% (Figure 6.1), There are 151 genes mutated in more than 10% of melanoma. 
GRIN2A is the 36th most mutated gene in the melanoma dataset.  
 
Figure 6.1 Histogram of mutated genes in the TCGA melanoma dataset vs. percentage of melanomas harbouring 
mutated gene. The mean mutation rate (4.67%) is highlighted with blue line. There are a total of 1485 genes 
mutated in the TCGA melanoma dataset, comprised of 358 melanoma samples with mutation data. 
 
This evidence further suggests that glutamate signalling may play an important role particularly in 
melanoma compared to other tumour types. For examples, glutamate receptors are only mutated in 
6.1% of chronic lymphocytic leukaemia (Figure 6.2).  
While there are many putative glutamate receptors that may be of interest in melanoma (and will warrant 
future investigation), here we focus on GRIK2. The ionotropic glutamate receptor subunit GRIK2 is 
highly expressed in A375M2 melanoma cells and there was an indication, in a previous microarray 
study (140), that expression of GRIK2 may be regulated by ROCK activity. In addition, silencing of 
GRIK2 expression led to significant changes in melanoma cell morphology while not affecting cell 
proliferation. We will interrogate GRIK2 further, by confirming that the morphological changes observed 







Figure 6.2. Glutamate receptors are often mutated in melanoma. Histogram of genetic alterations of the 26 glutamate receptors in the TCGA database. Melanoma datasets are 
shown in black in the cancer type segment. Mutations are shown in green, deletions in blue, amplifications in red and multiple alterations in grey. Cancer types are listed in 
descending order of mutation rates for the 26 glutamate receptor genes. Figure is generated from cbioportal.org.  A public repository and web-tool for visualising TCGA data 








Figure 6.3. Glutamate receptor genes are often genetically altered in melanoma. Individual melanoma sample are plotted along the x-axis along with genetic alterations. Individual 
glutamate receptor genes are mapped to the y-axis along with the percentage of cases in which genetic alterations are found. Only genes that show genetic alterations in more 
than 10% of samples are shown in figure. Mutations are shown in green, deletions in blue, amplifications in red and cases with no genetic alterations are in grey. Data and figure 




6.1.3 GRIK2 is mutated in A375M2 cells 
 
In the previous chapter we observed that GRIK2 was highly expressed in A375M2 human melanoma 
cells and that silencing of GRIK2 expression led to significant changes in morphology while not affecting 
cell proliferation. This motivated our further investigation into the role of GRIK2 in melanoma metastasis. 
The Catalogue of Somatic Mutations in Cancer (COSMIC)(349) shows that A375 human melanoma 
cells harbour a mutated form of GRIK2. It has a missense C > T mutation, which leads to the substitution 
of threonine 740 to an isoleucine reside. If mapped to a crystallographic model of GluK2 (GRIK2) (350), 
the mutated residue is T709, located very closely to the glutamate binding domain (Figure 6.4, mutated 
reside shown in black). This may possibly affect the function of the protein, although further studies 
would have to verify this. We addressed this possible confounding factor in A375M2 cells by also 
studying the role of GRIK2 in a murine model of melanoma, the B16F10 cells. 
 
Figure 6.4. GRIK2 is mutated in A375 human melanoma cells. GluK2 is a transmembrane protein that functions as 
an ion channel and is activated by glutamate binding. Pymol cartoon visualisation of the GluK2 receptor, a homo-
tetramer formed from the expressed GRIK2 gene. Alpha helices are coloured in blue, beta-sheets in red and 
unstructured regions in purple. The mutated residue found in A375M2 melanoma cells (residue T740) is shown in 
Black. (PDB ID: 4UQQ) 
• A375 Mutation (Black)
– c.2219C>T
– p.T740I 
• Corresponds to T709 









6.1.4 Studies of Ionotropic Glutamate receptor antagonists in melanoma 
We are also interested in targeting glutamate signalling with small molecule antagonists of ionotropic 
glutamate receptors to study their effects on melanoma cell proliferation, morphology and the metabolic 
profiles. This is done out of interest for potential translational research into the application of using drugs 
targeting glutamate signalling in melanoma. Glutamate antagonists are a class of drugs that have been 
mainly used to study the functions of glutamate signalling in the central nervous system as well as to 
treat illnesses associated with aberrant glutamate signalling such as Parkinson’s Disease 
(amantadine)(351), Alzheimer’s (Memantine/MK-801)(352), and Depression (ketamine)(353). Many of 
these drugs such as Memantine, and amantadine are already approved for clinical use in the US and 
the EU meaning their safety profiles are well established. Should sufficient evidence of glutamate 
signalling promoting melanoma progression be collected, translating use of currently approved 
glutamate antagonists in melanoma would be an attractive prospective. 
For our studies we have selected four ionotropic glutamate receptor antagonists to test their effect on 
melanoma cell proliferation (Table 9). Based on the data collect we will select one for metabolomic 
analysis in human melanoma.  
Antagonist Mechanism IC50 in A549 Lung Carcinoma 
Cells (Rzeski et al) 
MK-801 (Diclozipine) Non-competitive NMDA antagonist >500 μM 
GYKI-52466 Non-competitive AMPA antagonist ~250 μM 
CFM-2 Non-competitive AMPA antagonist ~10-100 μM 
Memantine Un-competitive NMDA antagonist ~100-250 μM 
Table 9. Glutamate antagonists used in study 
 
 
Glutamate antagonists were selected based on previously published data demonstrating anti-
proliferative effects in lung carcinoma (A549) and rhabdomyosarcoma/medulloblastoma (TE671) (354). 
Rzeski et al used quite high doses of small molecule inhibitors (up to 500 μM) to see a significant effect 
on cell proliferation. This was replicated in Stepulak et al (355) who also demonstrated that AMPA 
antagonists, GYKI-52466 and CFM-2 inhibit ERK1/2 signalling and reduce phosphorylation of CREB 




testing them at 5 μM and 25 μM since we expected any drug of significance, acting at the cell surface 
and hence not required to penetrate within the cell, to be active at concentrations comparable to the 
small molecule ROCK inhibitors. Activity at higher concentrations might also be attributable to non-
specific, off-target effects. 
We will compare the data collected on glutamate antagonists to see if we can replicate the findings 
found when inhibiting ROCK activity. The metabolic profiles of cells where glutamate signalling is 
inhibited may particularly reveal similarities and differences between the modes of action of ROCK 
inhibitors and glutamate antagonists. This will also be compared to the effects of the glutaminase 
inhibitor 968, which specifically targets glutaminolysis. It is possible that targeting a broad group of 
glutamate receptors with small molecule inhibitors may affect several signalling pathways in a similar 
manner to ROCK, while specific inhibition of glutaminolysis may show more narrow effects on 
proliferation, morphology and the metabolic profile. Data collected from these experiments will further 
develop the hypothesis that ROCK drives melanoma metastasis through glutamine/glutamate 





6.2.1 Glutamine and Glutamate Transporters differentially regulate melanoma cell proliferation and 
morphology 
The candidate did not generate the following data shown in this section. Data presented here was 
generated by Dr. Eva Crosas-Molit and Ms. Beatriz Padilla. It is presented here to help create a larger 
context for data presented further on.  
 
Figure 6.5. Glutamine and glutamate transporters have differential effects on cell proliferation and cell morphology. 
A) Cell proliferation assay of A375M2 cells siRNA knockdown of genes related to glutamine/glutamate transport. 
Cell counts are normalised to untreated cells. Measurements were taken 72 hours post transfection. Boxplots show 
median and 75% confidence interval, whiskers show 95% confidence interval. B) Morphology assay of A375M2 
cells seeded on a collagen 1 layer after knockdown of gln/glu transporter genes. Bar charts show mean +/- SEM. 
C) Verification of Knockdown by qPCR from proliferation and morphological experiments. For all experiments non-
targeting siRNA used as negative controls and ROCK1/2 knockdowns used as positive controls for both reductions 
in proliferation and change in morphology. Abbreviations: Untreated Cells and Control are cells without treatment. 
NC and Scramble are cells treated with non-targeting siRNAs. Experiments are n=4. * - p<0.05, *** p<0.001  
 
 
In the second RNAi screen, of glutamine and glutamate transporters, it was seen that silencing gene 
expression of the glutamine transporter SLC1A5 led to a significant reduction in cell proliferation while 
not affecting cell morphology. On the other hand, silencing expression of the genes SLC7A5 and 
SLC7A11 encoding the glutamine and glutamate transporters respectively led to a significant change 
in cellular morphology (Fig. 4), similar to that found in siROCK treated cells. They also affected 
melanoma proliferation but not to the extent of siSLC1A5 treated cells. Taken together, the data 
collected on GLS2 and SLC1A5 suggests that glutamine transport and glutaminolysis is important for 







































































































































































































































hand, genes involved in the secretion of glutamate or exchanging glutamine for leucine seem to be 
important in sustaining a rounded morphology.  
 
6.2.2 Knockdown of Glutamine/Glutamate Transporters significantly alter the cellular metabolome 
Based on the data from the in vitro screen of the glutamine/glutamate transporters three receptors were 
selected for metabolic profiling. In Chapter 4 we elucidated the metabolic profiles of melanoma cells 
when ROCK activity or expression was ablated. It was seen that glutamine and glutamate metabolism 
was significantly regulated by ROCK activity. We hypothesize that interfering directly with glutamine 
and glutamate transport may partially replicate the metabolic profiles observed in our ROCK studies. 
SLC1A5 was selected because of its large influence on cell proliferation while SLC7A5 and SLC7A11 
were selected due to their substantial effects on cell morphology. The three genes were knocked down 
individually in vitro using siRNA delivered by the LAH4-L1 pH responsive peptide, nucleic acid delivery 
system in A375M2 human melanoma cells and intracellular and extracellular metabolomes compared 
to non-targeting control siRNA treated cells. 
Both whole cell HR-MAS NMR metabolomic and NMR metabolomics of the spent media were analysed. 
The knockdown of these genes has yet to be confirmed by qPCR and/or Western blot in this set of 
experiments and will be essential future experiments to confirm the validity of the results explained 
below. Nevertheless, we observed a significant change in both the intracellular and extra-cellular 
environment of the melanoma cells after knockdown with siRNAs targeting the glutamine/glutamate 
transporters as opposed to scramble siRNA.  
siSLC1A5 treated cells saw a reduction in saturated lipids, methyl groups on lipid chains, lactic acid, 
phosphocholine and asparagine while there was an increase in alanine, leucine, creatine, 
glycerophosphocholine, and glycine (Figure 6.6, Figure 6.7). In the spent media there was a very weak 
change in the spent media profile (Q² = 0.157, Figure 6.8) suggesting a decrease in pyroglutamate, 
methionine, glutamine, leucine, glucose and lysine. There was an increase in lactate, alanine and 
glutamate (Figure 6.9). 
siSLC7A5 treated cells had an increase in choline, leucine, alanine, creatine, glycerophosphocholine, 
glycine, and acetate, while the CH2-CH2 bonds and CH3 groups of lipids, lactate and myo-inositol 
decreased in the cells (Figure 6.6, Figure 6.7). In the spent media there was a decrease in glucose, 




siSLC7A11 treated cells showed decreases in the CH2-CH2 bonds and CH3 groups of lipids, 
phosphocholine, glutamate, choline, myo-inositol, glutathione, asparagine, and acetate, while there was 
an observed increase in lactate and alanine (Figure 6.6, Figure 6.7). In the spent media we observed a 
decrease in lactate, pyroglutamate, alanine, glutamine and pyruvate while we observed an increase in 
glucose, glutamine, isoleucine, and valine (Figure 6.9).  
In the spent media there was a change in the lactate/glucose ratio in siSLC1A5 and siSLC7A5 
knockdown conditions compared to control, with a respective change in mean lac/glc ratio of 1.41 and 
1.09 respectively, this suggests a switch to glycosolysis after knockdown. On the other hand, 
siSLC7A11 conditions saw a mean decrease of lac/glc of 0.86, which suggests the cells made less use 
of glycolysis. These changes can be observed in the heatmap below (Figure 6.7). 
Additionally there was an increase in glutamate/glutamine ratio (glu/gln) in siSLC1A5 and siSLC7A5 
conditions, with a mean increas of 0.04, and 0.05 while there was a decrease in glu/gln of 0.06 in 
siSLC7A11. This suggests a slight change in the production of glutamate and consumpiton of glutamine 
in these conditions (Figure 6.7).  
There was a slight increase in glutamine uptake in siSLC1A5 and siSLC7A5 conditions, with a mean 
reduction of glutamine concentrations of 0.01 mM and 0.03 mM respectively. This is counter intuitive 
as the transporters knocked down are glutamine transporters. One would expect knockdown to inhibit 
and uptake of glutamine. This is a further point that would need validation although admitedley the 





Figure 6.6. Whole cell NMR metabolomics of transporter knockdowns in A375M2 cells. Scores plot, Q² histogram 
and back scale loadings plots of A) siSLC1A5 b) siSLC7A5 and C) siSLC7A11 knockdowns compared with Non-
targeting siControl. Experiments were conducted n=3 times, and each experimental replicate containing three 
technical replicates, for a total of 9 samples per experimental condition. 
 
 
Hierarchical clustering of the whole cell metabolomic data show that SLC1A5 and SLC7A5 have more 
similar profiles to each other than SLC7A11 (Figure 6.7). This is consistent with the known functions of 
these genes as SLC1A5 and SLC7A5 are glutamine transporters while SLC7A11 is a 
cysteine/glutamate exchanger. 
𝑄2 = 0.  692
𝑄2 𝑟 𝑑 = -0 .435
𝑄2 = 0.721










Figure 6.7. Heatmap with hierarchical clustering of loadings from OPLS-DA models for A375M2 whole cell 




SLC7A11 has quite a distinct profile in that the observed increases in leucine, alanine, creatine, 
glycerophosphocholine and glycine see in the glutamine transporters are not seen in the glutamate 
transporter. In addition, SLC7A11 knockdown led to a decrease in glutamate and choline not seen in 




achieved with siSLC7A5 (none was observed for siSLC1A5). It is curious that there is a decrease in 
glutamate after SLC7A11 knockdown as one would expect there to be an accumulation in intracellular 
glutamate after SLC7A11 knockdown. It could be that the additional glutamate is be re-directed into 
other pathways. 
 
Figure 6.8. Silencing of SLC7A5 and SLC7A11 causes strong changes in exometabolome while silencing of 
SLC1A5 has a weak effect on the exometabolome. OPLS-DA Scores plots and histograms of Q² for models built 
on generated data (blue) and permutated data (grey) from spent media NMR metabolomics of gln/glu transporter 
knockdowns, compared with non-targeting siControl treated A375M2 cells. Experiments were conducted n=3 
times, and each experimental replicate containing three technical replicates, for a total of 9 samples per 
experimental condition. 
Q²= 0.157
Q² rndy = -0.434
Q² = 0.563
Q² rndy = -0.534
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Figure 6.9.Heatmap with hierarchical clustering of OPLS-DA loadings from spent media metabolomics of A375M2 
human melanoma cells after gln/glu transporter knockdowns. Changes are shown relative to media of cells 






6.2.4 GRIK2 knockdown leads to decreased actomyosin contractility 
Little is known about the role of ionotropic glutamate receptors in melanoma. Based on work in the 
previous chapter we investigated if these receptors may play a role in regulating contractility. GRIK2, 
belonging to the Kainate glutamate receptor family was selected to investigate a potential regulation of 
cell morphology and contractility.  
We saw that knockdown of GRIK2 expression led to elongation of A375M2 cell along with a significant 
reduction in phosphorylated myosin light chain (Figure 6.10). Knockdown was confirmed by qPCR 
(Figure 6.10). These results were further validated in A375M2 cells by using individual siRNA 
oligonucleotides of GRIK2 to rule out off-target effects when using Smart Pools of siRNA. Single 
OnTargetplus™ oligonucleotides targeting GRIK2 also showed effects in elongating cells and lowering 
levels of p-MLC2 (Figure 6.11). 
 
Figure 6.10. GRIK2 knockdown leads to decreased actomyosin contractility. A) Immunostaining and Confocal 
imaging of A375M2 cells after GRIK2 knockdown show cells with more elongated phenotype and less p-MLC2 
staining. B) Quantification of p-MLC2 staining in A375M2 cells after GRIK2 knockdown. ROCK1/2 Knockdown 
shown for comparison. C) Quantification by qPCR of GRIK2 knockdown. D) Quantification of roundness index of 
A375M2 cells after GRIK2 knockdown. ROCK1/2 knockdown shown for comparison. Error bars show SEM*** = 










Figure 6.11. GRIK2 individual oligonucleotide knockdown confirms that GRIK2 regulates actomyosin contractility. 
A) Immunostaining and Confocal imaging of A375M2 cells after GRIK2 knockdown with individual oligonucleotides. 
B) Quantification of cell rounding after GRIK2 knockdown with individual oligonucleotides. C) Confirmation of 
knockdown by western blot (n=1). D) Quantification of p-MLC2 staining (n=3 with 10 cells quantified per 




















6.2.6 Protein levels of GluK2 but not GRIK2 RNA are regulated by ROCK activity 
Work in the previous chapter had shown that RNA levels of GRIK2 are not significantly altered by ROCK 
activity as treatment with H1152 did not significantly alter levels of GRIK2. However, we did observe 
that protein levels of GluK2 (GRIK2) are significantly reduced after 24-hour treatment with H1152 and 
Y27632 (Figure 6.12). GluK2 protein levels are reduced by 60% with H1152 while Y27632 leads to a 
48.8% reduction in GluK2. This suggests that ROCK activity may be acting post-translationally on 
GRIK2 expression and should be replicated with siRNA knockdowns of ROCK. Should knockdowns of 
ROCK not replicate these findings, it could be explained as an off-target effect of these small molecule 
inhibitors as both H1152 and Y27632 have been shown to bind to several other kinases such as PKA, 
PKC and AKT (145). 
 
Figure 6.12. Protein levels of GluK2 (GRIK2) but not RNA are regulated by ROCK activity in A375M2 cells. All 
experiments performed with 25 hour treatments of ROCK inhibitors. A) Quantification of RNA levels of GRIK2 after 
ROCK inhibition with 5 µM H1152 (n=3). B) Western blot of GluK2 (GRIK2) levels after ROCK inhibition with 5 μM 



























6.2.7 GRIK2 regulates actomyosin contractility in B16F10 mouse melanoma cells 
Studying the role of GRIK2 in a murine model of melanoma serves two purposes. First it is a first step 
toward syngeneic in vitro studies of glutamate receptors in melanoma. Secondly, we can see if the 
results observed in A375M2 cells where GRIK2 is mutated can be replicated in another melanoma cell 
line. The GRIK2 gene is 99.01% identical between human and mouse and is 100% identical in the 
region where GRIK2 is mutated in A375M2 cells.  
We saw in B16F10 mouse melanoma cells that GRIK2 knockdown again alters cell morphology along 
with a reduction of phosphorylated myosin light chain (Figure 6.13B). As this work was done on glass 
coverslips rather than a thick Collagen 1 matrix as in previous data the morphology of these cells 
remains poorly characterised. However, it is possible to see more protrusions in the knockdown cells 
when compared to the control cells (Figure 6.13A). 
These results strengthen our finding that GRIK2 regulates melanoma contractility despite the mutation 
found in A375 human melanoma cells. It is not known if GRIK2 is mutated in B16 mouse melanoma 





Figure 6.13. GRIK2 regulates actomyosin contractility in B16F10 mouse melanoma cells. A) Immunostaining and 
confocal imaging of B16F10 cells after GRIK2 knockdown illustrates reduced levels of p-MLC2. B) Quantification 
of p-MLC2 levels from images in (A) (n=3). C) Western blot of B16F10 cells after GRIK2 knockdown confirms 
optimal knockdown of GluK2 (GRIK2) after 72 hours and lowest levels of pp-MLC2 (n=1). Red arrow indicates the 
band for pp-MLC2.  *** - p<0.001 **** p<0.0001. Data generated in collaboration with Sogol Salamipour. 
 
 
6.2.8 Glutaminase inhibitor stops melanoma cell proliferation 
Amino acid transport is an essential step to sustain ‘glutamine addiction’ in melanoma cells. The 
glutaminase inhibitor 968 was first proposed by Wang et al(158) who demonstrated that 968 binds to 
glutaminase and can block rho dependent transformation of fibroblasts and inhibit the proliferation of 
breast cancer and lung cancer cells. More recently it was shown that 968 binds to monomeric 






We saw A375M2 melanomas cells are very sensitive to glutaminase inhibition. Logistic curve fitting of 
proliferation data show that a 50% reduction in proliferation after 48 hours can be achieved with doses 
as low as 3.25 μM (Figure 6.14A). In our metabolomic study we used a dose of 10 μM for 24 hours.  
6.2.9 968 Significantly Alters the Cellular Metabolome 
There was a significant shift in the intracellular metabolome in cells treated with 968 (Q² =0.660, Figure 
6.14B) however we saw that there was no observable change in consumption or secretion patters in 
the spent cell culture media (Q² = -0.364, Figure 6.14C). In the cells, we observed an increase in 
phosphocholine, glutamate, glutathione, myo-inositol, glycerophosphocholine and a reduction in 
saturated lipids, acetate, leucine, creatine, valine, CH3 groups of lipids and choline. The change in 
phosphocholine levels may be a marker for proliferation as has been shown in several studies 
investigating the effects of choline kinase in malignant tissue (356). An increase in intracellular 
phosphocholine in the treatment condition may point to an accumulation due to blocked phospholipid 




Figure 6.14. 968 Glutaminase inhibitor regulates melanoma proliferation and the metabolic profile while not 
regulating the exometabolome. Metabolomics of A375M2 cells after 24-hour treatment with 10 µM 968 glutaminase 
inhibitor. A) The glutaminase inhibitor 968 limits cell proliferation and B) significantly alters the melanoma 
metabolome. Scores plot, Scores plot, Q² histogram and back scale loadings of OPLS-DA models from HR-MAS 
NMR of whole A375M2 cells after 968 treatments. C) 968 does not significantly change metabolite consumption 
patterns in spent media. Scores and Q² histogram of spent media metabolomics of A375M2 cells after 968 
treatment. Back scale loadings not shown because of non-significance of data. Experiments were conducted n=3 
times, and each experimental replicate containing three technical replicates, for a total of 9 samples per 
experimental condition.
6.2.10 AMPA/Kainate antagonists but not NMDA antagonists regulate melanoma cell proliferation 
At both 5 μM and 25 μM doses we observed that only CFM-2 decreased cell proliferation significantly 
(Figure 6.15A, B). This is to be expected based on previous studies where GYKI-52466 required 100 











Figure 6.15. The AMPA/Kainate antagonist CFM-2 limits cell proliferation at low doses. A) boxplot of normalised 
cell count of A375M2 cells after 48-hour treatment with 5 μM of glutamate antagonists. B) Experiment repeated in 
(A) with 25 μM doses of glutamate antagonists C) Dose-response curve of CFM-2 show a KD50 of about 10 μM. 




As CFM-2 showed strong effects at even 5 μM, a dose response study was conducted and saw that a 
50% reduction in proliferation after 48 hours was observed at 10 μM doses (Figure 6.15C), which was 
then selected as the dose for all future experiments. It should be noted that initial experiments showed 
65% reduction in proliferation of melanoma cells at a 5 μM dose (Figure 6.15A), however further 
experiments showed a 10 μM dose was required to see 50% reduction in proliferation (Figure 6.15C). 
This could be explained by possible degradation of CFM-2 with storage. Despite reduced effects, we 
observed CFM-2 was also tested in combination with the ROCK inhibitor GSK269 with doses of 2.5 μM 
































































6.2.11 CFM-2 alters both the intracellular and extracellular metabolic profile of melanoma cells. 
As we observed that CFM-2 leads to a significant reduction in cell proliferation. We conducted NMR 
metabolomic studies of the spent cell culture media and whole cells after a 24-hour treatment with 10 
μM CFM-2 (Figure 6.16).  
OPLS-DA show that both the intracellular metabolome and spent media shift significantly (Q² = 0.626 
and Q² = 0.626 respectively, Figure 6.16A, B) after treatment with CFM-2. In the cells, there was a 
decrease in phosphocholine glycerophosphocholine, lactate, glutamate, glutathione, myo-inositol, 
arginine. There was an increase in saturated lipids, acetate, leucine, alanine, creatine, and valine. 
In the spent media we observed a reduction in glucose, valine, alanine and 2-hydroxybutryate, while 




Figure 6.16. AMPA/Kainate antagonist CFM-2 regulates both the endo- and exometabolome. A375M2 cells treated 
with 10 μM CFM-2 for 24 hours A) CFM-2 significantly alters the intracellular metabolome. Back scaled loadings 
and mean PQN normalised spectra for control (blue) and CFM-2 treated (red) cells. Scores plot and Q² histogram 
are inset into the back scaled loadings plot. B, PCA scores, OPLS-DA Scores and Q² histogram of spent cell culture 
media metabolomics control samples are blue, treatment are red. C) back scale loadings plot of OPLS-DA model 
for exometabolome. Boxplots of univariate analysis of Glucose and glutamate peaks are inset to highlight the 
changes in glucose consumption and glutamate secretion after CFM-2 treatment. Experiments were conducted 















6.2.12 Hierarchical clustering of small molecule inhibitor metabolomic data  
Hierarchical clustering of the gathered metabolomic data demonstrate that the metabolic profiles of 
melanoma cells between GSK269 and CFM-2 treatments are very similar (Figure 6.17).  The only 
differences being leucine and alanine where we observed an increase in CFM-2 and no change in 
GSK269. In the cells, a nearly opposite response was observed between cells treated with GSK269 or 
CFM-2 and cells treated with 968 glutaminase inhibitor. Nearly every measured metabolite showed an 
opposite response (Figure 6.17). 
In the spent media we also see that CFM-2 and GSK269 both have increased consumption of glucose 
and increased secretion of lactate, despite both drugs having strong anti-proliferative effects. This can 
be explained either as a metabolic switch as the cells become more dependent on glycolysis for energy. 
Another possible explanation is that this effect may be a partial response to increased oxidative stress 
in the cells after ROCK inhibition or blocking glutamate signalling as discussed in earlier chapters. 968 
had no significant effect on the spent media again suggesting that these drugs have very different 
mechanisms of action. 
Of interest was the observation was A375M2 cells treated with GSK269 at 1% FBS conditions showed 
reduced uptake of leucine while at 10% FBS conditions there was no change in extracellular leucine 
concentrations. As discussed in the previous chapter, ROCK expression is negatively correlated with 
SLC7A5 expression 
Clustering also reveals subtle changes in the exometabolome of cells cultured in 10%FBS media and 
1% FBS media. Pyroglutamate, valine, and glutamine saw slight changes in different serum conditions. 
This could be explained by different quantities of growth factors included in cell culture media.  Cell 
culture media is commonly supplemented with serum to provide growth factors, however this can add 
confounding factors and an extra layer of complexity as the components making up serum are not 
completely profiled. There can also be batch variability of serum between experiments. This study 




Figure 6.17. Hierarchical clustering of whole cell metabolomics of small molecule inhibitors of ROCK, 





Figure 6.18. Hierarchical clustering of spent media metabolomics of small molecule inhibitors of ROCK, 





6.3.1 Glutamine/Glutamate transporters and glutaminase inhibitors affect the metabolome 
It may seem obvious that interfering with the transport of major metabolites such as glutamine and 
glutamate would affect the cellular metabolome. However, it is interesting to observe the difference that 
different solute carriers have on regulating complex metabolic pathways. 
Silencing of SLC7A5 and SLC7A11 expression was seen to have a significant effect on melanoma cell 
morphology while silencing of SLC1A5 had minimal effects on cell morphology. This data adds an 
additional layer to current knowledge about amino acid transporters in cancer. As discussed in the 
previous chapter it has been shown that the LAT1 heterodimer (SLC3A2/SLC7A5) is coupled with 
ASCT2 (SLC1A5) in maintaining intracellular glutamine pools as ASCT2 brings glutamine into the cell 
while LAT1 exchanges intracellular glutamine for extracellular leucine (303,331). xCT (SLC7A11) 
exchanges intracellular glutamate for cysteine. We observed in chapter 3 that ROCK promotes levels 
of intracellular glutamine and glutamate. The fact that both genes involved in secreting 
glutamine/glutamate promoted a rounded morphology of melanoma cells while the gene involved in 
glutamine uptake did not influence cell morphology suggests that extracellular glutamate may play and 
important role in regulating cell morphology. In our studies there is an abundance of glutamine in the 
cell culture media (4mM) and the exchange of glutamine and leucine may also play an important role 
in regulating cell morphology. There is a possibility that glutamate may be signalling back to melanoma 
cells to sustain a rounded type morphology. 
SLC3A2 is required to form the functional heterodimers of LAT1 (SLC7A5), and xCT (SLC7A11). We 
observed that knockdown of both SLC7A5 and SLC7A11 lead to significant elongation of melanoma 
cells however surprisingly knockdown of SLC3A2 led to no changes in cell morphology. Knockdown of 
all three genes had a significant effect on cell proliferation although not to the extent of SLC1A5 
knockdown. Further work will need to be conducted to validate these findings and explain how 
knockdown of SLC3A2 does not influence cell morphology to the extent of SLC7A5 and SLC7A11 
knockdowns. It could be that only low levels of SLC3A2 are required to maintain levels of SLC7A5 and 
SLC7A11 at the plasma membrane and could not be ablated with transient knockdowns.  
Discussion on the results of metabolomic data from knockdowns of the solute carriers needs to start 
with the caveat that data confirming the knockdowns by qPCR or Western blot are not yet available. 
Nevertheless, the same siRNA delivery procedure was used as in Chapter 3 while qPCR indicates 
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these genes were successfully silenced using the same siRNAs in the screen. Most importantly, the 
metabolic profiles of A375M2 cells treated with the three differing siRNAs are quite distinct. Notably, 
the metabolome of siSLC7A5 treated cells is more similar to that of siSLC1A5 treated cells than 
siSLC7A11 treated cells. It is tempting to look for common traits between cells where SLC7A5, 
SLC7A11 and ROCK1/2 gene expression is silenced or ROCK activity is inhibited to establish a 
mechanistic link between ROCK and glutamine/glutamate in controlling cell morphology. It is seen that 
myo-inositol decreases after knockdown with both siSLC7A5 and siSLCA11, and this is not observed 
in siSLC1A5 treated cells; in chapter 3 it was also observed that myo-inositol decreases after ROCK 
inhibition. In the in vitro screen in chapter 5, the myo-inositol transporter SLC5A3 was also tested and 
it was seen that it has an effect on cell proliferation and morphology, however it was not one of the 
largest hits seen in the screen.  
We observed in the glutamine transporter knockdowns that there is an increase of lactic acid in the 
spent media along with corresponding decrease in in glucose. This was seen to be more pronounced 
in siSLC7A5 treated cells than in siSLC1A5 treated cells. 
As shown in Chapter 3, inhibition of ROCK led to an increase in the Warburg effect seen in the spent 
media, which would seem counter-intuitive as ROCK promotes cancer cell proliferation. This is seen 
again with the glutamine transporters. While the ability of the cells to absorb glutamine and other amino 
acids in the case of SLC7A5 is blocked, we would expect to observe less lactate in the spent media. 
Instead we see the opposite effect. On the other hand, knockdown of SLC7A11 showed a metabolic 
profile that would be consistent with a decrease in cell proliferation, with a reduced amount of lactic acid 
and an increased quantity of glucose in the spent media compared to controls. As discussed in the 
previous chapter, this increase in the Warburg effect after altering glutamine metabolism may be a 
response of the cells to potential increases in oxidative stress. 
Further work needs to be conducted to fully understand the roles that these genes play in regulating 
the flow of metabolites across the plasma membrane. Thus far we have discussed these genes primarily 
in their role in regulating glutamine and glutamate transport, however the proteins that are expressed 
from these genes are not fully understood.  
In recent years SLC7A11 has received additional interest with the elucidation of a novel non-canonical 
p53 controlled non-apoptotic regulated cell death pathway, called ferroptosis (357). In ferroptosis, p53 
inhibits cysteine uptake by repressing the expression of SLC7A11. This lack of cysteine then leads to 
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an increase in lipid reactive oxygen species which promote cell death (358). Ferroptosis is also 
characterised by morphological changes in the mitochondria. Mitochondria become smaller and have 
increased membrane density along with a reduction of cristae (359). 
As discussed in the previous chapter, ROCK plays an important role in regulating reactive oxygen 
species in melanomas. ROCK and JAK/STAT signalling pathways cooperate to sustain amoeboid 
migration(140) and it has been reported that STAT3 and STAT5A bind the SLC7A11 promoter region 
and thus repress expression. Inhibiting STAT lead to upregulation of SLC7A11 in breast cancer(348). 
A currently proposed view on how solute carriers may cooperate is that ASCT2 (SLC1A5) may aid cells 
to maintain glutamine homeostasis in cancer cells while LAT1 (SLC7A5) mediates the exchange of 
glutamine and leucine, another essential amino acid in cancers. In addition, xCT (SLC7A11) maintains 
the homeostasis of anti-oxidant species by exchanging cysteine and glutamate (331,347). Solute 
carriers are general understudied (267). As transmembrane proteins they are attractive drug targets 
and merit further research.  
6.3.2 Glutaminase as a therapeutic target in melanoma 
The glutaminase inhibitor 968 affected the intracellular metabolome significantly, but had quite a distinct 
profile compared to either ROCK or glutamate signalling inhibitors. Interestingly we did not observe a 
significant change in the metabolism of the spent cell culture media after treatment with 968. As 
glutaminolysis is blocked, one might suspect that the cells become more reliant on glucose and 
glycolysis as an energy source, however that was not seen. It could be that the inhibition of glutaminase 
does not lead to the same levels of oxidative stress as that found in after inhibiting ROCK or glutamate 
signalling. It is known that both the ROCK inhibitors and the glutamate antagonist CFM-2 alter signalling 
pathways important to cell survival and proliferation (143,184,355) and the metabolic effects we see 
after using these drugs could be a response to the added stresses. The glutaminase inhibitor instead 
is thought to act principally on mitochondrial glutaminase (159,230,360) and so may not have the broad 
spectrum of effects as the other inhibitors.  
Glutaminase is an attractive therapeutic target in cancer therapy as glutamine in normal tissue is not 
an essential amino acid, however can be conditionally essential during periods of growth or pregnancy 
(361). Inhibition of glutaminase could function well with rapidly proliferating cells such as cancers. 
Currently available glutaminase specific inhibitors such as BTPES and 968 have low micro-molar 
specificity and poor aqueous solubility (265) and so research continues to develop molecules with 
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improved activity and solubility. Recently another glutaminase inhibitor CB-389 was shown to have anti-
tumour activity in triple negative breast cancers (362) and is being brought forward by Calithera 
Biosciences Inc. in 5 separate phase 1 clinical trials to test in a wide range of solid tumours as well as 
lymphomas and leukaemia (clinicaltrials.gov search term: ‘cb-839’). 
6.3.3 Targeting metastasis for therapy 
Consideration needs to be made when thinking of cancers in terms of cancer stem cells or dormant 
tumours (113). Several studies have shown that melanomas are highly plastic cells (189,256,363) and 
even that a neural crest type environment may promote invasiveness in melanomas (363). Melanomas 
have also been seen to disseminate at early stages of disease (364) and thus it becomes even more 
important to think of ways of treating not just melanoma proliferation but ways of inhibiting invasive 
phenotypes. Slowly dividing melanoma cells that retain the capacity to form tumours at distant site 
would remain a challenge if thinking of targeting melanomas solely with proliferation blocking 
treatments. There are several ways to approach the disease from this perspective. One possible 
strategy would be to aim to treat cancer essentially as a chronic disease (365), similar to the way HIV 
is currently treated. Otherwise strategies need to be developed to ultimately target disseminated tumour 
cells (366). While many ideas have been proposed, there is currently debate as to the clinical relevance 
of these strategies(367). From this perspective our initial observations that silencing GRIK2 expression 
altered melanoma cell morphology but not proliferation bolstered our interest in understanding the role 
that glutamate signalling plays in melanoma metastasis.  
6.3.4 AMPA antagonists regulate cell proliferation and affect the metabolome 
Several groups have shown that AMPA antagonists potentially regulate melanoma cell proliferation 
(354,355,368). In our studies we confirmed these results and additionally show that CFM-2 was able to 
reduced proliferation substantially at very low doses. Glutamate receptor antagonists are already used 
clinically to treat neuronal diseases such as epilepsy. As safety profiles have already been established 
for some of these drugs it would be an attractive proposal to convert these anti-epileptic drugs to treat 
melanoma or other cancers. Future research will be done to understand if there are antagonists that 
also affect cell morphology. 
We observed that the metabolic changes associated with CFM-2 treatment resemble those found during 
ROCK inhibition. As discussed in previous chapters, ROCK inhibition leads to an increase in oxidative 
stress in melanoma cells and we observed depletion in several key metabolites involved in anti-oxidant 
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pathways. Changes in glutamine, glutamate, and glutathione concentrations along with an increase in 
glycolysis observed in the spent media all point to a possible compensatory action by melanoma cells 
to the increases in oxidative stress. This suggests again that CFM-2 may cause an increase in oxidative 
stress in melanoma cells, which respond by upregulating anti-oxidant pathways. It has previously been 
suggested that CFM-2 regulates other kinase signalling pathways in lung cancer(355) and It could be 
a similar case in melanoma, thus explaining their anti-proliferative effects. 
All of these changes observed in ROCK inhibited cells were also observed in cells treated with CFM-2, 
with the exception of glutamate. CFM-2 treated cells increase the amount of extracellular glutamate as 
opposed to ROCK inhibited cells in which a decrease in glutamate was observed. A possible 
explanation could be that melanoma cells attempt to compensate for the blockage of glutamate 
signalling by increasing the secretion of glutamate. Experiments could be conducted to study the 
expression of genes required for glutamate production in these conditions. 
6.3.5 GRIK2 regulates contractility but not proliferation 
In the final part of our study we have focussed on the roles of one subunit of the kainate receptor family, 
GRIK2 (called GluK2 or GluR6 at protein level). GRIK2 codes for the GluR6 protein which forms hetero-
tetramers with other kainate receptor subunits at the plasma membrane giving functional proteins with 
different binding and activation activities (210) while being present as homo-tetramers at the 
endoplasmic reticulum (369). GRIK2 has three splice variants which alter the intracellular domain of the 
protein and thus the possible phosphorylation sites which control trafficking (370). We observed that 
interfering with GRIK2 expression in both human and mouse melanoma led to a decrease in myosin 
phosphorylation and changes in cell morphology while not affecting capacity for cell proliferation. We 
also observed that GRIK2 is mutated in 11% of melanomas (Figure 6.3) and GRIK2 is mutated in our 
in vitro model of human melanoma. The functional consequences of this mutation have still to be 
elucidated. 
There is some contradictory research pointing to the involvement of ionotropic glutamate receptors in 
malignant disease. Wu et al propose that GRIK2 may have tumour suppressor activity in gastric 
epithelium as GRIK2 overexpression leads to decreased invasion (371). Their results contradict our 
current findings as we propose that GRIK2 activity promotes the highly invasive, blebbing type 
migration. This may be due to tissue specific roles of GRIK2.  Melanomas are of neural crest origin and 
so they may be re-wiring glutamate signalling pathways to promote a highly invasive phenotype. 
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The question of how GluK2 regulates actomyosin contractility remains open. GluK2 could promote 
contractility by facilitating influx of calcium ions into the cell. Calcium is a known promoter of contractility 
via calmodulin kinase(372) and calcium homeostasis is considered important in tumour progression 
(76). Another possibility is that GluR6 could be regulating contractility via G-protein coupled signalling 
pathways as suggested in Rodrigues et al (343). Tashiro et al showed that filopodial motility of 
hippocampal mossy fibres were regulated by kainate receptors (373). They suggested that kainate 
receptors may be sensors for axonal filopodia to probe the local environment for synapse formation. In 
non-neuronal cells it is well established that the Rho GTPase cdc42, promotes filopodia formation in a 
variety of cell types (374). This highlights again the possible parallels between cells of neural crest 
origin, of which melanocytes and thus melanomas are part. 
There is a gap in the literature to look systematically at ionotropic glutamate receptors signalling in 
melanoma. Currently studies have focussed almost exclusively at the expression of the glutamate 
receptors themselves. The downstream targets of iGluR and more specifically kainate signalling has 
thus far been ignored. This is due to a general ignorance of the complexes that stabilize kainite 
receptors and the signalling pathways in which kainate receptors take part. Their functions are still being 
elucidated in neurons, as reviewed in (210,375). The difficulties in elucidating the functions of kainate 
receptors is in part due to the difficulty in studying the specific functions of ionotropic receptors because 
there is a lack of specific agonists and antagonists. Further research into the binding partners of kainate 
receptors and their downstream signalling targets could also reveal interesting novel therapeutic targets 
of metastasis. 
A final interesting observation was that GluK2 expression (GRIK2) is dependent on ROCK activity while 
RNA expression of GRIK2 does not seem to be affected by ROCK activity. There could be several 
explanations for this observation. ROCK may be trafficking and/or stabilizing the protein at the plasma 
membrane. It has already been shown that ROCK1 regulates the transport of GLUT3 to the plasma 
membrane (156). It has been shown that phosphorylation of GluK2 by PKC at the S846 enhances 
SUMOylation at K886. This ultimately accelerates endocytosis of GluK2 and trafficking to late 
endosomes for degradation (370). It has been suggested that substrates of PKC are readily 
phosphorylated by ROCK, but not vice versa (376), so it would not be surprising to find that ROCK 
could phosphorylate GluK2. What would be surprising would be to find that ROCK activity has the 
opposite effect in terms of trafficking GluK2 than PKC. The limitation of our study is that this data has 
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thus far been observed with two ROCK inhibitors H1152 and Y27632, however we have not validated 
these results with ROCK knockdown. It remains a possibility that these results could be due to off target 
effects of ROCK inhibitors as they have been known to also inhibit the activity of PKA and PKC (145). 
Further studies will need to be conducted to confirm this finding.  
We did not observe any change in cell proliferation after GRIK2 knockdown while there was a large 
reduction in cell proliferation when using the AMPA receptor antagonist CFM-2. This could be due to 
differential effects of specific glutamate receptor subunits or could be due to the broader effects of small 
molecule inhibitors compared to genetic silencing. More work should be conducted to tease out which 
glutamate receptor subunits are responsible for melanoma proliferation. In the previous chapter we 
made observations on how different NMDA receptor subtypes may work in the opposite manner in 
promoting melanoma progression. For example, GRIN2A is often mutated in melanomas(377) and may 
contribute to poor prognosis (346) while we observed that GRIN3A forms atypical NMDA receptors 
(344)  and correlates with better prognosis in patients. This data adds another layer of complexity as 
we now see that kainate receptors may also contribute to certain aspects of tumour progression by 
promoting a highly invasive phenotype while not regulating proliferation. 
6.3.6 Toward a mechanistic explanation of the regulation of metabolism by ROCK 
In this chapter we have explored how interfering with cellular metabolism at different stages of metabolic 
and signalling pathways influence cell proliferation, morphology and metabolism. We have not yet 
arrived at a complete mechanistic explanation for how ROCK may regulate cellular metabolism as thus 
far the collected data is circumstantial and based on correlations. ROCK is already known to be in a 
tight interplay with several other signalling hubs such as p53(184,378), c-Myc(379), PI3K/AKT-
mTOR(380,381), so attempting to pick apart the subtle roles that it may be playing in regulating cell 
metabolism is quite an undertaking. We have seen through the metabolomics work that several 
metabolites and thus pathways may be regulated either directly or indirectly through ROCK activity. 
Despite these challenges, there are possible explanations gained from the literature that should be 
explored in the future to arrive at a mechanistic explanation for the observations made in this work. 
6.3.6.1.1 ROCK activating c-Myc 
c-Myc is a major oncogene and has been extensively linked to playing a major role in rewiring cancer 
cell metabolism. It has been termed the ‘master regulator’ of cancer metabolism (382,383) 
(264,266,383-387). It has been shown in prostate cancer that ROCK directly phosphorylates c-Myc 
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(379) so it is not a stretch to hypothesize that the same situation could be true in melanomas. Future 
work could be conducted to identify what aspects of regulating cancer metabolism ROCK and Myc 
overlap and if there are areas that are specific to one protein or the other. 
6.3.6.1.2 ROCK and reactive oxygen species and p53 
P53 is known as the gatekeeper of cell growth and division (388) and is known to regulate metabolism 
by regulating the expression of genes involved in glycolysis, fatty acid metabolism, and oxidative stress 
(389). It is established that p53 can regulate RhoA/ROCK signalling. A mutant gain of function form of 
P53 found in some tumours has also been shown to promote the Warburg effect by upregulating 
RhoA/ROCK signalling (155). In mouse endothelial fibroblasts it has been shown that p53 regulates 
RhoA activation and a loss of p53 leads to increased cell migration due to RhoA/ROCK signalling (160). 
Additionally, p53 can regulate RhoE expression, which is a ROCK suppressor (390).  
There is also some evidence that ROCK can interact with p53. Vermula et al show via 
immunoprecipitation assay that ROCK1 can interact with and stabilise p53 in splenocytes (391). In their 
model of haemolytic anaemia, ROCK1 deficient mice had increased survival compared to wild type 
mice. While there is little available in the literature, further studies could be conducted to see how ROCK 
interacts with p53 and thus cellular metabolism. 
6.3.6.1.3 ROCK direct phosphorylation of metabolic targets (GLS, GRIK, Transporters) 
Experiments could be designed to investigate if ROCK directly interacts with GLS or glutamate 
receptors such as GluK2 (GRIK2). This could be conducted by co-immunoprecipitation (co-IP) to see if 
ROCK and the candidate proteins interact in complex. More specific kinase assays could be conducted 
with 𝐏𝟑𝟐  to see if GLS or GluK2 are direct substrates of ROCK. On a broader scale, novels substrates 
of ROCK could be identified with phosphor-proteomics studies. Phospho-proteomics is a rapidly 
growing field and there is already a study into how the phosphor-proteome changes during resistance 
to BRAF inhibitors in melanoma (4). A potential study that could be conducted would be to identify 
substrates of ROCK in melanoma and how the phosphor-proteome changes after ROCK inhibition or 





In this chapter we aimed to gain a deeper understanding of how interfering with glutamine/glutamate 
metabolism, transport and glutamate signalling affects cell proliferation, morphology and metabolic 
profiles. In addition, we made preliminary attempts to directly connect ROCK activity with aspects of 
cellular metabolism.  
The data presented in this chapter shows that glutamine/glutamate transporters play different roles in 
regulating melanoma proliferation and morphology. Genes involved in glutamine import showed strong 
effects on cell proliferation while genes involved in glutamine/glutamate secretion showed strong 
regulation of cell morphology and regulated cell proliferation to a much smaller extent.  
Glutamate signalling was also investigated; it was seen that NMDA receptor antagonists did not inhibit 
cell proliferation while the AMPA/kainate antagonist CFM-2 strongly inhibited cell proliferation at low 
doses. The glutaminase inhibitor 968 also showed strong regulation of cell proliferation at low doses. 
Both treatments significantly altered the metabolic profiles of melanoma cells. CFM-2 led to a metabolic 
profile that was comparable to that of the ROCK inhibitor GSK269 while 968 led to a very distinct 
metabolic profile. Additionally, 968 treatments did not lead to a change in the spent cell culture media 
while CFM-2 and GSK269 both led to increases in the Warburg effect, possible as a response to 
oxidative stress.  
Data presented in this chapter support the hypothesis that glutamate signalling plays an important role 
in regulating melanoma proliferation, cell morphology and that ROCK may play a role in regulating 
ionotropic glutamate signalling. Silencing of genes involved in glutamate secretion led to elongation of 
melanoma cells. Silencing of GRIK2, a gene encoding for the ionotropic glutamate receptor GluK2, also 
led to cell elongation and reduced actomyosin contractility. Inhibiting ROCK activity with small molecule 
inhibitors led to a reduction in protein levels of GluK2 while not affecting the expression of GRIK2. 
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Chapter 7 : Conclusion and Future Work
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7.1 Overview of Work 
Malignant Melanoma remains he deadliest form of skin cancer despite incredible advances in treatment 
that have come into the clinic in the past five years. In addition, non-response or development of 
resistance remains an important issue when attempting to treat melanoma patients. Rho-ROCK 
signalling has been thought to be an attractive therapeutic target for treating a variety of cancers since 
the early 2000s (125). 
Cancer metabolism has long been known to be altered compared to normal tissue and the past two 
decades have seen a renaissance of research into cancer metabolism as the scientific community has 
entered the post-genomic era aided by technological developments allowing for -omics level studies of 
the metabolic landscape of biological systems (161).  
 In this body of work, we aimed to address a gap in knowledge of if and how ROCK regulates melanoma 
cell metabolism to sustain increased levels of cell proliferation and invasion. We started by examining 
if altering ROCK activity in metastatic melanoma would change the cellular metabolome by interfering 
with ROCK activity or expression in human and murine melanomas. We observed that altering ROCK 
activity led to significant changes in several metabolites and metabolic pathways that are important in 
maintaining cell proliferation and anti-oxidant pathways. In particular glutamine and glutamate 
metabolism was suggested to be the most regulated pathway by ROCK activity. We also saw that 
ROCK1 and ROCK2 may play differing role in regulating cell metabolism, however further research 
should elucidate these differences 
We then aimed to understand if the results found in vitro could be more broadly applicable in a clinical 
setting. We studied how genes involved in glutamine and glutamate pathways are expressed in both 
primary melanomas and metastasized melanomas using publically available transcriptome data. We 
observed that genes involved in glycolysis were more expressed in primary tumours compared to 
normal tissue while genes involved in glutamine and glutamate metabolism were more expressed in 
metastatic melanomas compared to primary melanomas. It was also observed that genes involved in 
glutamine metabolism correlated with ROCK expression while ROCK expression negatively correlated 
with genes involved in glycolysis.  In vitro we tested the expression of a selection of genes in A375M2 
cells and observed that SLC7A11, a gene involved in glutamate, cysteine exchange and GRIK2, 
encoding for an ionotropic glutamate receptor, are highly expressed. GRIK2 was also seen to regulate 
cell morphology and not cell proliferation. It was also observed that the expression of the 
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transglutaminase gene TGM2, which is upregulated in metastatic melanomas compared to primary 
melanomas, is regulated by ROCK activity. These results lend support to our in vitro findings that 
glutamine metabolism and ROCK play an important role in the progression of melanoma in the 
metastatic cascade. 
We then took a closer look at these pathways with further in vitro studies, examining their roles in cell 
proliferation, morphology, and actomyosin contractility in models of metastatic melanoma. We aimed to 
see if the metabolic phenotype observed in our studies of ROCK could be replicated by targeting genes 
involved in glutamine and glutamate transport. Silencing of genes involved in glutamine influx showed 
regulation of cell proliferation while genes involved in glutamine/leucine exchange and 
glutamate/cysteine exchange showed significant effects on cell morphology. This pointed to a potential 
role in glutamate signalling in melanoma morphology.  
We further investigated the role of GRIK2 in melanoma cell morphology and observed that silencing of 
GRIK2 led to more elongated cells and a decrease in actomyosin contractility in both human and murine 
melanomas. Additionally, we observed that ROCK activity regulated the expression of GluK2, the 
expressed protein of GRIK2, while not regulating the expression of GRIK2. These demonstrate that 
contractility in melanoma is regulated by glutamate receptors.  
We finally aimed to understand the effects of glutamate receptor antagonists in melanoma. Several 
glutamate antagonists are already approved for clinical use for several neurodegenerative diseases 
and so the translation of these drugs into treating melanoma represents an attractive proposal. We 
observed that blanket targeting of the AMPA/kainate receptor subgroup with CFM-2 at low doses 
showed substantial decreases in cell proliferation and led to a metabolic profile similar to that found in 
melanoma cells after ROCK inhibition. Interestingly, we observed that CFM-2 led to an increase in the 
Warburg effect in melanoma cells, similar to what we had observed with ROCK inhibitors. This was not 
seen with the glutaminase inhibitor 968, which showed strong anti-proliferative effects at low 
concentrations and a significant change in intracellular metabolism, but no change in the 
exometabolome. While in this work we studied the effects of the small molecule inhibitors on melanoma 
proliferation and the metabolic profiles, future work should elucidate their effects also on cell 
morphology and actomyosin contractility.  
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In this thesis we have shown that ROCK regulates the metabolic profiles of metastatic melanomas and 
is correlated with glutamine/glutamate metabolism and glutamate signalling while being negatively 
correlated with glycolysis.  
 
7.2 Discussion/Model 
From the data presented in this thesis we have implicated ROCK activity with a variety of metabolic 
pathways (Figure 7.1). We correlated ROCK with intracellular glutamine, glutamate and glutathione 
levels. It is known that ROCK can directly phosphorylate c-Myc(379) which is a known regulator of 
cellular metabolism in cancer(266,382,383). Therefore, it is possible that ROCK can promote 
glutaminolysis via c-Myc. It is also known that ROCK supresses reactive oxygen species to promote 
survival in metastatic melanoma. The picture that is forming from this work is that metabolism is 
intrinsically tied to several signalling pathways and anti-oxidant homeostasis. While the role of ROCK 
in regulating Reactive oxygen species has been previously proposed(184), to date a role for ROCK in 
cancer cell metabolism has not been examined in depth. 
 
Figure 7.1. Proposed model for regulation of cellular metabolism and glutamate signalling by ROCK. ROCK 
promotes actomyosin contractility and thus cell proliferation and metastasis. In this work we have shown 
associations of ROCK activity with both glutamine/glutamate metabolism and glutamate signalling. ROCK activity 
regulates the protein levels of ionotropic glutamate receptors such as GluK2. In the literature it has been shown 
that ROCK regulates the function of c-MYC, which is known as a key regulator of cancer cell metabolism. ROCK 
could be potentially regulating cellular metabolism via activation of c-MYC or other proteins involved in regulating 



























We have seen that blocking glutamate signalling pharmacologically can block cell proliferation while 
knocking down representative ionotropic glutamate receptor genes can lower contractility in melanoma 
cells.  Blanket inhibition of glutamate receptors with small molecule inhibitors lead to significant changes 
in proliferation while targeting individual members will lead to a more nuanced view of which family 
members contribute to different cellular functions.  
Not shown in our model but that is however very important to mention is the role that ROCK was 
observed to play in supressing the Warburg effect. We consistently observed increases in the Warburg 
effect after ROCK inhibition in the spent cell culture media. Whether this is to compensate for a blockage 
of glutamine metabolism or as a response to increased oxidative stress in these cells is yet to be 
established. 
7.3 Future Work 
As with many research projects, this results of this study creates many more questions than it can 
answer. We have made associations between ROCK activity and glutamine/glutamate transport, 
metabolism and glutamate signalling. However, no definitive mechanistic explanations have been 
proven in this work.  
Future work will also aim to investigate other metabolic pathways that were observed to be regulated 
by ROCK activity or expression in melanoma. In this work we have focussed primarily on glutamine and 
glutamate metabolic pathways and have overlooked many other finding that the metabolomic studies 
have suggested. For example, we have only taken a cursory look into what myo-inositol could be doing 
in melanoma cells in terms of promoting cell proliferation or cell morphology. Inositide signalling is a 
large area of biomedical research in itself, linked with PLCγ and PTEN (236). 
We also saw significant changes in how lipid bodies are changed in melanoma cells after perturbing 
ROCK activity or expression. ROCK plays a major role in regulating the actin cytoskeleton and 
influencing modes of migration in cancer cells. It would be interesting to understand if the changes in 
lipids are a consequence of or partially responsible for the changes in cell shape induced by ROCK 
signalling. Some preliminary work has been performed with live imaging of A375M2 cells using di-4-
ANEPPDHQ (Figure 7.2), a fluorescent dye that emits at two different wavelengths depending on the 
fluidity of cellular membranes, allowing for live cell imaging of lipid order in cells(392). It will be 






Figure 7.2. Live fluorescence imaging of A375M2 human melanoma cells plated on plastic and stained with di-4-
ANEPPDHQ. Colours represent rigidity of cell membrane with green representing rigid membrane and red 
representing more fluid membranes. Blue is oversaturated pixels. 
 
 
Future work would also aim to add additional layers of information regarding ROCK and melanoma 
cells.  Additional experimental systems such as proteomic and phospho-proteomics could add new 
insight to the substrates of ROCK in melanoma and how these affect cellular metabolism. Multi-block 
OPLS algorithms (82,83) could be incorporated to help identify trends within melanoma cells that may 
not be apparent using network analysis that requires a priori knowledge of biological pathways.  
It will take many years to tease apart how different members of each pathway contribute to specific 
effects in cancer cells. Eventually it is hoped that the data presented here can contribute to further 
understanding of cancer progression and eventually support the progress toward novel therapies for 
melanoma and other forms of cancer.
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Appendix A: Full Gene Lists 
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AADAT AADAT HK1 DLD SLC1A5 GRIA1 GRM1 SLC7A1 SLC2A1 
AASS AADAT HK2 OGDH SLC38A1 GRIA2 GRM2 SLC7A2 SLC2A2 
ABAT AASS HK3 SULA2 GLS1 GRIA3 GRM3 SLC7A3 SLC2A3 
ACO1 ABAT TPI1 SUCLG1 GLS2 GRIA4 GRM4 SLC7A4 SLC2A4 
ACO2 ADC GCK SUCLG2 GOT1 GRID1 GRM5 SLC7A5 SLC2A14 
ADC AGXT2 PFKM SDHD GOT2 GRID2 GRM6 SLC7A6 SLC5A1 
AGXT ALDH18A1 PFKL SDHC GLUD1 GRIK1 GRM7 SLC7A7 SLC5A2 
AGXT2 ASNS PFKP SDHA GLUD2 GRIK2 GRM8 SLC7A8 SLC5A4 
ALDH18A1 BCAT1 GAPDH SDHB GPT GRIK3 
 
SLC7A9 SLC5A9 





















































CTPS2 FTCD LDHA IDH3 
   
SLC1A5 
 
DLD GAD1 LDHB IDH1 
     
 214 
 
DNPEP GAD2 LDHC IDH2 
     
EARS2 GCLC SLC2A1 IDH3B 
     
ENO1 GCLM SLC2A2 IDH3G 
     
ENO2 GFPT1 SLC2A4 
      
ENO3 GFPT2 
       
ENPEP GGT1 
       
EPRS GGT5 
       
F13A1 GGT6 
       
FH GGT7 
       
FOLH1 GGT7 
       
FPGS GIG18 
       
FTCD GLS 
       
GAD1 GLS2 
       
GAD2 GLUL 
       
GAPDH GLYATL1 
       
GAPDHS GOT1 
       
GATC GOT1L1 
       
GCK GOT2 
       
GCLC GPT 
       
GCLM GPT2 
       
GFPT1 GRIA1 
       
GFPT2 GRIK1 
       
GGCX GRIK3 
       
GGT1 GSS 




       
GGT3P NAGS 
       
GGT5 OAT 
       
GGT6 OPLAH 
       
GGT7 PET112 
       
GIG18 PFAS 
       
GLS PIG59 
       
GLS1 PSAT1 
       
GLS2 QARS 
       
GLUD1 QRSL1 
       
GLUD2 SLC25A18 
       
GLUL SLC25A22 
       
GLYATL1 TAT 
       
GMPS SLC16A1 
       
GOT1 SLC16A10 
       
GOT1L1 SLC1A5 
       
GOT2 SLC38A3 
       
GPT SLC7A8 
       
GPT2 AASS 
       
GRIA1 AGXT 
       
GRIA2 ALDH4A1 
       
GRIA3 CAD 
       
GRIA4 CTPS1 
       
GRID1 F13A1 




       
GRIK1 GATC 
       
GRIK2 GGCX 
       
GRIK3 GGT2 
       
GRIK4 GGT3P 
       
GRIK5 GLUD1 
       
GRIN1 GLUD2 
       
GRIN2A GMPS 
       
GRIN2B GRIA2 
       
GRIN2C GRIK2 
       
GRIN2D GRIN1 
       
GRIN3A GRIN2A 
       
GRIN3B GRIN2B 
       
GRM1 GRIN2C 
       
GRM2 GRIN2D 
       
GRM3 GRIN3A 
       
GRM4 GRIN3B 
       
GRM5 GRM1 
       
GRM6 GRM4 
       
GRM7 GRM7 
       
GRM8 GRM8 
       
GSR GSR 
       
GSS NADSYN1 
       
HK1 PPAT 




       
HK3 RIMKLB 
       
IDH1 SLC1A1 
       
IDH2 SLC1A2 
       
IDH3 SLC1A3 
       
IDH3B SLC1A6 
       
IDH3G SLC1A7 
       
LDHA SLC7A11 
       
LDHAL6B TGM1 
       
LDHB TGM2 
       
LDHC TGM3 
       
LGSN TGM4 
       
MDH1 TGM5 
       
ME1 TGM6 
       
ME2 TGM7 
       
ME3 
        
NADSYN1 
        
NAGS 
        
OAT 
        
OGDH 
        
OPLAH 
        
PC 
        
PET112 
        
PFAS 




        
PFKM 
        
PFKP 
        
PGAM1 
        
PGAM2 
        
PIG59 
        
PKLR 
        
PKM2 
        
PPAT 
        
PSAT1 
        
QARS 
        
QRSL1 
        
RIMKLA 
        
RIMKLB 
        
SDHA 
        
SDHB 
        
SDHC 
        
SDHD 
        
SLC16A1 
        
SLC16A10 
        
SLC1A1 
        
SLC1A2 
        
SLC1A3 
        
SLC1A5 




        
SLC1A7 
        
SLC25A18 
        
SLC25A22 
        
SLC2A1 
        
SLC2A14 
        
SLC2A2 
        
SLC2A3 
        
SLC2A4 
        
SLC38A1 
        
SLC38A3 
        
SLC3A1 
        
SLC3A2 
        
SLC5A1 
        
SLC5A10 
        
SLC5A2 
        
SLC5A4 
        
SLC5A9 
        
SLC7A1 
        
SLC7A10 
        
SLC7A11 
        
SLC7A2 
        
SLC7A3 
        
SLC7A4 




        
SLC7A6 
        
SLC7A7 
        
SLC7A8 
        
SLC7A9 
        
SUCLG1 
        
SUCLG2 
        
SULA2 
        
TAT 
        
TGM1 
        
TGM2 
        
TGM3 
        
TGM4 
        
TGM5 
        
TGM6 
        
TGM7 
        
TPI1 




Genes Upregulated in Databases 
Avery Talantov Kabbarah Riker Xu TCGA 
Primary Melanomas Metastatic Melanomas 
Gene Pathway Gene Pathway Gene Pathway 
  
Gene Pathway Gene Pathway 
SLC2A3 glucose 
transport 
ASNS Asparagine synthesis AASS Glutamate 
synthesis 
    ACO2 TCA cycle BCAT1 Branched Amino Acid 
Synthesis 
  
CAD Pyrimidine Synthesis ASNS Asparagine 
synthesis 
    ALDH18A1 Proline Synthesis HK3 Glycolysis 
  
ENO1 Glycolysis DLD Glycolysis     ASNS Asparagine synthesis SLC7A7 Glutamine Transport 
  




GOT2 Glutaminolysis GFPT1 Glycolysis     DLD Lipoamide dehydrogenase 
  
  
GRIK1 Glutamate receptor GLS Glutaminolysis     ENO2 Glycolysis 
  
  
GRIK2 Glutamate receptor PPAT Purine Synthesis     ENO3 Glycolysis 
  
  
GRIN2D Glutamate receptor TGM2 Transglutaminase     FOLH1 Glutamate synthesis 
  
  
ME2 TCA Cycle         GFPT1 Glycolysis 
  
  
OGDH Glycolysis         GGCX Glutamate Carboxylation 
  
  
PFKL Glycolysis         GLS Glutaminolysis 
  
  
PFKP Glycolysis         GRIA4 Glutamate Receptor 
  
  
PKM2 Glycolysis         GSR Antioxidant homeostasis 
  
  
PPAT Purine Synthesis         HK3 Glycolysis 
  
  
SLC1A5 Glutamine transport         MDH1 TCA cycle 
  
  
SLC2A3 Glucose Transport         ME2 TCA cycle 
  
  
SLC3A2 Glutamine transport         PPAT Purine Synthesis 
  
  
SLC7A1 Amino Acid transport         SLC16A1 Lactate Transport 
  
  





SLC7A8 Glutamine transport         SLC7A5 Glutamine Transport 
  
  
TGM4 Transglutaminase         SLC7A7 Glutamine Transport 
  
  





Genes Downregulated in Databases 
Primary Melanoma Metastatic Melanoma 
Avery Talantov Kabbarah Riker Xu TCGA 
Gene Pathway Gene Pathway Gene Pathway Gene Pathway Gene Pathway Gene Pathway 
CCBL2 Kynurenic Acid 
Synthesis 




F13A1 Transglutaminase TGM1 Transglutaminase 
CS TCA cycle F13A1 Transglutaminase GPT Glycolysis TGM
1 
Transglutaminase GGT5 Glutathione 
catabolism 
TGM3 Transglutaminase 
GCLM Glutathione Synthesis GAD1 GABA synthesis GRM5 Glutamate 
Receptor 
  
GPT Glycolysis TGM5 Transglutaminase 
GGCX Glutamate 
Carboxylation 

















PFKM Glycolysis GPT Glycolysis 
    
SLC2A1 Glucose Transport 
  
PSAT1 Serine Synthesis GRIA1 Glutamate Receptor 
    
TGM1 Transglutaminase 
  
SDHA TCA cycle GRIN2A Glutamate Receptor 
    
TGM3 Transglutaminase 
  
SDHC TCA cycle IDH2 TCA Cycle 
    
TGM5 Transglutaminase 
  
SLC3A2 Glutamine Transport ME1 TCA Cycle 
        
SLC5A10 Glucose Transport ME3 TCA Cycle 
        
SLC7A8 Glutamine Transport OAT Glutamate/GABA 
Synthesis 
        
TGM7 Transglutaminase OPLAH Glutamate Synthesis 
        
  
PC TCA Cycle 




PSAT1 Serine Synthesis 
        
  
SLC16A10 Amino Acid Transport 
        
  
SLC1A2 Glutamate import 
        
  
SLC1A6 Glutamate import 
        
  
SLC2A1 Glucose Transport 
        
  
SLC38A1 Glutamine Transport 
        
  
SLC5A1 Glucose Transport 
        
  
SUCLG1 TCA cycle 
        
  
TGM1 Transglutaminase 
        
  
TGM3 Transglutaminase 
        
  
TGM5 Transglutaminase 
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Appendix B: Notes on Metabolite Assignment 
Metabolomics software has developed greatly in recent years with the advent of both publically available 
(Bayesil automated assignment for liquid NMR (393)) and commercial software (ChenomX) to aid 
metabolite assignment. A full discussion on the methods is beyond the scope of this work however a 
few notes and figures are presented here to give an idea of the efforts made to verify metabolite 
assignments.  
A challenge that comes with 1D NMR metabolomics are overlapping spectra that increase difficulty in 
making confident assignments of metabolites. One method to increase confidence is to include 2 
dimensional NMR experiments which can spread peaks over a second dimension, thus increasing the 
separation between individual peaks. Due to the long time-frames required for obtaining 2D spectra, 
we obtained J-Res, COSY, and HSQC 2D spectra for one sample per condition studied. Figure 7.3 
shows a representative 2D homonuclear correlation spectroscopy (COSY) experiment. 
Software aided assignment is also become more accessible. Bayesil is an online web took that allows 
for fully automated metabolite assignment for plasma, serum or cerebrospinal fluid (393), and can have 
some use with other fluids if used with caution.  The Chenomx software package allows users to overlay 
1D spectra of standard compound atop the spectra of interest and creates a summed spectrum (Figure 
7.4). This increases confidence in assignments as users can easily visualise if all resonances from a 
candidate metabolite are present in the spectra of study.  
These additional techniques are very useful to assign spectra, however they do not yet replace the 
value of human expertise and the data previously published. (60). This is particularly true for HR-MAS 






METABOLITE CHEBI ID PPM 
1 Acetate CHEBI:15366 1.92 
2 Alanine CHEBI:16449 1.48 
3 Asparagine CHEBI:22653 2.80 
4 Aspartate CHEBI:22660 2.73 
5 Choline CHEBI:15354 3.21 
6 Creatine CHEBI:16919 3.02 
7 Glucose CHEBI:17234 3.44 
8 Glutamate CHEBI:18237 2.36 
9 Glutamine CHEBI:28300 2.46 
10 Glycerophosphocholine CHEBI:16870 3.26 
11 Triglycerides CHEBI:17855 4.47 
12 Inosine CHEBI:17596 8.19 
13 Isoleucine CHEBI:24898 1.03 
14 Lactate CHEBI:78320 1.33 
15 Leucine CHEBI:25017 0.97 
16 Lipid CH2-CH2-CO 
 
2.25 
17 Methyl Group of Lipids CH3 
 
0.90 
18 Myo-Inositol CHEBI:17268 3.55 
19 Phenylalanine CSID 136705 7.35 
20 Phosphocholine CHEBI:18132 3.23 
21 Lipid Chain CH2-CH2 
 
1.30 
22 Tyrosine CHEBI:18186 6.90 
23 Valine CHEBI:27266 5.33 




Table 10. Assignments used for HR-MAS NMR experiments including Chemical Entities of Biological Interest 





METABOLITE CHEBI ID PPM 
1 Leucine CHEBI:25017 0.97 
2 Isoleucine CHEBI:24898 1.01 
3 Valine CHEBI:27266 1.04 
4 Lactate CHEBI:78320 1.33 
5 Alanine CHEBI:16449 1.48 
6 Methionine CHEBI:16811 2.14 
7 Glutamate CHEBI:18237 2.33 
8 Pyruvate CHEBI:32816 2.38 
9 Pyroglutamate CHEBI:16010 2.41 
10 Glutamine CHEBI:28300 2.44 
11 Lysine CHEBI:25094 3.04 
12 Myo-inositol CHEBI:17268 4.07 
13 Glucose CHEBI:17234 5.24 
14 Fumarate CHEBI:18012 6.52 
15 T-Methyl histidine CHEBI 10960 7.04 
16 Tyrosine CHEBI:18186 7.19 
17 Phenylalanine CHEBI:28044 7.33 
18 Tryptophan CHEBI:27897 7.55 
19 Formate CHEBI:30751 8.46 
20 Nicotinamide CHEBI:17154 8.72 
 
Table 11. Assignments of cell culture media NMR metabolomics including Chemical Entities of Biological Interest 




Figure 7.3. Representative 2D COSY 1H HR-MAS NMR spectra of ROCK2 KO murine melanomas. A partial assignment is shown of identified metabolites.  the spectrum was 

















Figure 7.4. Representative metabolite assignment with Chenomx software. Chenomx permits users to overlay NMR 
spectra of standard compounds (red) with the NMR spectrum under study (black). A particular strength of the 
Chenomx software is the ability to account for shifting of peaks due to changes in pH between samples. The 








Figure 7.5. H1152 interferes with the redox state of melanoma cells. Left) Mean PQN normalised 1H HR-MAS NMR spectra of melanoma cells where ROCK activity has been 
interfered with. Control spectra are plotted in blue while treatment spectra re plotted in red. Spectra highlight the changes in Alanine (Ala) and Lactate (Lac). Right) The ratios 

















Figure 7.6  GPC/PC ratio of mouse melanoma cells decrease after KO of ROCK.  Left) Mean PQN normalised 1H HR-MAS NMR spectra of melanoma cells where ROCK activity 
has been interfered with. Control spectra are plotted in blue while treatment spectra re plotted in red. Spectra highlight the changes in choline, Phosphocholine (PC), and 
glycerophosphocholine (GPC). Right) The ratios between GPC and PC are shown between control cells and treatment cells. All experiments are n=3 with 3 internal replicates 















Figure 7.7   Glutamine, glutamate and glutathione are altered by different levels of ROCK activity. A) Top: Spectral overlays of 1H HR-MAS NMR of human and murine melanoma 
cells highlighting the spectral regions with glutathione (Gth), glutamine (Gln), and glutamate (Glu). Control cells are plotted in blue while treatment cells are plotted in red.  From 
left to right the treatments are H1152, Y27632, GSK269, siROCK and ROCK double knock-out. Below: mean spectra from the same data to illustrated the differences in controls 
(blue) vs. treatment (red). B) Bar charts taken from data in A illustrating the relative changes in signal intensity of melanoma cells are interfering with ROCK expression/activity.  
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